Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
991e8baf4cfe77c5f35a819b82da4220438295ccd21f4489a80fdf97898f5dbc.png
complex
<table><tr><td colspan="2">Initial Experiment Results</td><td colspan="2">Enhanced Results</td></tr><tr><td>Total Length Ratio</td><td>RMSE (m)</td><td>Total Length Ratio</td><td>RMSE (m)</td></tr><tr><td>0.94</td><td>3.2</td><td>0.96</td><td>0.93</td></tr></table>
4b01d2f9a5dff16bbecc33e5ec35a1bcd29340f37e669562b4b842699a570a1c.png
complex
<table><tr><td></td><td>Acute</td><td>Chronic</td><td>No Pain</td><td><i>p</i> Value</td></tr><tr><td>Total Number (<i>n</i> = 218)</td><td>140 (64)</td><td>33 (15)</td><td>45 (21)</td><td></td></tr><tr><td colspan="4">Age <i>n</i> (%)</td><td rowspan="3">0.897</td></tr><tr><td>19&#8211;25</td><td>97 (69)</td><td>23 (70)</td><td>33 (73)</td></tr><tr><td>26+</td><td>42 (30)</td><td>10 (30)</td><td>12 (27)</td></tr><tr><td colspan="4">Sex <i>n</i> (%)</td><td rowspan="3">0.066</td></tr><tr><td>Male</td><td>50 (36)</td><td>14 (42)</td><td>25 (56)</td></tr><tr><td>Female</td><td>89 (64)</td><td>19 (58)</td><td>20 (44)</td></tr><tr><td colspan="4">Year in program <i>n</i> (%)</td><td rowspan="4">0.490</td></tr><tr><td>First year</td><td>46 (33)</td><td>15 (45)</td><td>18 (40)</td></tr><tr><td>Second year</td><td>52 (37)</td><td>12 (36)</td><td>13 (29)</td></tr><tr><td>Third year</td><td>41 (29)</td><td>6 (18)</td><td>14 (31)</td></tr><tr><td>Pain intensity mean (SD) <sup>1</sup></td><td>5.2 (2.0)</td><td>5.9 (1.7)</td><td>-</td><td>0.035 <sup>2</sup></td></tr><tr><td>Level of pain tolerated mean (SD) <sup>1</sup></td><td>6.1 (1.9)</td><td>6.3 (1.8)</td><td>-</td><td>0.544</td></tr></table>
aa9cb5a3733d4c0d362cb60d91cb69d1b3c6c801198f7f51a53e82128749f960.png
simple
<table><tr><td> </td><td>White (<i>n</i> = 93,325)</td><td>Black (<i>n</i> = 8,718) </td><td>Hispanic (<i>n</i> = 24,078) </td><td>Asian/Pacific Islander (<i>n</i> = 16,476) </td><td>American Indian (<i>n</i> = 587) </td><td>Total <i>N</i> = 143,184 </td></tr><tr><td>Mean age in years &#177; SD </td><td>61.49 &#177; 13.47</td><td>57.72 &#177; 13.51</td><td>55.13 &#177; 13.35</td><td>55.87 &#177; 12.93 </td><td>57.50 &#177; 12.44 </td><td>59.53 &#177; 13.67 </td></tr><tr><td> Age </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&lt;45 </td><td>12.1%</td><td>19.4%</td><td>25.5% </td><td>22.6%</td><td>16.5% </td><td>22,944 </td></tr><tr><td>46&#8211;69 </td><td>58.9%</td><td>59.9%</td><td>58.4% </td><td>61.1%</td><td>66.1% </td><td>84,704 </td></tr><tr><td>70+ </td><td>29.0%</td><td>20.7%</td><td>16.0% </td><td>16.2%</td><td>17.4% </td><td>35,536 </td></tr><tr><td>AJCC stage </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Stage 1 </td><td>50.7%</td><td>37.1%</td><td>38.3% </td><td>45.0%</td><td>43.8% </td><td>67,435 </td></tr><tr><td> Stage 2 </td><td>37.1%</td><td>43.4%</td><td>42.8% </td><td>41.6%</td><td>38.3% </td><td>55,782 </td></tr><tr><td> Stage 3 </td><td>9.5%</td><td>14.5%</td><td>15.3% </td><td>10.6%</td><td>13.6% </td><td>15,664 </td></tr><tr><td> Stage 4 </td><td>2.7%</td><td>5.1%</td><td>3.6% </td><td>2.8%</td><td>4.3% </td><td>4,303 </td></tr><tr><td>ER/PR/HER2 subtype </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ER+/PR+/HER2&#8722;</td><td>61.3%</td><td>44.2%</td><td>52.2% </td><td>56.1%</td><td>56.9% </td><td>83,169 </td></tr><tr><td> ER+/PR+/HER2+ </td><td>8.7%</td><td>8.9% </td><td>10.3% </td><td>11.3%</td><td>9.5% </td><td>13,293 </td></tr><tr><td> ER+/PR&#8722;/HER2&#8722;</td><td>9.7%</td><td>10.1% </td><td>8.7% </td><td>8.0%</td><td>9.7% </td><td>13,363 </td></tr><tr><td> ER+/PR&#8722;/HER2+ </td><td>3.0%</td><td>3.3%</td><td>3.4% </td><td>3.6%</td><td>3.6% </td><td>4,535 </td></tr><tr><td> ER&#8722;/PR+/HER2&#8722;</td><td>0.7%</td><td>1.1%</td><td>1.0% </td><td>0.8%</td><td>0.7% </td><td>1,131 </td></tr><tr><td> ER&#8722;/PR+/HER2+ </td><td>0.3%</td><td>0.6%</td><td>0.6% </td><td>0.4% </td><td>0.2% </td><td>539 </td></tr><tr><td> ER&#8722;/PR&#8722;/HER2&#8722;</td><td>11.2%</td><td>24.5%</td><td>15.9% </td><td>11.0%</td><td>14.0% </td><td>18,299 </td></tr><tr><td> ER&#8722;/PR&#8722;/HER2+ </td><td>5.2%</td><td>7.3%</td><td>7.9% </td><td>8.8%</td><td>5.5% </td><td>8,855 </td></tr><tr><td>Socioeconomic status (SES) </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> SES1-low </td><td>6.6%</td><td>25.4%</td><td>28.0% </td><td>7.2%</td><td>18.4% </td><td>16,424 </td></tr><tr><td> SES2 </td><td>13.8%</td><td>24.9%</td><td>24.4% </td><td>14.3%</td><td>25.7% </td><td>23,383 </td></tr><tr><td> SES3 </td><td>20.2%</td><td>21.8%</td><td>20.1% </td><td>19.3%</td><td>26.1% </td><td>28,953 </td></tr><tr><td> SES4 </td><td>26.1%</td><td>17.6%</td><td>16.2% </td><td>26.9%</td><td>18.7% </td><td>34,332 </td></tr><tr><td> SES5-high </td><td>33.3%</td><td>10.3%</td><td>11.4% </td><td>32.3%</td><td>11.1% </td><td>40,092 </td></tr><tr><td>Tumor grade </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Well differentiated; grade I (low) </td><td>25.6%</td><td>14.5%</td><td>16.9% </td><td>18.3%</td><td>20.3% </td><td>32,367 </td></tr><tr><td> Moderately differentiated; grade II (low) </td><td>43.7%</td><td>35.1%</td><td>40.2% </td><td>43.0%</td><td>42.6% </td><td>60,820 </td></tr><tr><td> Poorly differentiated; grade III (high) </td><td>29.5%</td><td>48.4%</td><td>41.1% </td><td>37.3%</td><td>36.1% </td><td>47,969 </td></tr><tr><td> Undifferentiated; grade IV (high) </td><td>1.3%</td><td>2.0%</td><td>1.8% </td><td>1.3%</td><td>1.0% </td><td>2,028 </td></tr><tr><td>Tumor size (mm) </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> &lt;1&#8211;4.99</td><td>6.3%</td><td>4.8%</td><td>5.0% </td><td>6.7%</td><td>5.6% </td><td>8,650 </td></tr><tr><td> 5.00&#8211;9.99 </td><td>18.7%</td><td>12.0%</td><td>12.6% </td><td>14.5%</td><td>14.3% </td><td>23,968 </td></tr><tr><td> 10.00&#8211;19.99 </td><td>38.6%</td><td>33.0%</td><td>34.2% </td><td>36.1%</td><td>35.8% </td><td>53,306 </td></tr><tr><td> 20.00&#8211;49.99 </td><td>28.7%</td><td>36.9%</td><td>36.6% </td><td>34.0%</td><td>32.9% </td><td>44,623 </td></tr><tr><td> 50.00+ </td><td>7.7%</td><td>13.3%</td><td>11.6% </td><td>8.6%</td><td>11.4% </td><td>12,637 </td></tr></table>
67dcc1e5384d5cd26104c79f3a3515f4fe6503364d017a2fc9c8eb37804581c6.png
complex
<table><tr><td>Threshold</td><td>Net benefit</td><td>Point Estimate</td><td>Bootstrap Mean</td><td colspan="2">Bootstrap confidence interval</td></tr><tr><td></td><td>For:</td><td></td><td>(2000 replications)</td><td>2.5<sup>th </sup>percentile</td><td>97.5<sup>th </sup>percentile</td></tr><tr><td>15</td><td>All</td><td>0.1288</td><td>0.1288</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Base</td><td>0.1288</td><td>0.1290</td><td>0.0922</td><td>0.1669</td></tr><tr><td></td><td>Full</td><td>0.1590</td><td>0.1613</td><td>0.1280</td><td>0.1955</td></tr><tr><td></td><td>Full vs All</td><td>0.0302</td><td>0.0325</td><td>0.0172</td><td>0.0490</td></tr><tr><td></td><td>Full vs Base</td><td>0.0302</td><td>0.0322</td><td>0.0170</td><td>0.0488</td></tr><tr><td>25</td><td>All</td><td>0.0126</td><td>0.0126</td><td>-0.0288</td><td>0.0559</td></tr><tr><td></td><td>Base</td><td>0.0748</td><td>0.0735</td><td>0.0432</td><td>0.1036</td></tr><tr><td></td><td>Full</td><td>0.1167</td><td>0.1214</td><td>0.0919</td><td>0.1522</td></tr><tr><td></td><td>Full vs All</td><td>0.1041</td><td>0.1088</td><td>0.0802</td><td>0.1369</td></tr><tr><td></td><td>Full vs Base</td><td>0.0419</td><td>0.0479</td><td>0.0257</td><td>0.0712</td></tr><tr><td>35</td><td>All</td><td>-0.1393</td><td>-0.1393</td><td>-0.1871</td><td>-0.0894</td></tr><tr><td></td><td>Base</td><td>0.0428</td><td>0.0410</td><td>0.0181</td><td>0.0662</td></tr><tr><td></td><td>Full</td><td>0.0940</td><td>0.0965</td><td>0.0652</td><td>0.1291</td></tr><tr><td></td><td>Full vs All</td><td>0.2333</td><td>0.2358</td><td>0.1990</td><td>0.2712</td></tr><tr><td></td><td>Full vs Base</td><td>0.0511</td><td>0.0555</td><td>0.0293</td><td>0.0836</td></tr><tr><td>60</td><td>All</td><td>-0.8514</td><td>-0.8513</td><td>-0.9291</td><td>-0.7703</td></tr><tr><td></td><td>Base</td><td>0.0149</td><td>0.0159</td><td>-0.0041</td><td>0.0378</td></tr><tr><td></td><td>Full</td><td>0.0547</td><td>0.0569</td><td>0.0331</td><td>0.0838</td></tr><tr><td></td><td>Full vs All</td><td>0.9061</td><td>0.9083</td><td>0.8345</td><td>0.9824</td></tr><tr><td></td><td>Full vs Base</td><td>0.0399</td><td>0.0410</td><td>0.0176</td><td>0.0676</td></tr><tr><td>80</td><td>All</td><td>-2.7027</td><td>-2.7026</td><td>-2.8581</td><td>-2.5405</td></tr><tr><td></td><td>Base</td><td>-0.0149</td><td>-0.0028</td><td>-0.0230</td><td>0.0243</td></tr><tr><td></td><td>Full</td><td>0.0189</td><td>0.0223</td><td>-0.0054</td><td>0.0527</td></tr><tr><td></td><td>Full vs All</td><td>2.7216</td><td>2.7249</td><td>2.5649</td><td>2.8757</td></tr><tr><td></td><td>Full vs Base</td><td>0.0338</td><td>0.0251</td><td>0.0000</td><td>0.0595</td></tr></table>
eacaa4f7575a8e04e674c7906e7d1d947a5109abc2d7f2a0b91385ba770e7aa1.png
simple
<table><tr><td></td><td>AIM HI</td><td>CPRT</td></tr><tr><td>Initial didactic training&#8212;lecture material, video examples, case illustrations, and hands-on practice with coaching and discussion</td><td>12 h (over 2 days)</td><td>8 h</td></tr><tr><td>Ongoing consultation/coaching&#8212;occurs while provider delivers intervention to target child and includes video-based feedback<sup>1</sup></td><td>11 1-h sessions over 6 months (9 group, 2 indiv.)</td><td>4 1-h group sessions and 6 individual coaching sessions over 5 months</td></tr><tr><td>Total length of training</td><td>22 h/6 months</td><td>18 h/6 months</td></tr></table>
cd648ccf5a84955b30128b0787d84824003da271ffda3815339b1f04bee53665.png
complex
<table><tr><td>Category</td><td>No. of children</td><td>No. of diarrheal episodes</td><td>Total time at risk (years)</td><td>Diarrheal incidence (episodes/child year)</td><td>Unadjusted IRR (95% CI)</td><td>Adjusted IRR* (95% CI)</td><td><i>P</i> value</td></tr><tr><td colspan="8">Study arm</td></tr><tr><td> No intervention</td><td>109</td><td>85</td><td>80.8</td><td>1.05 (0.85&#8211;1.30)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> Intervention (without safe storage)</td><td>65</td><td>54</td><td>44.1</td><td>1.22 (0.94&#8211;1.60)</td><td>1.15 (0.75&#8211;1.77)</td><td>1.14 (0.75&#8211;1.77)</td><td>0.530</td></tr><tr><td> Intervention (with safe storage)</td><td>102</td><td>61</td><td>76.8</td><td>0.79 (0.62&#8211;1.02)</td><td>0.77 (0.52&#8211;1.14)</td><td>0.76 (0.51&#8211;1.13)</td><td>0.178</td></tr><tr><td colspan="8">Gender</td></tr><tr><td> Male</td><td>146</td><td>102</td><td>102.7</td><td>0.99 (0.82&#8211;1.20)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> Female</td><td>130</td><td>98</td><td>99.0</td><td>0.98 (0.81&#8211;1.21)</td><td>1.00 (0.71&#8211;1.40)</td><td>1.05 (0.74&#8211;1.48)</td><td>0.790</td></tr><tr><td colspan="8">Age of child (months)&#8224;</td></tr><tr><td> 0&#8211;6</td><td>94</td><td>37</td><td>40.9</td><td>0.90 (0.65&#8211;1.25)</td><td>Ref</td><td>Ref</td><td>&#8211;</td></tr><tr><td> 6&#8211;12</td><td>62</td><td>67</td><td>52.4</td><td>1.28 (1.00&#8211;1.62)</td><td>1.32 (0.87&#8211;2.00)</td><td>1.30 (0.85&#8211;1.98)</td><td>0.222</td></tr><tr><td> 12&#8211;18</td><td>58</td><td>44</td><td>59.1</td><td>0.75 (0.55&#8211;1.00)</td><td>0.75 (0.47&#8211;1.21)</td><td>0.74 (0.46&#8211;1.19)</td><td>0.221</td></tr><tr><td> 18&#8211;24</td><td>43</td><td>52</td><td>48.8</td><td>1.06 (0.81&#8211;1.40)</td><td>1.09 (0.69&#8211;1.74)</td><td>1.07 (0.67&#8211;1.70)</td><td>0.783</td></tr></table>
1f08b1af2f364112dca9e9d4692c9242111e94c506f6bd929f8e8b491cbc8e4b.png
simple
<table><tr><td> Factor</td><td><i>n</i></td><td>2-year locoregional failure-free survival</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>Age</td><td></td><td></td><td></td><td>0.005</td></tr><tr><td> Age &#8804;40</td><td>54</td><td>0.86</td><td>0.75&#8211;0.98</td><td></td></tr><tr><td> Age &gt;40</td><td>158</td><td>0.98</td><td>0.95&#8211;1.00</td><td></td></tr><tr><td>Menopausal status</td><td></td><td></td><td></td><td>0.52</td></tr><tr><td> Premenopausal</td><td>129</td><td>0.99</td><td>0.97&#8211;1.00</td><td></td></tr><tr><td> Postmenopausal</td><td>84</td><td>0.97</td><td>0.91&#8211;1.00</td><td></td></tr><tr><td>BMI</td><td></td><td></td><td></td><td>0.31</td></tr><tr><td> BMI &lt;30</td><td>72</td><td>0.95</td><td>0.88&#8211;1.00</td><td></td></tr><tr><td> BMI &#8805;30</td><td>83</td><td>0.97</td><td>0.92&#8211;1.00</td><td></td></tr><tr><td>T stage</td><td></td><td></td><td></td><td>0.03</td></tr><tr><td> Tis, T0&#8211;2</td><td>159</td><td>0.98</td><td>0.95&#8211;1.00</td><td></td></tr><tr><td> T3-4</td><td>47</td><td>0.89</td><td>0.78&#8211;1.00</td><td></td></tr><tr><td>N stage</td><td></td><td></td><td></td><td>0.13</td></tr><tr><td> N0</td><td>77</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> N+</td><td>128</td><td>0.94</td><td>0.88&#8211;1.00</td><td></td></tr><tr><td>Grading</td><td></td><td></td><td></td><td>0.27</td></tr><tr><td> G1-2</td><td>80</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> G3</td><td>93</td><td>0.93</td><td>0.86&#8211;1.00</td><td></td></tr><tr><td>Tumor subtype</td><td></td><td></td><td></td><td>0.03</td></tr><tr><td> Luminal A</td><td>75</td><td>0.91</td><td>0.83&#8211;0.99</td><td></td></tr><tr><td> Others*</td><td>114</td><td>0.99</td><td>0.97&#8211;1.00</td><td></td></tr><tr><td>Lymphovascular status</td><td></td><td></td><td></td><td>0.02</td></tr><tr><td> LV0</td><td>67</td><td>1.00</td><td>1.00-1.00</td><td></td></tr><tr><td> LV1</td><td>68</td><td>0.90</td><td>0.79&#8211;1.00</td><td></td></tr><tr><td>Type of surgery</td><td></td><td></td><td></td><td>0.59</td></tr><tr><td> Mastectomy</td><td>121</td><td>0.96</td><td>0.91&#8211;1.00</td><td></td></tr><tr><td> BCS</td><td>91</td><td>0.97</td><td>0.92&#8211;1.00</td><td></td></tr><tr><td>Residual tumor status</td><td></td><td></td><td></td><td>0.56</td></tr><tr><td> R0</td><td>163</td><td>0.97</td><td>0.93&#8211;1.00</td><td></td></tr><tr><td> R1</td><td>15</td><td>1.00</td><td>1.00-1.00</td><td></td></tr></table>
117e64a393b7efcc8f1e579e134595db30be901b84b27c2cc83f9b3e933ba5ab.png
complex
<table><tr><td>A. Adolescents and adults</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2"><i>Vaccination health states</i></td><td colspan="3"><i>Disease health states</i></td></tr><tr><td></td><td>Local reaction</td><td>Systemic reaction</td><td>Mild cough</td><td>Severe cough</td><td>Pneumonia</td></tr><tr><td>Mean (SD) adolescent utilities for short-term TTO (N = 94)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.80 (0.32)</td><td>0.68 (0.36)</td><td>0.51 (0.39)</td><td>0.35 (0.38)</td><td>0.35 (0.37)</td></tr><tr><td> 5%</td><td>0.95 (0.14)</td><td>0.92 (0.16)</td><td>0.87 (0.22)</td><td>0.80 (0.28)</td><td>0.80 (0.26)</td></tr><tr><td> 10%</td><td>0.99 (0.03)</td><td>0.99 (0.04)</td><td>0.97 (0.08)</td><td>0.96 (0.11)</td><td>0.96 (0.08)</td></tr><tr><td>Mean (SD) adolescent utilities for long-term TTO (N = 81)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.96 (0.06)</td><td>0.92 (0.09)</td><td>0.88 (0.10)</td><td>0.82 (0.13)</td><td>0.82 (0.14)</td></tr><tr><td> 5%</td><td>0.97 (0.07)</td><td>0.94 (0.11)</td><td>0.91 (0.12)</td><td>0.85 (0.18)</td><td>0.85 (0.17)</td></tr><tr><td> 10%</td><td>0.99 (0.05)</td><td>0.97 (0.09)</td><td>0.95 (0.11)</td><td>0.91 (0.17)</td><td>0.91 (0.15)</td></tr><tr><td>Mean (SD) adult utilities for short-term TTO (N = 72)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.91 (0.24)</td><td>0.83 (0.29)</td><td>0.67 (0.38)</td><td>0.58 (0.42)</td><td>0.62 (0.40)</td></tr><tr><td> 5%</td><td>0.97 (0.13)</td><td>0.96 (0.14)</td><td>0.90 (0.22)</td><td>0.88 (0.23)</td><td>0.88 (0.25)</td></tr><tr><td> 10%</td><td>0.99 (0.04)</td><td>0.99 (0.04)</td><td>0.97 (0.07)</td><td>0.97 (0.08)</td><td>0.97 (0.08)</td></tr><tr><td>Mean (SD) adult utilities for long-term TTO (N = 56)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.99 (0.02)</td><td>0.97 (0.06)</td><td>0.93 (0.09)</td><td>0.88 (0.17)</td><td>0.88 (0.18)</td></tr><tr><td> 5%</td><td>1.0 (0.01)</td><td>0.99 (0.03)</td><td>0.97 (0.05)</td><td>0.94 (0.13)</td><td>0.94 (0.15)</td></tr><tr><td> 10%</td><td>1.0 (0.00)</td><td>1.0 (0.01)</td><td>0.99 (0.02)</td><td>0.97 (0.09)</td><td>0.96 (0.12)</td></tr><tr><td>B. Infants</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2"><i>Infant health states</i></td><td></td><td></td><td></td></tr><tr><td></td><td>Infant respiratory complications</td><td>Infant neurologic complications</td><td></td><td></td><td></td></tr><tr><td>Short-term TTO (N = 166)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.27 (0.36)</td><td>0.21 (0.33)</td><td></td><td></td><td></td></tr><tr><td> 5%</td><td>0.71 (0.35)</td><td>0.66 (0.36)</td><td></td><td></td><td></td></tr><tr><td> 10%</td><td>0.92 (0.17)</td><td>0.90 (0.19)</td><td></td><td></td><td></td></tr><tr><td>Long-term TTO (N = 147)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0%</td><td>0.36 (0.18)</td><td>0.33 (0.19)</td><td></td><td></td><td></td></tr><tr><td> 5%</td><td>0.84 (0.21)</td><td>0.78 (0.26)</td><td></td><td></td><td></td></tr><tr><td> 10%</td><td>0.89 (0.20)</td><td>0.84 (0.27)</td><td></td><td></td><td></td></tr></table>
58fd8001be2e18a8a4ce5d31dd911258fdbe052666dad6797f2a39cbdf6608bb.png
simple
<table><tr><td>Compound</td><td>Description</td><td>Applications</td><td>Remarks</td></tr><tr><td>In111-Capromab pendetide (ProstaScint)</td><td>A conjugation between the murine antibody 7E11.C5.3 and <sup>111</sup>Inin the source of <sup>111</sup>InCl<sub>3</sub> by the action of the GYK-DTPA as a chelating agent.</td><td>Indicated for use in immunoscintigraphy, proven prostate carcinoma and patients who have undergone a prostatectomy and have rising prostate specific antigen (PSA) values and equivocal nonevidenced metastasis.</td><td>It is not indicated with patients with a high clinical suspicion of occult metastatic disease or for screening of prostate carcinoma.</td></tr><tr><td>In111-Satumomab pendetide (OncoScint)</td><td>It contains the murine MAb B72.3 which is directed to tumor-associated glycoprotein. It is labeled with <sup>111</sup>InCl<sub>3</sub> by conjugation with the chelating agent, GYK-DTPA.HCl.</td><td>Used for the detection of colorectal and ovarian cancers [35].</td><td>After an incubation time of 30 min, the labeled mixture is suitable for use in the first 8 hours.</td></tr><tr><td>In111-Imciromab pentetate (MyoScint)</td><td>An antibody produced against myosin in the cell culture, and therefore binds to the heavy chain of myosin after in vivo administration.</td><td>Detection of myocardial infarction.</td><td>Contains the Fab fragment of a murine monoclonal antibody that is covalently bound to DTPA giving <sup>111</sup>In -Imciromab pentetate. </td></tr><tr><td>In-111 and Y90-ibritumomab tiuxetan (Zevalin)</td><td><i>Zevalin</i> consists of a murine monoclonal anti-CD20 antibody covalently conjugated to the metal chelator DTPA, which forms a stable complex with <sup>111</sup>Infor imaging and with <sup>90</sup>Y for therapy.</td><td><sup>90</sup>Y-ibritumomab tiuxetan is used for the treatment of some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system while its <sup>111</sup>Inderivative is used to scan the predicted distribution of a therapeutic dosage of <sup>90</sup>Y-ibritumomab in the body [36].</td><td>The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors) allowing radiation from the attached isotope (Yetrium-90) and the cytotoxicity induced by the antibody serve to eliminate B cells from the body allowing a new population of healthy B cells to develop from lymphoid stem cells [37]. </td></tr><tr><td>Rituximab</td><td>An earlier version of anti-CD20 antibody and has also been approved under the brand name Rituxan for the treatment of non-Hodgkin's lymphoma (NHL).</td><td>It was approved for the treatment of patients with relapsed or refractory, lowgrade or follicular Bcell NHL, including patients with rituximab refractory follicular NHL.</td><td>In September 2009, ibritumomab received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular NHL, who achieve a partial or complete response to first-line chemotherapy.</td></tr></table>
094bf483c5031052e435b64dec8ed5d5eb9d96a388ca93bc9cd95260780b6b9f.png
simple
<table><tr><td>Questions</td><td>Sub-questions</td></tr><tr><td>1. What is the first thing that comes to mind when you hear the phrase &#8220;oral health&#8221;?</td><td>a. <sup>a</sup>What does &#8220;good oral health&#8221; mean to you?i. <sup>b</sup>When you think of your child, would you say that he or she has &#8220;good oral health&#8221;?ii. <sup>b</sup>How would you describe a child who has good oral health?iii. <sup>b</sup>Think about your child&#8217;s friends, how would you describe those that have good oral health?</td></tr><tr><td>2. What comes to mind when you hear the phrase &#8220;poor oral health&#8221;?</td><td>a. <sup>a</sup>When you think of your child, what could be thought of as poor oral health?i. <sup>b</sup>What could be thought as the worst thing for poor oral health?ii. <sup>b</sup>How would you describe a child with poor oral health?b. <sup>a</sup>How much of a problem is this among children in your family?i. <sup>b</sup>How common is it among children in other families who live in this community? Among your friends?ii. <sup>b</sup>How concerned are you about your son or daughter developing dental problems (dental decay)?</td></tr><tr><td>3. As parents, how do you help your child have healthy teeth?</td><td>a. <sup>a</sup>What do you think parents can do (or you as a parent can do) to prevent dental problems in kids (your kids)?b. <sup>a</sup>As a parent, what do you think are the most important ways to help a child have good oral health?c. <sup>b</sup>What activities can you do to improve your child&#8217;s oral health?d. <sup>c</sup>What about diet and oral health?e. <sup>c</sup>What about flouride and oral health?f. <sup>c</sup>What about the experiences of your other children?</td></tr><tr><td>4. Tell me whether you think you can control your child&#8217;s oral health?</td><td>a. <sup>b</sup>Are there oral health problems that you feel you can control?i. <sup>c</sup>What would they be?ii. <sup>c</sup>What steps can you take to control the problem?iii. <sup>c</sup>Yourself?iv. <sup>c</sup>What about other people? Can they do anything to control the problem?b. <sup>b</sup>When you can control an oral health problem, how does you child respond?c. <sup>b</sup>When you dealt with an oral health problem, how successful were you?d. <sup>c</sup>So, you could not control a problem, then what did you do?i. <sup>b</sup>What was your child&#8217;s response?ii. <sup>b</sup>When you think about it now, does the problem still exist?</td></tr><tr><td>5. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child&#8217;s oral health?</td><td>a. <sup>b</sup>Why? What do you think they can do to help?i. <sup>c</sup>What about role models in entertainment?ii. <sup>c</sup>What about advertising and media messages?iii. <sup>c</sup>What about public policies?iv. <sup>c</sup>What about insurance?</td></tr><tr><td>6. What concerns do you have about your child&#8217;s future oral health?</td><td>a. <sup>b</sup>As your child grows older, what oral health problems can affect him/her?i. <sup>c</sup>How can poor oral health affect a child&#8217;s social and psychological well-being?ii. <sup>c</sup>How can it affect a person&#8217;s chances of economic success?iii. <sup>c</sup>How can it affect one&#8217;s general health over a lifetime?</td></tr><tr><td>7. Tell me whether you think you can control your child&#8217;s oral health?</td><td>a. <sup>b</sup>Are there oral health problems that you feel you can control?i. <sup>c</sup>What would they be?ii. <sup>c</sup>What steps can you take to control the problem?iii. <sup>c</sup>Yourself?iv. <sup>c</sup>What about other people? Can they do anything to control the problem?b. <sup>b</sup>When you can control an oral health problem, how does you child respond?c. <sup>b</sup>When you can dealt an oral health problem, how successful were you?d. <sup>c</sup>So, you could not control a problem, then what did you do?i. <sup>b</sup>What was your child&#8217;s response?ii. <sup>b</sup>When you think about it now, does the problem still exist?</td></tr><tr><td>8. Other than your family and those who provide care, is there anyone else that you think should or could have an important role in your child&#8217;s oral health?</td><td>a. <sup>b</sup>Why? What do you think they can do to help?i. <sup>c</sup>What about role models in entertainment?ii. <sup>c</sup>What about advertising and media messages?iii. <sup>c</sup>What about public policies?iv. <sup>c</sup>What about insurance?</td></tr><tr><td>9. What concerns do you have about your child&#8217;s future oral health?</td><td>a. <sup>b</sup>As your child grows older, what oral health problems can affect him/her?</td></tr></table>
c4128e50eff6b2e2fbf6800852789b7b18fb486ad303f10dfa734bdf66ec98f9.png
simple
<table><tr><td>Dependent variable</td><td>Explanatory variable</td><td>Beta</td><td>Chi&#8208;square</td><td><i>p</i> value</td><td>OR (95% confidence interval [CI])</td></tr><tr><td></td><td>Female gender</td><td>1.13</td><td>5.18</td><td>.023</td><td>3.08 (95% CI [1.17, 8.11])</td></tr><tr><td>MMP&#8208;13 saliva</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CAL</td><td>1.27</td><td>4.35</td><td>.037</td><td>3.57 (95% CI [1.08, 11.82])</td></tr></table>
fb47b3a3693827d63e2542d4ee7b1a14eb46585f3e58b871d3f18169dc54463f.png
complex
<table><tr><td>Patient code</td><td>Age (years)</td><td>Sex</td><td>Clinical form</td><td colspan="2">Location of lesion/Code</td></tr><tr><td colspan="4"> </td><td>Cutaneous</td><td>Mucosal</td></tr><tr><td>1</td><td>52</td><td>M</td><td>MCL</td><td>Arm/1MCL-C</td><td>Oral / 1MCL-O</td></tr><tr><td>2</td><td>48</td><td>M</td><td>MCL</td><td>Nostril/2MCL-C</td><td>Oral/2MCL-O</td></tr><tr><td>3</td><td>25</td><td>M</td><td>MCL</td><td>Arm/3MCL-C</td><td>Nasal/3MCL-N</td></tr><tr><td>4</td><td>54</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/4MCL-O</td></tr><tr><td rowspan="2">5</td><td rowspan="2">47</td><td rowspan="2">M</td><td rowspan="2">MCL</td><td rowspan="2">Arm/5MCL-C</td><td>Nasal/5MCL-N</td></tr><tr><td>Oral/5MCL-O</td></tr><tr><td>6</td><td>16</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/6MCL-N</td></tr><tr><td>7</td><td>50</td><td>M</td><td>MCL</td><td>Face/7MCL-C</td><td>Nasal/7MCL-N</td></tr><tr><td>8</td><td>29</td><td>M</td><td>MCL</td><td>Trunk/8LMC-C</td><td>Nasal/8MCL-N</td></tr><tr><td>9</td><td>55</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/9MCL-O</td></tr><tr><td>10</td><td>42</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/10MCL-N</td></tr><tr><td>11</td><td>52</td><td>F</td><td>MCL</td><td>Arm/11MCL-C</td><td>Nasal/11MCL-N</td></tr><tr><td>12</td><td>25</td><td>M</td><td>MCL</td><td>Trunk/12MCL-C</td><td>Oral/12MCL-O</td></tr><tr><td>13</td><td>52</td><td>F</td><td>MCL</td><td>ND</td><td>Oral/13MCL-O</td></tr><tr><td>14</td><td>54</td><td>M</td><td>MCL</td><td>Upper lip/14MCL-C</td><td>Nasal/14MCL-N</td></tr><tr><td>15</td><td>69</td><td>M</td><td>MCL</td><td>ND</td><td>Nasal/15MCL-N</td></tr><tr><td>16</td><td>65</td><td>M</td><td>MCL</td><td>ND</td><td>Oral/16MCL-O</td></tr><tr><td>17</td><td>63</td><td>F</td><td>ML</td><td>A</td><td>Nasal/17ML-N</td></tr><tr><td>18</td><td>53</td><td>M</td><td>ML</td><td>A</td><td>Nasal/18ML-N</td></tr><tr><td>19</td><td>66</td><td>F</td><td>ML</td><td>A</td><td>Nasal/19ML-N</td></tr><tr><td>20</td><td>71</td><td>M</td><td>ML</td><td>A</td><td>Nasal/20ML-N</td></tr><tr><td>21</td><td>12</td><td>M</td><td>ML</td><td>A</td><td>Nasal/21ML-N</td></tr><tr><td>22*</td><td>49</td><td>F</td><td>ML</td><td>A</td><td>Nasal/22ML-N</td></tr><tr><td>23*</td><td>69</td><td>M</td><td>ML</td><td>A</td><td>Nasal/23ML-N</td></tr><tr><td>24*</td><td>60</td><td>M</td><td>ML</td><td>A</td><td>Nasal/24ML-N</td></tr><tr><td>25*</td><td>77</td><td>M</td><td>ML</td><td>A</td><td>Nasal/25ML-N</td></tr><tr><td>26*</td><td>72</td><td>M</td><td>ML</td><td>A</td><td>Nasal/26ML-N</td></tr><tr><td>27*</td><td>71</td><td>F</td><td>ML</td><td>A</td><td>Nasal/27ML-N</td></tr><tr><td>28*</td><td>39</td><td>M</td><td>ML</td><td>A</td><td>Nasal/28ML-N</td></tr><tr><td>29*</td><td>63</td><td>M</td><td>ML</td><td>A</td><td>Nasal/29ML-N</td></tr><tr><td>30*</td><td>44</td><td>F</td><td>ML</td><td>A</td><td>Nasal/30ML-N</td></tr><tr><td rowspan="2">31*</td><td rowspan="2">31</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/31ML-N1</td></tr><tr><td>Nasal/31ML-N2</td></tr><tr><td rowspan="2">32*</td><td rowspan="2">29</td><td rowspan="2">F</td><td rowspan="2">ML</td><td rowspan="2">A</td><td>Nasal/32ML-N1</td></tr><tr><td>Nasal/32ML-N2</td></tr><tr><td>33*</td><td>72</td><td>F</td><td>ML</td><td>A</td><td>Oral/33LM-O</td></tr><tr><td rowspan="3">34</td><td rowspan="3">49</td><td rowspan="3">M</td><td rowspan="3">DL</td><td>Arm/ 34DL-C1</td><td rowspan="3">Nasal/34DL-N</td></tr><tr><td>Trunk/34DL-C2</td></tr><tr><td>Leg/34DL-C3</td></tr><tr><td>35</td><td>41</td><td>M</td><td>DL</td><td>Nose/35DL-C</td><td>Nasal/35DL-N</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Oral/35DL-O</td></tr></table>
0be0df9a64f01f87cda9b02feff47f61b9e5c41408160eb0a58e04c6f94b754e.png
complex
<table><tr><td></td><td>Tested population</td><td>NGO facilities</td><td>Services for migrants</td><td>DU services</td></tr><tr><td></td><td><i>N</i> = 2949 (%)</td><td><i>N</i> = 1597 (%)</td><td><i>N</i> = 928 (%)</td><td><i>N</i> = 424 (%)</td></tr><tr><td>Median age (IQR)</td><td>33 years (26&#8211;43)</td><td>31 years (25&#8211;41)</td><td>37 years (29&#8211;47)</td><td>35 years (28&#8211;44)</td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Men</td><td>1934 (65.6)</td><td>1123 (70.3)</td><td>531 (57.2)</td><td>280 (66. 0)</td></tr><tr><td> Women</td><td>973 (33)</td><td>445 (27.9)</td><td>391 (42.1)</td><td>137 (32.3)</td></tr><tr><td> Transgender</td><td>32 (1.1)</td><td>23 (1.5)</td><td>4 (0.4)</td><td>5 (1.2)</td></tr><tr><td> Unknown</td><td>10 (0.3)</td><td>6 (0.4)</td><td>2 (0.2)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Origin</td></tr><tr><td> Italian</td><td>1782 (60.4)</td><td>1432 (89.7)</td><td>86 (9.3)</td><td>264 (62.3)</td></tr><tr><td> Foreigners</td><td>1167 (39.6)</td><td>165 (10.3)</td><td>842 (90.7)</td><td>160 (37.7)</td></tr><tr><td colspan="5">Education (yy)</td></tr><tr><td>&#8804; 8</td><td>684 (23.2)</td><td>167 (10.5)</td><td>340 (36.6)</td><td>177 (41.7)</td></tr><tr><td>&gt; 8</td><td>2249 (76.3)</td><td>1421 (88.9)</td><td>583 (62.8)</td><td>245 (57.8)</td></tr><tr><td> Unknown</td><td>16 (0.5)</td><td>9 (0.6)</td><td>5 (0.6)</td><td>2 (0.5)</td></tr><tr><td colspan="5">Occupation</td></tr><tr><td> Employed</td><td>1478 (50.1)</td><td>939 (58.8)</td><td>413 (44.5)</td><td>126 (29.7)</td></tr><tr><td> Occasional employed</td><td>485 (16.4)</td><td>426 (26.7)</td><td>37 (4)</td><td>22 (5.2)</td></tr><tr><td> Unemployed</td><td>968 (32.8)</td><td>223 (14)</td><td>472 (50.9)</td><td>273 (64.4)</td></tr><tr><td> Unknown</td><td>18 (0.6)</td><td>9 (0.6)</td><td>6 (0.6)</td><td>3 (0.7)</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td> Never married</td><td>1895 (64.3)</td><td>1283 (80.3)</td><td>374 (40.3)</td><td>238 (56.1)</td></tr><tr><td> Married/Cohabiting</td><td>694 (23.5)</td><td>206 (12.9)</td><td>378 (40.7)</td><td>110 (25.9)</td></tr><tr><td> Married before</td><td>305 (10.3)</td><td>78 (4.9)</td><td>156 (16.8)</td><td>71 (16.7)</td></tr><tr><td> Unknown</td><td>55 (1.9)</td><td>30 (1.9)</td><td>20 (2.2)</td><td>5 (1.2)</td></tr><tr><td colspan="5">Previous HIV test</td></tr><tr><td> No</td><td>1334 (45.2)</td><td>565 (35.4)</td><td>613 (66.1)</td><td>156 (36.8)</td></tr><tr><td> Yes</td><td>1545 (52.4)</td><td>1016 (63.3)</td><td>283 (30.5)</td><td>246 (58.0)</td></tr><tr><td> Unknown</td><td>70 (2.4)</td><td>16 (1.0)</td><td>32 (3.4)</td><td>22 (5.2)</td></tr><tr><td colspan="5">Previous STI<sup>a</sup></td></tr><tr><td> No</td><td>2406 (81.6)</td><td>1289 (80.7)</td><td>777 (83.7)</td><td>431 (80.4)</td></tr><tr><td> Yes</td><td>392 (13.3)</td><td>257 (16.1)</td><td>90 (9.7)</td><td>45 (10.6)</td></tr><tr><td> Unknown</td><td>151 (5.1)</td><td>52 (3.3)</td><td>61 (6.6)</td><td>38 (9.0)</td></tr></table>
a22f87e3f822e11bb8ecf5767b9ceeaf40b1807f7427ed3f9eb67f72b4b49e82.png
simple
<table><tr><td>Diagnosis</td><td><i>n</i></td><td>Percent</td></tr><tr><td>Small for gestational age</td><td>11</td><td>26.8</td></tr><tr><td>Disseminated intravascular coagulation</td><td>5</td><td>12.2</td></tr><tr><td>Respiratory distress syndrome</td><td>7</td><td>17.1</td></tr><tr><td>Sepsis</td><td>21</td><td>51.2</td></tr><tr><td>Anemia</td><td>2</td><td>4.9</td></tr><tr><td>Shock</td><td>5</td><td>12.2</td></tr><tr><td>Meconium aspiration syndrome</td><td>2</td><td>4.9</td></tr><tr><td>Hypoxic ischaemic encephalopathy</td><td>19</td><td>46.3</td></tr><tr><td>Acute kidney injury</td><td>7</td><td>17.1</td></tr><tr><td>Meningitis</td><td>2</td><td>4.9</td></tr><tr><td>Pulmonary hemorrhage</td><td>2</td><td>4.9</td></tr><tr><td>Hyperbilirubinemia</td><td>3</td><td>7.3</td></tr><tr><td>Necrotising enterocolitis</td><td>1</td><td>2.4</td></tr><tr><td>Persistent pulmonary hypertension</td><td>3</td><td>7.3</td></tr><tr><td>Intracranial haemorrhage</td><td>1</td><td>2.4</td></tr><tr><td>Congenital heart disease</td><td>6</td><td>14.6</td></tr></table>
5fda7661b1b2c2f18aaa21981d9bf63b7e7f6f8392e142ba9da0d58cf1d73fbf.png
complex
<table><tr><td>Gastric ulcer model</td><td>Treatments (p.o.)</td><td>Dose (g/kg)</td><td><i>n</i></td><td>Ulcer index (mm)</td><td>Inhibition (%)</td></tr><tr><td rowspan="4">Ethanol-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>14.37 &#177; 2.88</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.04</td><td>8</td><td>11.27 &#177; 2.49<sup><i>&#8727;&#8727;</i></sup></td><td>29.01</td></tr><tr><td>AIG</td><td>1.50</td><td>8</td><td>3.11 &#177; 0.47<sup><i>&#8727;&#8727;</i></sup></td><td>80.43</td></tr><tr><td>AIG</td><td>0.75</td><td>8</td><td>4.46 &#177; 0.51<sup><i>&#8727;&#8727;</i></sup></td><td>71.93</td></tr><tr><td rowspan="4">Pylorus ligature-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>11.33 &#177; 3.78</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.55 &#177; 0.63<sup><i>&#8727;&#8727;</i></sup></td><td>68.68</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.76 &#177; 0.67<sup><i>&#8727;&#8727;</i></sup></td><td>75.63</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.36 &#177; 0.78<sup><i>&#8727;&#8727;</i></sup></td><td>70.33</td></tr><tr><td rowspan="4">Acetic acid-induced</td><td>Saline</td><td>&#8211;</td><td>8</td><td>10.26 &#177; 1.52</td><td>&#8211;</td></tr><tr><td>Ranitidine</td><td>0.03</td><td>8</td><td>3.89 &#177; 0.48<sup><i>&#8727;&#8727;</i></sup></td><td>64.37</td></tr><tr><td>AIG</td><td>1.0</td><td>8</td><td>2.84 &#177; 0.53<sup><i>&#8727;&#8727;</i></sup></td><td>72.49</td></tr><tr><td>AIG</td><td>0.5</td><td>8</td><td>3.38 &#177; 0.64<sup><i>&#8727;&#8727;</i></sup></td><td>63.15</td></tr></table>
f94c6b3b3896b385eece9f86ffd5c8672f9e36f0b11f93dffa79fb980fbdc224.png
simple
<table><tr><td>Characteristics</td><td>Total <i>(n = 140)</i></td><td>TB Group <i>(n = 70)</i></td><td>Control Group <i>(n = 70)</i></td><td><i>P </i>value</td></tr><tr><td>Gender: Male</td><td>95 (68%)</td><td>56 (80%)</td><td>39 (56%)</td><td>0.002</td></tr><tr><td>Age, years, mean &#177; SD</td><td>35.7 &#177; 7.6</td><td>34.4 &#177; 6.2</td><td>37.2 &#177; 8.7</td><td>0.028</td></tr><tr><td>Body weight, Kgs, mean &#177; SD</td><td>54.6 &#177; 9.6</td><td>54.7 &#177; 8.7</td><td>54.4 &#177; 10.6</td><td>0.827</td></tr><tr><td>Body mass index, mean &#177; SD</td><td>20.1 &#177; 2.9</td><td>19.7 &#177; 2.4</td><td>20.5 &#177; 3.4</td><td>0.097</td></tr><tr><td>CD4 cell counts, cells/mm<sup>3</sup>, mean &#177; SD</td><td>62 &#177; 74</td><td>61 &#177; 74</td><td>76 &#177; 75</td><td>0.823</td></tr><tr><td>%CD4, median (IQR)</td><td>5 &#177; 5</td><td>6 &#177; 5</td><td>5 &#177; 5</td><td>0.226</td></tr><tr><td>Plasma HIV RNA, copies/ml, median (IQR)</td><td>433,500 (169,000&#8211;750,000)</td><td>505,000 (269,000&#8211;750,000)</td><td>291,000 (94,600&#8211;714,000)</td><td>0.014</td></tr><tr><td>Plasma HIV RNA, Log copies/ml, median (IQR)</td><td>5.6 (5.2&#8211;5.9)</td><td>5.7 (5.4&#8211;5.9)</td><td>5.6 (5.0&#8211;5.9)</td><td>0.004</td></tr><tr><td>ALP, mg/dl, median (IQR)</td><td>98 (71&#8211;142)</td><td>110 (75&#8211;154)</td><td>91 (70&#8211;128)</td><td>0.072</td></tr><tr><td>AST, U/l, median (IQR)</td><td>30 (20&#8211;50)</td><td>36 (27&#8211;60)</td><td>35 (26&#8211;47)</td><td>0.371</td></tr><tr><td>ALT, U/l, median (IQR)</td><td>27 (19&#8211;42)</td><td>27 (18&#8211;51)</td><td>32 (22&#8211;49)</td><td>0.169</td></tr><tr><td>Total bilirubin, mg/dl, median (IQR)</td><td>0.6 (0.4&#8211;0.7)</td><td>0.6 (0.5&#8211;0.8)</td><td>0.5 (0.4&#8211;0.7)</td><td>0.051</td></tr></table>
09646d2365083a3f028efa2b478645049e985d83ef8ef79235d2fa1a3669bc60.png
complex
<table><tr><td colspan="6">Most significant GO Biological Processes</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Cholesterol biosynthesis</td><td>GO:0006695</td><td>12</td><td>20</td><td>7.04E-09</td><td>0.600</td></tr><tr><td>Nuclear mRNA splicing, via spliceosome</td><td>GO:0000398</td><td>29</td><td>110</td><td>9.77E-09</td><td>0.264</td></tr><tr><td>glycolysis</td><td>GO:0006096</td><td>14</td><td>39</td><td>1.16E-07</td><td>0.359</td></tr><tr><td>Protein biosynthesis</td><td>GO:0006412</td><td>38</td><td>247</td><td>8.00E-07</td><td>0.154</td></tr><tr><td>transport</td><td>GO:0006810</td><td>50</td><td>415</td><td>8.94E-07</td><td>0.120</td></tr><tr><td>Protein metabolism</td><td>GO:0019538</td><td>9</td><td>17</td><td>4.90E-06</td><td>0.529</td></tr><tr><td>Protein folding</td><td>GO:0006457</td><td>28</td><td>174</td><td>5.59E-06</td><td>0.161</td></tr><tr><td>Ribosome biogenesis</td><td>GO:0007046</td><td>6</td><td>14</td><td>3.22E-05</td><td>0.429</td></tr><tr><td>metabolism</td><td>GO:0008152</td><td>39</td><td>316</td><td>9.36E-05</td><td>0.123</td></tr><tr><td>tRNA processing</td><td>GO:0008033</td><td>8</td><td>33</td><td>5.32E-04</td><td>0.242</td></tr><tr><td>Regulation of the cyclin dependent protein kinase activity</td><td>GO:0000079</td><td>8</td><td>34</td><td>9.72E-04</td><td>0.235</td></tr><tr><td>Amino acid biosynthesis</td><td>GO:0008652</td><td>6</td><td>22</td><td>1.01E-03</td><td>0.273</td></tr><tr><td>Lipid metabolism</td><td>GO:0006629</td><td>24</td><td>193</td><td>1.02E-03</td><td>0.124</td></tr><tr><td>Regulation of progression through cell cycle</td><td>GO:0000074</td><td>27</td><td>200</td><td>1.14E-03</td><td>0.135</td></tr><tr><td>Cell cycle</td><td>GO:0007049</td><td>41</td><td>338</td><td>1.64E-03</td><td>0.121</td></tr><tr><td>Regulation of translational initiation</td><td>GO:0006446</td><td>7</td><td>22</td><td>1.88E-03</td><td>0.318</td></tr><tr><td colspan="6">Most significant GO Molecular Function.</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed Genes</td><td>Total Genes in Class</td><td>P-Value</td><td>Fraction</td></tr><tr><td>Nucleotide binding</td><td>GO:0000166</td><td>173</td><td>1405</td><td>6.92E-11</td><td>0.123</td></tr><tr><td>RNA binding</td><td>GO:0003723</td><td>78</td><td>389</td><td>4.22E-10</td><td>0.201</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016491</td><td>61</td><td>382</td><td>6.44E-10</td><td>0.160</td></tr><tr><td>ATP binding</td><td>GO:0005524</td><td>123</td><td>1116</td><td>1.20E-09</td><td>0.110</td></tr><tr><td>Unfolded protein binding</td><td>GO:0051082</td><td>28</td><td>143</td><td>2.68E-08</td><td>0.196</td></tr><tr><td>Protein binding</td><td>GO:0005515</td><td>220</td><td>2514</td><td>1.77E-07</td><td>0.088</td></tr><tr><td>Transferase activity</td><td>GO:0016740</td><td>101</td><td>958</td><td>1.86E-07</td><td>0.105</td></tr><tr><td>L-ascorbic acid binding</td><td>GO:0031418</td><td>6</td><td>11</td><td>1.65E-05</td><td>0.545</td></tr><tr><td>Lyase activity</td><td>GO:0016829</td><td>16</td><td>89</td><td>1.37E-04</td><td>0.180</td></tr><tr><td>binding</td><td>GO:0005488</td><td>47</td><td>399</td><td>2.37E-04</td><td>0.118</td></tr><tr><td>ATP-dependent RNA helicase activity</td><td>GO:0004004</td><td>7</td><td>18</td><td>4.61E-04</td><td>0.389</td></tr><tr><td>Isomerase activity</td><td>GO:0016853</td><td>15</td><td>90</td><td>5.54E-04</td><td>0.167</td></tr><tr><td>Ligase activity</td><td>GO:0016874</td><td>27</td><td>184</td><td>5.54E-04</td><td>0.147</td></tr><tr><td>Oxidoreductase activity</td><td>GO:0016702</td><td>6</td><td>18</td><td>6.72E-04</td><td>0.333</td></tr><tr><td>NAD binding</td><td>GO:0051287</td><td>8</td><td>24</td><td>7.05E-04</td><td>0.333</td></tr><tr><td>Catalytic activity</td><td>GO:0003824</td><td>27</td><td>192</td><td>7.40E-04</td><td>0.141</td></tr><tr><td>Transporter activity</td><td>GO:0005215</td><td>29</td><td>281</td><td>1.50E-03</td><td>0.103</td></tr><tr><td>Kinase activity</td><td>GO:0016301</td><td>22</td><td>163</td><td>1.65E-03</td><td>0.135</td></tr><tr><td>tRNA binding</td><td>GO:0000049</td><td>5</td><td>13</td><td>1.87E-03</td><td>0.385</td></tr><tr><td colspan="6">Most significant GO Cellular Component</td></tr><tr><td>GO Term</td><td>GO ID</td><td>Changed genes</td><td>Total genes in class</td><td>P-value</td><td>Fraction</td></tr><tr><td>cytoplasm</td><td>GO:0005737</td><td>114</td><td>895</td><td>5.00E-10</td><td>0.127</td></tr><tr><td>nucleus</td><td>GO:0005634</td><td>281</td><td>2999</td><td>5.00E-10</td><td>0.094</td></tr><tr><td>mitochondrion</td><td>GO:0005739</td><td>70</td><td>528</td><td>1.01E-09</td><td>0.133</td></tr><tr><td>endoplasmic reticulum</td><td>GO:0005783</td><td>49</td><td>405</td><td>2.47E-06</td><td>0.121</td></tr><tr><td>mitochondrial inner membrane presequence translocase complex</td><td>GO:0005744</td><td>5</td><td>11</td><td>2.82E-04</td><td>0.455</td></tr><tr><td>soluble fraction</td><td>GO:0005625</td><td>24</td><td>194</td><td>3.22E-04</td><td>0.124</td></tr><tr><td>nucleolus</td><td>GO:0005730</td><td>12</td><td>59</td><td>1.09E-03</td><td>0.203</td></tr></table>
93b6a0568ab67bdea09f45bc798579fffe9df45946324a28cd2cdd33ae11b378.png
complex
<table><tr><td>Parameters</td><td colspan="2">Vildagliptin (n-29)</td><td>P value*</td><td colspan="2">Placebo (n-29)</td><td>P value*</td><td>P value<sup>+</sup></td></tr><tr><td></td><td>Pre treatment</td><td>Post treatment</td><td></td><td>Pre-treatment</td><td>Post treatment</td></tr><tr><td>Body weight(kg)</td><td>88&#177;11.3</td><td>79&#177;12.6</td><td>0.036</td><td>82 &#177;16.4</td><td>81&#177;12.4</td><td>0.74</td><td>0.04</td></tr><tr><td>BMI(kg/m<sup>2</sup>)</td><td>30.7&#177;4.2</td><td>27.5&#177;5.2</td><td>0.005</td><td>29.6 &#177;0.4</td><td>29.4&#177;0.7</td><td>0.88</td><td>0.028</td></tr><tr><td>TC (mg/dl)</td><td>252.6&#177;24.4</td><td>220.6&#177;20.2</td><td>0.031</td><td>260&#177; 28.5</td><td>262&#177;28.2</td><td>0.62</td><td>0.01</td></tr><tr><td>TG(mg/dl)</td><td>190&#177;24.9</td><td>115&#177;22.9</td><td>0.005</td><td>197&#177;21.2</td><td>199&#177;20.4</td><td>0.88</td><td>0.001</td></tr><tr><td>LDL-C(mg/dl</td><td>160&#177;15.24</td><td>145&#177;13.2</td><td>0.004</td><td>169&#177;12.8</td><td>167&#177;11.2</td><td>0.57</td><td>0.011</td></tr><tr><td>HDL-C(mg/dl)</td><td>29.6&#177;5.8</td><td>45.5&#177;4.9</td><td>0.001</td><td>28.3&#177;6.0</td><td>33&#177;6.2</td><td>0.98</td><td>0.02</td></tr><tr><td>ALT(IU/L)</td><td>78.2&#177;17.2</td><td>48.6&#177;14.8</td><td>0.036</td><td>76&#177;18.9</td><td>72&#177;2.2</td><td>0.76</td><td>0.04</td></tr><tr><td>AST(IU/L)</td><td>63.5&#177;10.5</td><td>41.5&#177; 9.6</td><td>0.002</td><td>61.2&#177;11.1</td><td>58&#177;10.5</td><td>0.81</td><td>0.001</td></tr><tr><td>GGT (IU/L)</td><td>18.5&#177;5.8</td><td>19.7&#177;7.7</td><td>0.62</td><td>19.7&#177;6.43</td><td>20.8&#177;7.5</td><td>0.43</td><td>0.67</td></tr></table>
380704db9284ab8defc23b6e7acb8a958af471eaf8c870f9ef8e28829c6654a3.png
simple
<table><tr><td>Feature</td><td>Control group (A)</td><td>Study group (B)</td></tr><tr><td>Number of pin-sites</td><td>268</td><td>368</td></tr><tr><td>AO tubular external fixation</td><td>43</td><td>41</td></tr><tr><td>Unilateral rail</td><td>0</td><td>2</td></tr><tr><td>Ilizarov device</td><td>6</td><td>8</td></tr><tr><td>Pin tract infection (patients)<sup>a</sup></td><td>11 (22.5 %)</td><td>2 (4.1 %)</td></tr><tr><td>Pin tract infection (pin-sites)<sup>a</sup></td><td>38 (14.2 %)</td><td>7 (1.9 %)</td></tr></table>
6381676b6a4f28642224e4e0b695e0f88608b6726092f10efb2bd6c784f651a6.png
simple
<table><tr><td>Trials</td><td> </td><td>Intervention (<i>n</i>/<i>N</i>)</td><td>Control (<i>n</i>/<i>N</i>)</td><td>RR (95% CI)</td><td><i>P </i>value</td></tr><tr><td>LWDHW plus enalapril versus enalapril</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr><tr><td>Meta-analysis</td><td>1</td><td>34/42</td><td>21/36</td><td>3.04 (1.10, 8.38)</td><td>0.03</td></tr></table>
16e67e3aaa3be8153f6dfe75c280e7d80a4e834613f55d4190f026e5012370d5.png
complex
<table><tr><td></td><td colspan="2">Non-hospitalsN = 191</td><td colspan="2">HospitalsN = 34</td><td>Chi-square (p-value)</td></tr><tr><td></td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td>Yesn (%)</td><td>Don't normally stockn (%)</td><td></td></tr><tr><td>AMT</td><td>17</td><td>18</td><td>2</td><td>13</td><td>23.0 (.0001)</td></tr><tr><td>CQ</td><td>111</td><td>1</td><td>5</td><td>1</td><td>20.4 (.0001)</td></tr><tr><td>Antibiotics</td><td>16</td><td>5</td><td>4</td><td>3</td><td>4.6 (.10)</td></tr><tr><td>SP</td><td>97</td><td>11</td><td>3</td><td>6</td><td>21.0 (.0001)</td></tr><tr><td>Quinine</td><td>17</td><td>25</td><td>5</td><td>9</td><td>7.5 (.023)</td></tr><tr><td>Halofantrine</td><td>24</td><td>28</td><td>3</td><td>14</td><td>15.9 (.0001)</td></tr><tr><td>Others</td><td>46</td><td>5</td><td>5</td><td>1</td><td>1.0 (.60)</td></tr></table>
ffe74f072a1af365443c483dc9d39e9f1c6152d70a581b6cb9802a45474b4daa.png
simple
<table><tr><td>Isolate</td><td>Collection</td><td>Country</td><td>Yr of entry into collection</td><td>Sequencing technology</td><td>Reference</td></tr><tr><td>NCTC86_Dunne</td><td>NCTC</td><td>England</td><td>1920</td><td>Pacific Biosciences RS II, Illumina</td><td>2</td></tr><tr><td>NCTC86_Meric</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td><td>4</td></tr><tr><td>NCTC86</td><td>NCTC</td><td>England</td><td>1920</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>CIP61.11</td><td>Centre de Ressources Biologiques de l&#8217;Institut Pasteur</td><td>France</td><td>1961</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>ATCC 4157</td><td>ATCC</td><td>United States</td><td>Unknown</td><td>Illumina MiSeq</td><td>This study</td></tr><tr><td>DSM301</td><td>DSMZ</td><td>Germany</td><td>1970</td><td>Illumina MiSeq</td><td>This study</td></tr></table>
8fdc3e31cafeac7499b63c876a68382c69f8536d05358fe8114d06e628b98f0b.png
complex
<table><tr><td></td><td colspan="2">Placebo (<i>N </i>= 112)</td><td colspan="2">25 mg/d Neramexane (<i>N </i>= 108)</td><td colspan="2">50 mg/d Neramexane (<i>N </i>= 107)</td><td colspan="2">75 mg/d Neramexane (<i>N </i>= 102)</td></tr><tr><td></td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td></tr><tr><td>Any adverse event</td><td>4</td><td>3.6</td><td>7</td><td>6.5</td><td>9</td><td>8.4</td><td>21</td><td>20.6</td></tr><tr><td> Dizziness</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>7</td><td>6.5</td><td>15</td><td>14.7</td></tr><tr><td> Vertigo</td><td>0</td><td>0.0</td><td>1</td><td>0.9</td><td>2</td><td>1.9</td><td>5</td><td>4.9</td></tr><tr><td> Nausea</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>2</td><td>2.0</td></tr><tr><td> Fatigue</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>3</td><td>2.9</td></tr></table>
e1f84b58e16d4ed114576f2274a11efc48770c7a3b7f22b5acb889cb8119d05d.png
complex
<table><tr><td colspan="6">Prevalence of elevated CRP (&gt;10 mg/L)</td></tr><tr><td>Group</td><td></td><td>%</td><td>Univariate p-value</td><td>Multivariate OR *</td><td>Multivariate p-value**</td></tr><tr><td>Age</td><td>&lt;50</td><td>14</td><td>0.49</td><td></td><td></td></tr><tr><td></td><td>50&#8211;59</td><td>13</td><td></td><td></td><td></td></tr><tr><td></td><td>60&#8211;69</td><td>13</td><td></td><td></td><td></td></tr><tr><td></td><td>70+</td><td>18</td><td></td><td></td><td></td></tr><tr><td>Sex</td><td>Male</td><td>14</td><td>0.28</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>18</td><td></td><td></td><td></td></tr><tr><td>NIHSS</td><td>&lt;7</td><td>13</td><td>0.015</td><td>(ref)</td><td>0.03</td></tr><tr><td></td><td>7&#8211;13</td><td>25</td><td></td><td>2.15</td><td></td></tr><tr><td></td><td>14+</td><td>21</td><td></td><td>1.89</td><td></td></tr><tr><td>OCSP classification</td><td>LACI</td><td>15</td><td>0.005</td><td></td><td></td></tr><tr><td></td><td>TACI</td><td>26</td><td></td><td></td><td></td></tr><tr><td></td><td>PACI</td><td>10</td><td></td><td></td><td></td></tr><tr><td></td><td>POCI</td><td>19</td><td></td><td></td><td></td></tr><tr><td>Prior Cerebrovascular disease</td><td>No</td><td>16</td><td>0.97</td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>16</td><td></td><td></td><td></td></tr><tr><td>Pre-existing diabetes mellitus</td><td>No</td><td>14</td><td>0.01</td><td>(ref)</td><td>0.04</td></tr><tr><td></td><td>Yes</td><td>27</td><td></td><td>1.96</td><td></td></tr><tr><td>Smoking habits</td><td>Never smoker</td><td>19</td><td>0.29</td><td></td><td></td></tr><tr><td></td><td>Former smoker</td><td>14</td><td></td><td></td><td></td></tr><tr><td></td><td>Current smoker</td><td>12</td><td></td><td></td><td></td></tr><tr><td>Time to hospital</td><td>&lt;3 hours</td><td>13</td><td>0.20</td><td></td><td></td></tr><tr><td></td><td>3&#8211;5.9 hours</td><td>20</td><td></td><td></td><td></td></tr><tr><td></td><td>6&#8211;11.9 hours</td><td>10</td><td></td><td></td><td></td></tr><tr><td></td><td>12&#8211;23.9 hours</td><td>18</td><td></td><td></td><td></td></tr><tr><td></td><td>Woke up with Stroke (&lt;24 hours)</td><td>17</td><td></td><td></td><td></td></tr><tr><td></td><td>Other (&lt;24 hours)</td><td>26</td><td></td><td></td><td></td></tr></table>
f9b1af56ad42e58079a2ac526a9004f8e369c969ab59730d6ad6aa68b3c7bf3d.png
complex
<table><tr><td> </td><td colspan="2">Insular cortex</td><td rowspan="2">Posterior cingulate cortex</td></tr><tr><td> </td><td>Right</td><td>Left</td></tr><tr><td>No. of participants</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Peak latency (ms)</td><td>191.0 &#177; 10.6</td><td>184.0 &#177; 4.6</td><td>468.0 &#177; 13.5</td></tr><tr><td>GOF (%)</td><td>95.3 &#177; 2.1</td><td>93.5 &#177; 1.6</td><td>95.8 &#177; 1.5</td></tr><tr><td>Intensity (nA &#183; m)</td><td>25.0 &#177; 2.8</td><td>16.7 &#177; 2.5</td><td>16.4 &#177; 3.3</td></tr><tr><td>Locations*</td><td> </td><td> </td><td> </td></tr><tr><td> x (mm)</td><td>41.8 &#177; 2.7</td><td>&#8722;41.7 &#177; 3.1</td><td>&#8722;8.3 &#177; 2.6</td></tr><tr><td> y (mm)</td><td>&#8722;20.8 &#177; 4.2</td><td>&#8722;26.2 &#177; 6.1</td><td>&#8722;47.3 &#177; 5.0</td></tr><tr><td> z (mm)</td><td>8.9 &#177; 4.2</td><td>3.3 &#177; 7.9</td><td>25.7 &#177; 6.4</td></tr><tr><td>Orientations*</td><td> </td><td> </td><td> </td></tr><tr><td> &#952; (degrees)</td><td>43.6 &#177; 12.9</td><td>34.8 &#177; 5.7</td><td>116.5 &#177; 23.3</td></tr><tr><td> &#966; (degrees)</td><td>82.6 &#177; 9.3</td><td>99.7 &#177; 12.9</td><td>275.6 &#177; 56.1</td></tr></table>
12372347dd4830ec385018ef16b672975711a9e7d552437ad880f5300715b3f7.png
simple
<table><tr><td></td><td>Males (n = 196)</td><td>Females (n = 210)</td><td>Total (n = 406)</td></tr><tr><td>Career aspiration</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Private practice (n = 192)</td><td>1.18 (1.44)</td><td>0.61 (0.98)</td><td>0.84 (1.22)</td></tr><tr><td>Hospital career (n = 172)</td><td>2.19 (2.16)</td><td>1.25 (1.41)</td><td>1.72 (1.88)</td></tr><tr><td>Academic career (n = 42)</td><td>6.66 (2.28)</td><td>4.78 (2.49)</td><td>6.24 (2.80)</td></tr><tr><td>Total (n = 406)</td><td>2.51 (2.77)</td><td>1.05 (1.51)</td><td>1.76 (2.33)</td></tr><tr><td>Effect</td><td>F</td><td>P</td><td>Partial eta squared</td></tr><tr><td>Gender</td><td>F(1,400) = 21.77</td><td>0.001</td><td>0.05</td></tr><tr><td>Career aspiration</td><td>F(2,400) = 101.61</td><td>&lt;0.001</td><td>0.34</td></tr><tr><td>Gender &#215; Career aspiration</td><td>F(2,400) = 2.04</td><td>0.131</td><td>0.01</td></tr></table>
5398953270c4d87f2c9931e2d94a3ae6a987028ff05c6c0aaa16dbcca2a4c66d.png
simple
<table><tr><td></td><td>Odds ratio</td><td>95% Confidentialinterval</td><td><i>P</i>-value</td></tr><tr><td>Laboratory variables</td><td></td><td></td><td></td></tr><tr><td>Gamma-glutamyltranspeptidase, IU/L</td><td>1.009</td><td>0.953, 1.068</td><td>0.757</td></tr><tr><td>Cumulative dose of medications, mg</td><td></td><td></td><td></td></tr><tr><td>Leflunomide (53 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.007</td></tr><tr><td>Prednisolone (89 patients)</td><td>1.000</td><td>1.000, 1.000</td><td>0.547</td></tr></table>
618c16b01d28d2472741ae491f4bd5b2482cce3c2ca86f8cc8ca1d4f730afc27.png
simple
<table><tr><td>Clinical presentatiton</td><td>No. of patients</td><td>No. of episods</td><td>Time* (median/month)</td><td>Treatment</td></tr><tr><td>Cholangitis</td><td>5</td><td>9</td><td>19.5 (14&#8211;47)</td><td>Medical</td></tr><tr><td> -without real stricture</td><td>3</td><td>3</td><td>28.3</td><td>Medical</td></tr><tr><td> -with real stricture</td><td>2</td><td>6</td><td>15.5</td><td>Endoscopic (dilatation and/or stenting)</td></tr><tr><td>CBD stone</td><td>2</td><td>2</td><td>21.5 (16&#8211;27)</td><td>Endoscopic (stone extraction)</td></tr><tr><td>Total</td><td>7</td><td>11</td><td></td><td></td></tr></table>
f4468aef0d2094bef50b01cd4d4737674626fb82c87e5d1a6b0f8f83310754f1.png
complex
<table><tr><td> </td><td colspan="5">Awareness of ESCCAP Heartworm Guidelines</td><td> </td></tr><tr><td> </td><td colspan="5">Number clinics responding (% responding)</td><td> </td></tr><tr><td>Country</td><td>Not aware</td><td>Slightly aware</td><td>Moderately aware</td><td>Quite aware</td><td>Very aware</td><td>Responders</td></tr><tr><td>UK (non-endemic)</td><td>22 (67)</td><td>5 (15)</td><td>3 (9)</td><td>3 (9)</td><td>0 (0)</td><td>33</td></tr><tr><td>Germany (non-endemic)</td><td>40 (40)</td><td>38 (38)</td><td>20 (20)</td><td>3 (3)</td><td>0 (0)</td><td>101</td></tr><tr><td>Netherlands (non-endemic)</td><td>32 (94)</td><td>1 (3)</td><td>1 (3)</td><td>0 (0)</td><td>0 (0)</td><td>34</td></tr><tr><td>France (non-endemic)</td><td>63 (73)</td><td>9 (10)</td><td>10 (12)</td><td>2 (2)</td><td>2 (2)</td><td>86</td></tr><tr><td>France (endemic)</td><td>29 (62)</td><td>9 (19)</td><td>4 (9)</td><td>4 (9)</td><td>1 (2)</td><td>47</td></tr><tr><td>Spain (non-endemic)</td><td>25 (37)</td><td>13 (19)</td><td>22 (32)</td><td>6 (9)</td><td>2 (3)</td><td>68</td></tr><tr><td>Spain (endemic)</td><td>15 (37)</td><td>4 (10)</td><td>10 (24)</td><td>9 (22)</td><td>3 (7)</td><td>41</td></tr><tr><td>Italy (non-endemic)</td><td>35 (52)</td><td>11 (16)</td><td>14 (21)</td><td>5 (7)</td><td>2 (3)</td><td>67</td></tr><tr><td>Italy (endemic)</td><td>56 (52)</td><td>19 (18)</td><td>20 (19)</td><td>8 (7)</td><td>4 (4)</td><td>107</td></tr><tr><td>Total (non-endemic)</td><td>217 (56)</td><td>77 (20)</td><td>70 (18)</td><td>19 (5)</td><td>6 (2)</td><td>389</td></tr><tr><td>Total (endemic)</td><td>100 (51)</td><td>32 (16)</td><td>34 (17)</td><td>21 (11)</td><td>8 (4)</td><td>195</td></tr><tr><td>Total</td><td>317 (54)</td><td>109 (19)</td><td>104 (18)</td><td>40 (7)</td><td>14 (2)</td><td>584</td></tr></table>
cdd86b7310d60f3433a4ee4a12383e6c5d2c7085adbaa542dd0086b9768e281f.png
simple
<table><tr><td>Type of model or algorithm</td><td>Target product</td><td>Model-based target: knockout gene A or overexpress gene B</td><td>References</td></tr><tr><td>Dynamic flux balance analysis</td><td>Ethanol</td><td>Ethanol production pathway after 20 h</td><td>[163]</td></tr><tr><td>Genome-scale metabolic model</td><td>Prediction of growth rate with respect to photosynthetic quotient for ethanol and butanol production</td><td>Double reaction knock out of hydrolyase and dehydrogenase</td><td>[164]</td></tr><tr><td>In vivo carbon flux analysis</td><td>Homolanthionine</td><td>Deletion of methionine and cysteine biosynthesis repressor protein</td><td>[165]</td></tr><tr><td>Metabolic flux analysis</td><td>Hydrogen production</td><td>Deletion and addition of GAP1 and dehydrogenase, respectively</td><td>[166]</td></tr><tr><td>Metabolic flux analysis</td><td>Astaxanthin synthesis</td><td>&#8211;</td><td>[167]</td></tr><tr><td>Metabolic flux analysis</td><td>Fixed more CO<sub>2</sub> and had a higher biomass yield</td><td>Alternate pathway for isoleucine synthesis (via citramalate synthase, CimA</td><td>[168]</td></tr><tr><td>Metabolic net fluxes</td><td>Hydrogen production</td><td>Disruption of hydrogenase and poly-&#946;-hydroxybutyrate synthase</td><td>[169]</td></tr></table>
fad23e29abf6cdc4ffe204b801328adc3cafc93637dbb245b0e76639af474f88.png
complex
<table><tr><td colspan="2">Severity of stress</td></tr><tr><td><i>n</i> = 85</td><td>%</td></tr><tr><td>Severe</td><td>33</td></tr><tr><td>Moderate</td><td>27</td></tr><tr><td>Extreme</td><td>22</td></tr><tr><td>None/light</td><td>8</td></tr><tr><td>Catastrophic</td><td>6</td></tr></table>
3083d5f0ce0722431af6d04c1bc0e68b248c0f818055bff9e2770c2759277424.png
complex
<table><tr><td colspan="2"> </td><td><i>N</i></td><td>%</td><td>Age (mean &#177; SD)</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>50</td><td>54.0%</td><td rowspan="2">39.60 &#177; 7.32</td></tr><tr><td>Female</td><td>40</td><td>46.0%</td></tr></table>
c0003d710a380e3f0be04b76e5a38166bbafa883e1fa7839667c3510290c2410.png
complex
<table><tr><td> </td><td colspan="6">Any first-degree relative</td></tr><tr><td> </td><td colspan="3">History of cancer (any site)</td><td colspan="3">History of head and neck cancer</td></tr><tr><td> </td><td><sup>&#8225;</sup>No</td><td>Yes</td><td>OR (95% CI)<sup>&#8224;</sup></td><td><sup>&#167;</sup>No</td><td>Yes</td><td>OR (95% CI)<sup>&#8224;</sup></td></tr><tr><td> </td><td>Cases/controls</td><td>Cases/controls</td><td> </td><td>Cases/controls</td><td>Cases/controls</td><td> </td></tr><tr><td>Smoking</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Never</td><td>19/563</td><td>27/559</td><td>1.1 (0.6-2.1)</td><td>35/994</td><td>6/51</td><td>2.4 (1.0-7.0)</td></tr><tr><td>Ever</td><td>231/1002</td><td>306/1030</td><td>1.3 (1.1-1.5)</td><td>427/1785</td><td>58/104</td><td>2.7 (1.8-3.4)</td></tr><tr><td>Drinking</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804;2 glasses/day</td><td>75/961</td><td>75/954</td><td>0.9 (0.6-1.4)</td><td>123/1704</td><td>11/88</td><td>1.9 (1.0-3.5)</td></tr><tr><td>&gt;2 glasses/day</td><td>167/597</td><td>254/631</td><td>1.4 (1.0-1.8)</td><td>329/1066</td><td>52/67</td><td>2.6 (1.2-3.3)</td></tr><tr><td colspan="2">Smoking &amp; drinking</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>NS &amp; D &#8804;2 glasses/day</td><td>16/412</td><td>17/425</td><td>0.9 (0.4-1.9)</td><td>30/740</td><td>1/39</td><td>1.2 (0.3-4.7)</td></tr><tr><td>ES &amp; D &#8804;2 glasses/day</td><td>59/548</td><td>58/526</td><td>0.9 (0.6-1.4)</td><td>93/962</td><td>10/47</td><td>1.6 (1.0-3.9)</td></tr><tr><td>NS &amp; D &gt;2 glasses/day</td><td>3/147</td><td>8/129</td><td>2.7 (0.6-11.6)</td><td>5/248</td><td>4/10</td><td>18.8 (2.9-119.8)</td></tr><tr><td>ES &amp; D &gt;2 glasses/day</td><td>164/449</td><td>246/499</td><td>1.4 (1.0-1.8)</td><td>324/815</td><td>48/57</td><td>2.1 (1.3-2.9)</td></tr></table>
c5e9f5e53084f43e43157bbb2a3214b82d5b18ed96eb8b55675c289a2b50134f.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>HR</td><td>95% CI</td><td><i>P</i> value</td><td>HR</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>Sex (Female, Male)</td><td>1.2533</td><td>0.7767-2.0222</td><td>0.3550</td><td colspan="3"></td></tr><tr><td>Age (&#8804; 60, &gt; 60)</td><td>0.6990</td><td>0.4635-1.0542</td><td>0.0876</td><td colspan="3"></td></tr><tr><td>Macroscopic types (Ul, Fu, Me)</td><td>1.0699</td><td>0.7665-1.4935</td><td>0.6912</td><td colspan="3"></td></tr><tr><td>Tumor location (Up, Mi, Lo)</td><td>0.9403</td><td>0.6827-1.2950</td><td>0.7061</td><td colspan="3"></td></tr><tr><td>Tumor size (&#8804; 5, &gt; 5)</td><td>2.3524</td><td>0.8957-2.0419</td><td>0.1510</td><td colspan="3"></td></tr><tr><td>pT (T1-2, T3-4)</td><td>1.3584</td><td>0.7046-2.6187</td><td>0.3604</td><td colspan="3"></td></tr><tr><td>pN (N0, N1-3)</td><td>2.0212</td><td>1.3201-3.0947</td><td>0.0012</td><td>1.8234</td><td>1.1259-2.9528</td><td>0.0146</td></tr><tr><td>Grade (G1, G2, G3)</td><td>1.0777</td><td>0.7912-1.4679</td><td>0.6352</td><td colspan="3"></td></tr><tr><td>Stage (I/IIA, IIB/IIIC)</td><td>1.9646</td><td>1.0188-3.7884</td><td>0.0438</td><td>1.3322</td><td>0.6337-2.8008</td><td>0.4493</td></tr><tr><td>ANO1 (Neg, Pos)</td><td>1.9141</td><td>1.2729-2.8782</td><td>0.0018</td><td>1.9031</td><td>1.2653-2.8624</td><td>0.0020</td></tr></table>
b3b07a886640a8b58e68ae35592f1e922b79e67902cad97fdee399bf49fac84d.png
complex
<table><tr><td></td><td colspan="2">Pre-VT SC-IAT</td><td colspan="2">Embodiment after first session of VT</td><td colspan="2">Embodiment after second session of VT</td><td colspan="2">Post-VT SC-IAT</td></tr><tr><td></td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td><td><i>M</i></td><td>SD</td></tr><tr><td>Synch black</td><td>0.01</td><td>0.38</td><td>0.91</td><td>1.32</td><td>1.14</td><td>1.31</td><td>0.05</td><td>0.30</td></tr><tr><td>Synch white</td><td>-0.05</td><td>0.35</td><td>1.32</td><td>1.46</td><td>1.31</td><td>1.68</td><td>-0.01</td><td>0.37</td></tr><tr><td>Asynch black</td><td>0.01</td><td>0.44</td><td>-0.82</td><td>1.51</td><td>-0.39</td><td>1.71</td><td>-0.11</td><td>0.28</td></tr><tr><td>Asynch white</td><td>0.05</td><td>0.35</td><td>-0.93</td><td>1.46</td><td>-0.74</td><td>1.64</td><td>0.10</td><td>0.37</td></tr></table>
73d2272368e805637c8c419454b12ec6b3d9752b8df7b76997ce03bd57032097.png
complex
<table><tr><td rowspan="3">Group</td><td rowspan="3">n</td><td rowspan="3">Age (year)</td><td rowspan="3">Infertility duration (year)</td><td rowspan="3">BMI</td><td colspan="4">Reproductive hormone level</td></tr><tr><td>FSH/IU&#183;L<sup>-1</sup></td><td>LH/IU&#183;L<sup>-1</sup></td><td>E2/pg&#183;mL<sup>-1</sup></td><td>T/mmol&#183;L<sup>-1</sup></td></tr><tr><td>LE group</td><td>52</td><td>26.4&#177;4.2</td><td>3.4&#177;1.1</td><td>22.4&#177;4.5</td><td>7.1&#177;1.5</td><td>5.7&#177;1.1</td><td>57.7&#177;13.5</td><td>1.41&#177;0.5</td></tr><tr><td>CC group</td><td>52</td><td>27.1&#177;4.7</td><td>3.2&#177;0.7</td><td>23.4&#177;1.5</td><td>6.9&#177;1.2</td><td>5.5&#177;0.9</td><td>54.5&#177;12.7</td><td>1.45&#177;0.3</td></tr><tr><td>LE + HMG group</td><td>52</td><td>27.7&#177;5.2</td><td>3.3&#177;1.3</td><td>22.6&#177;2.6</td><td>6.8&#177;1.1</td><td>5.9&#177;1.2</td><td>61.5&#177;15.8</td><td>1.42&#177;0.2</td></tr><tr><td>F</td><td>-</td><td>0.703</td><td>0.311</td><td>0.515</td><td>0.211</td><td>0.163</td><td>1.635</td><td>1.785</td></tr><tr><td>P</td><td>-</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td><td>&gt;0.05</td></tr></table>
42e3dae8597b8ff4119c06b0fa9007c1381c0894148373c0903d60356aa3643b.png
simple
<table><tr><td></td><td>Input type</td><td>Database update</td><td>Functional Database support</td><td>Multiple organism support</td><td>Limitations for input genes</td><td>Statistics</td></tr><tr><td>GeneSCF v1.1</td><td>List of genes</td><td>Real-time</td><td>KEGG, GO, Reactome and NCG</td><td>Yes</td><td>No upper or lower limit</td><td>FE test <sup>a</sup> &amp; FDR <sup>b</sup></td></tr><tr><td>GeneSCF v1.0</td><td>List of genes</td><td>Manual (preparation needed)</td><td>KEGG, GO, Reactome and NCG</td><td>No (<i>Homo sapiens</i>)</td><td>No upper or lower limit</td><td>FE test &amp; FDR</td></tr><tr><td>GOrilla</td><td>List of genes</td><td>Weekly auto-update</td><td>GO</td><td>Yes</td><td>No upper limit but has lower limit</td><td>FE test &amp; FDR</td></tr><tr><td>DAVID 6.7</td><td>List of genes</td><td>Last known update 2010)</td><td>KEGG, GO, Reactome and Biocarta</td><td>Yes</td><td>Upper limit 3000 and no lower limit</td><td>FE test &amp; FDR</td></tr></table>
fb4326c5de8dcb7a40b870d7d2d857a601e0fa96bc0623091e22c74843293daa.png
complex
<table><tr><td>DHFR</td><td colspan="5">Regions (%)</td><td>Total N (%)</td></tr><tr><td>Repeat Type</td><td>Delhi</td><td>Nadiad</td><td>Panna</td><td>Chennai</td><td>Kamrup</td><td></td></tr><tr><td>Type 1</td><td>54.54</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>8 (11.26)</td></tr><tr><td>Type 2</td><td>36.34</td><td>100</td><td>76.47</td><td>100</td><td>100</td><td>60 (84.5)</td></tr><tr><td>Type 3</td><td>9.09</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (1.4)</td></tr><tr><td>Type 4</td><td>0</td><td>0</td><td>11.76</td><td>0</td><td>0</td><td>2 (2.81)</td></tr><tr><td>Total (N)</td><td>11</td><td>3</td><td>17</td><td>19</td><td>21</td><td>71</td></tr><tr><td colspan="7">DHPS</td></tr><tr><td>Type A</td><td>10</td><td>10</td><td>0</td><td>5</td><td>21.05</td><td>9.27</td></tr><tr><td>Type B</td><td>90</td><td>85</td><td>83.34</td><td>90</td><td>26.31</td><td>75.25</td></tr><tr><td>Type C</td><td>0</td><td>0</td><td>5.55</td><td>5</td><td>0</td><td></td></tr><tr><td>Type D</td><td>0</td><td>5</td><td>5.55</td><td>0</td><td>15.79</td><td>5.15</td></tr><tr><td>Type E</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type F</td><td>0</td><td>0</td><td>0</td><td>0</td><td>10.52</td><td>2.06</td></tr><tr><td>Type G</td><td>0</td><td>0</td><td>5.55</td><td>0</td><td>10.52</td><td>3.09</td></tr><tr><td>Type H</td><td>0</td><td>0</td><td>0</td><td>0</td><td>5.26</td><td>1.03</td></tr><tr><td>Total (N)</td><td>20</td><td>20</td><td>18*</td><td>20</td><td>19*</td><td>97</td></tr></table>
7239276a48784427fd77c047178a18e8bec860617499717089cdaf0d34cfa400.png
simple
<table><tr><td>Items</td><td>Cronbach&#8217;s alpha if items were deleted</td></tr><tr><td>Physical functioning</td><td>0.845</td></tr><tr><td>Mental health</td><td>0.847</td></tr><tr><td>Vitality</td><td>0.849</td></tr><tr><td>Role physical</td><td>0.858</td></tr><tr><td>General health</td><td>0.853</td></tr><tr><td>Bodily pain</td><td>0.857</td></tr><tr><td>Role emotional</td><td>0.862</td></tr><tr><td>Social functioning</td><td>0.856</td></tr><tr><td>Educational rescue policy</td><td>0.871</td></tr><tr><td>Orphan rescue policy</td><td>0.871</td></tr><tr><td>Employment rescue policy</td><td>0.871</td></tr><tr><td>Poverty rescue policy</td><td>0.871</td></tr><tr><td>Social security policy</td><td>0.872</td></tr><tr><td>Legal rescue policy</td><td>0.872</td></tr></table>
c18afd04261552ab10312747cee2a43ae0fe83363f72c79a0c45e72f051ee565.png
simple
<table><tr><td>Crude extract<sup>a</sup></td><td>Yield<sup>b</sup>(g)</td><td>Yield<sup>c</sup>(% of pollen sample)</td><td>Appearance</td></tr><tr><td><i>Corn bee pollen extracts</i></td><td> </td><td> </td><td> </td></tr><tr><td>CMEb</td><td>35.29</td><td>8.40</td><td>Dark brown sticky solid</td></tr><tr><td>CDEb</td><td>2.40</td><td>0.57</td><td>Dark brown solid</td></tr><tr><td>CHEb</td><td>18.13</td><td>4.32</td><td>Yellow solid</td></tr><tr><td><i>Floral corn pollen extracts</i></td><td> </td><td> </td><td> </td></tr><tr><td>CMEp</td><td>9.02</td><td>2.15</td><td>Dark brown solid</td></tr><tr><td>CDEp</td><td>4.82</td><td>1.15</td><td>Brown solid</td></tr><tr><td>CHEp</td><td>7.87</td><td>1.87</td><td>Dark green oil/wax</td></tr></table>
190cc89e660dfa4f641ab5861e88e9a0e80418d4f3a1f2c2f1eb6a9c7a9b02c5.png
complex
<table><tr><td>The Job stress Survey (JSS) Items</td><td>Lack of support leaders</td><td>Demanding job tasks</td><td>Time pressure</td><td>Lack of support co-workers</td></tr><tr><td>No participating in decisions</td><td>0.84</td><td><i>0.20</i></td><td><i>0.03</i></td><td><i>0.04</i></td></tr><tr><td>Lack recognition for good work</td><td>0.80</td><td><i>0.14</i></td><td><i>0.03</i></td><td><i>0.28</i></td></tr><tr><td>Poor or inadequate supervision</td><td>0.61</td><td><i>0.28</i></td><td><i>0.13</i></td><td><i>0.18</i></td></tr><tr><td>Difficult working with superior</td><td>0.81</td><td><i>0.16</i></td><td><i>0.17</i></td><td><i>0.19</i></td></tr><tr><td>Inadequate support by supervisor</td><td>0.57</td><td><i>0.24</i></td><td><i>0.19</i></td><td><i>0.25</i></td></tr><tr><td>Difficulty getting along with supervisor</td><td>0.79</td><td><i>0.01</i></td><td><i>0.19</i></td><td><i>0.22</i></td></tr><tr><td>Working overtime</td><td><i>0.16</i></td><td>0.56</td><td><i>0.05</i></td><td><i>0.12</i></td></tr><tr><td>Critical on the spot decisions</td><td><i>0.20</i></td><td>0.73</td><td><i>0.16</i></td><td><i>0.10</i></td></tr><tr><td>Assigned increased responsibility</td><td><i>0.32</i></td><td>0.62</td><td><i>0.19</i></td><td><i>0.11</i></td></tr><tr><td>Assignment of new duties</td><td><i>0.11</i></td><td>0.75</td><td><i>0.24</i></td><td><i>0.03</i></td></tr><tr><td>Perform duties not in job description</td><td><i>0.04</i></td><td>0.67</td><td><i>0.33</i></td><td><i>0.16</i></td></tr><tr><td>Frequent interruptions</td><td><i>0.26</i></td><td><i>0.28</i></td><td>0.53</td><td><i>0.42</i></td></tr><tr><td>Frequent change simple to demanding tasks</td><td><i>0.06</i></td><td><i>0.44</i></td><td>0.61</td><td><i>0.16</i></td></tr><tr><td>Excessive paperwork</td><td><i>0.09</i></td><td><i>0.19</i></td><td>0.79</td><td><i>0.12</i></td></tr><tr><td>Meeting deadline</td><td><i>0.06</i></td><td><i>0.20</i></td><td>0.82</td><td><i>0.14</i></td></tr><tr><td>Insufficient personal time</td><td><i>0.24</i></td><td><i>0.12</i></td><td>0.66</td><td><i>0.04</i></td></tr><tr><td>Fellow workers not doing job</td><td><i>0.26</i></td><td><i>0.21</i></td><td><i>0.01</i></td><td>0.77</td></tr><tr><td>Covering work for others</td><td><i>0.31</i></td><td><i>0.18</i></td><td><i>0.27</i></td><td>0.56</td></tr><tr><td>Poorly motivated co-workers</td><td><i>0.26</i></td><td><i>0.05</i></td><td><i>0.24</i></td><td>0.79</td></tr><tr><td>Sums of squared loadings</td><td>3.9</td><td>2.9</td><td>2.9</td><td>2.1</td></tr><tr><td>% variance</td><td>20.4</td><td>15.3</td><td>15.1</td><td>11.0</td></tr><tr><td colspan="2">The Norwegian Ambulance Stress Survey (NASS)</td><td>Non-Emergency tasks</td><td>Serious operational tasks</td><td>Physical demands</td></tr><tr><td>Hide feelings towards patients and relatives</td><td></td><td>0.83</td><td><i>0.13</i></td><td><i>0.16</i></td></tr><tr><td>Not being able to express own opinion to patients or relatives</td><td></td><td>0.82</td><td><i>0.08</i></td><td><i>0.19</i></td></tr><tr><td>Medical responsibility in the vehicle</td><td></td><td>0.63</td><td><i>0.34</i></td><td><i>0.17</i></td></tr><tr><td>Negative attitude from relatives about the job you are doing</td><td></td><td>0.60</td><td><i>0.29</i></td><td><i>0.07</i></td></tr><tr><td>The cumulative effect of frequently driving chronically ill patients</td><td></td><td>0.54</td><td><i>0.25</i></td><td><i>0.24</i></td></tr><tr><td>Take care of seriously injured and dying patients</td><td></td><td><i>0.52</i></td><td>0.57</td><td><i>0.15</i></td></tr><tr><td>Uncertainty about what you will meet on the scene of accident</td><td></td><td><i>0.51</i></td><td>0.60</td><td><i>0.11</i></td></tr><tr><td>Incident with seriously injured friend or people you know</td><td></td><td><i>0.19</i></td><td>0.73</td><td><i>0.12</i></td></tr><tr><td>Incident with seriously injured children</td><td></td><td><i>0.09</i></td><td>0.83</td><td><i>0.15</i></td></tr><tr><td>Deal with acting-out and threatening patients</td><td></td><td><i>0.18</i></td><td>0.70</td><td><i>0.22</i></td></tr><tr><td>Driving under difficult conditions</td><td></td><td><i>0.34</i></td><td>0.62</td><td><i>0.18</i></td></tr><tr><td>Heavy lifting</td><td></td><td><i>0.22</i></td><td><i>0.12</i></td><td>0.91</td></tr><tr><td>Carrying out the work under difficult conditions</td><td></td><td><i>0.20</i></td><td><i>0.22</i></td><td>0.91</td></tr><tr><td>Working in bent or twisted positions</td><td></td><td><i>0.18</i></td><td><i>0.25</i></td><td>0.87</td></tr><tr><td>Sums of squared loadings</td><td></td><td>3.3</td><td>3.2</td><td>2.7</td></tr><tr><td>% variance</td><td></td><td>23.3</td><td>22.7</td><td>19.3</td></tr></table>
e97e56c55386a325297274d2706a9fa01c62ef42e4e6a962e6da8dcbf959dadc.png
complex
<table><tr><td></td><td>English 1st Language</td><td>N</td><td>Mean</td><td>SD</td><td>Age</td><td>N</td><td>Mean</td><td>SD</td><td>Student</td><td>N</td><td>Mean</td><td>SD</td></tr><tr><td rowspan="2">Sum 18 Item</td><td>Yes</td><td>229</td><td>37.96</td><td>7.72</td><td>Younger</td><td>133</td><td>38.56</td><td>7.66</td><td>Yes</td><td>114</td><td>38.19</td><td>7.99</td></tr><tr><td>No</td><td>28</td><td>39.57</td><td>9.37</td><td>Older</td><td>123</td><td>37.58</td><td>8.14</td><td>No</td><td>143</td><td>38.09</td><td>7.88</td></tr><tr><td rowspan="2">Sum Production</td><td>Yes</td><td>236</td><td>20.05</td><td>4.56</td><td>Younger</td><td>138</td><td>20.42</td><td>4.54</td><td>Yes</td><td>117</td><td>20.15</td><td>4.65</td></tr><tr><td>No</td><td>29</td><td>20.93</td><td>5.18</td><td>Older</td><td>126</td><td>19.80</td><td>4.71</td><td>No</td><td>148</td><td>20.14</td><td>4.63</td></tr><tr><td rowspan="2">Sum Perception</td><td>Yes</td><td>238</td><td>16.58</td><td>4.37</td><td>Younger</td><td>141</td><td>16.54</td><td>4.29</td><td>Yes</td><td>116</td><td>17.00</td><td>4.55</td></tr><tr><td>No</td><td>29</td><td>17.31</td><td>5.15</td><td>Older</td><td>125</td><td>16.75</td><td>4.63</td><td>No</td><td>151</td><td>16.40</td><td>4.38</td></tr><tr><td rowspan="2">Sum EQ</td><td>Yes</td><td>224</td><td>17.34</td><td>5.72</td><td>Younger</td><td>133</td><td>18.28*</td><td>5.40</td><td>Yes</td><td>112</td><td>17.35</td><td>5.87</td></tr><tr><td>No</td><td>29</td><td>19.28</td><td>5.85</td><td>Older</td><td>119</td><td>16.71*</td><td>6.05</td><td>No</td><td>141</td><td>17.73</td><td>5.68</td></tr></table>
768489888c11bc3bce26d86ba71a9f0944166ef169145243c0111e948f4ba6e5.png
simple
<table><tr><td>Cut-off</td><td>No of studies</td><td>Co-sensitivity (95 % CI)</td><td>Co-specificity (95 % CI)</td><td>I<sup>2</sup> (95%CI)</td><td>Pooled positive LR</td><td>Pooled negative LR</td></tr><tr><td>1.5 cm</td><td>1</td><td>0.93</td><td>0.16</td><td>&#8211;</td><td>1.1</td><td>0.43</td></tr><tr><td>2 cm</td><td>2</td><td>0.95, 1</td><td>0.41, 0.20</td><td>&#8211;</td><td>1.61, 1.25</td><td>0.12, 0</td></tr><tr><td>2.5 cm</td><td>3</td><td>0.79, 1, 0.84</td><td>0.84, 0.58, 0.66</td><td>&#8211;</td><td>4.93, 2.38, 2.47</td><td>0.25, 0, 0.24</td></tr><tr><td>3 cm</td><td>7</td><td>0.83, (0.56&#8211;0.95)</td><td>0.64, (0.45&#8211;0.79)</td><td>92, (86&#8211;99)</td><td>2.3, (1.5&#8211;3.5)</td><td>0.27, (0.1&#8211;0.74)</td></tr><tr><td>4 cm</td><td>6</td><td>0.56, (0.35&#8211;0.75)</td><td>0.85, (0.69&#8211;0.94)</td><td>94, (89&#8211;99)</td><td>3.8, (2.3&#8211;6.4)</td><td>0.51, (0.35&#8211;0.75)</td></tr><tr><td>5 cm</td><td>6</td><td>0.31, (0.14&#8211;0.57)</td><td>0.92, (0.80&#8211;0.97)</td><td>93, (86&#8211;99)</td><td>4, (1.9&#8211;8.3)</td><td>0.74, (0.56&#8211;0.98)</td></tr><tr><td>6 cm</td><td>6</td><td>0.32, (0.11&#8211;0.63)</td><td>0.92, (0.85&#8211;0.96)</td><td>92, (85&#8211;99)</td><td>4, (1.9&#8211;8.7)</td><td>0.74, (0.51&#8211;1.08)</td></tr></table>
4a457cdd517762d49279d19b5e77dae518b03ed67ae52dcc5668b61a67fcb8f2.png
simple
<table><tr><td> </td><td>Men</td><td>Women</td><td>p-value*</td></tr><tr><td>Number of patients</td><td>289</td><td>284</td><td> </td></tr><tr><td>Number of deaths</td><td>41</td><td>21</td><td> </td></tr><tr><td>Number of admissions</td><td>1924</td><td>3139</td><td> </td></tr><tr><td>Total time of follow-up (person-years)</td><td>3420</td><td>3204</td><td> </td></tr><tr><td>Follow-up time in years (mean, SD)</td><td>11.8 (7.4)</td><td>11.3 (7.4)</td><td>0.37</td></tr><tr><td>Age at first admission in years (mean, SD)</td><td>31.2 (9.9)</td><td>30.2(12.2)</td><td>0.28</td></tr><tr><td>Total number of days admitted (median, 1 and 3 quartile)</td><td>70 (18.0, 214.5)</td><td>111 (25.3, 293.0)</td><td>0.013</td></tr><tr><td>Number of admissions (median, 1 and 3 quartile)</td><td>3 (1,8)</td><td>4 (2,1)</td><td>0.004</td></tr><tr><td>% with personality disorder as only diagnosis (N)</td><td>30.1 (89)</td><td>23.9 (68)</td><td>0.07</td></tr></table>
a456d971532e7deb33a4a068b6ccc6ac85b538fdd784f444a8ac6aaa725493de.png
complex
<table><tr><td colspan="2">PBMS</td><td colspan="3">DMT status</td><td colspan="2"> </td></tr><tr><td colspan="2">Domains</td><td>pre-test</td><td>RCT</td><td>pos-</td><td colspan="2">p-value</td></tr><tr><td> </td><td>Sub-domains</td><td>without /with</td><td>without /with</td><td>sible range</td><td>pre</td><td>RCT</td></tr><tr><td colspan="2">1: Attitude</td><td>2.1 / 4.6</td><td>2.4 / 4.1</td><td>0-9</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>a: expectations regarding outcomes</td><td>1.4 / 2.0</td><td>1.5 / 1.9</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: values of expected outcomes</td><td>1.4 / 2.2</td><td>1.5 / 2.1</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td colspan="2">2: Social norm</td><td>1.2 / 1.8</td><td>1.5 / 2.4</td><td>0-9</td><td>.23</td><td>&lt;.01</td></tr><tr><td> </td><td>a: assumed attitudes of important others</td><td>1.2 / 2.0</td><td>1.5 / 2.2</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: motivation to comply with these norms</td><td>1.0 / .9</td><td>1.0 / 1.1</td><td>0-3</td><td>&lt;.01</td><td>.34</td></tr><tr><td colspan="2">3: Control beliefs</td><td>1.6 / 4.7</td><td>2.1 / 4.1</td><td>0-9</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>a: assumed facilitators or barriers</td><td>1.0 / 2.1</td><td>1.2 / 1.9</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td> </td><td>b: perceived power of these factors</td><td>1.4 / 2.2</td><td>1.5 / 2.0</td><td>0-3</td><td>&lt;.01</td><td>&lt;.01</td></tr><tr><td colspan="2">Intention estimate</td><td>4.8 / 11.1</td><td>6.0 / 10.1</td><td>0-27</td><td>&lt;.01</td><td>&lt;.01</td></tr></table>
951d0c0551bc13f9e7483fefd1b901b0e6ed8a9ffbbd07f1772e02c06752c2a5.png
simple
<table><tr><td>SNP</td><td>Position</td><td>Alleles<sup>&#8224;</sup></td><td>MAF</td><td>Beta</td><td>s.e.</td><td><i>P</i></td><td><i>P</i><sub><i>emp</i></sub></td></tr><tr><td>rs1333049</td><td>22,115,503</td><td>C/G</td><td>0.421</td><td>0.0119</td><td>0.012</td><td>3.45E-01</td><td>3.44E-01</td></tr></table>
60c70fcd5d96f7d3fbd7a86998713df099ed8c97a4d471bcf4ef8c48435b0b5d.png
simple
<table><tr><td>Characteristics</td><td>Yes (%)</td><td>No (%)</td></tr><tr><td>Ever received an introduction into work place ergonomics</td><td>24 (14.7%)</td><td>136 (83.4%)</td></tr><tr><td>Ever experienced work-related musculoskeletal problems</td><td>123 (75.5%)</td><td>40 (24.5%)</td></tr><tr><td>Musculoskeletal problems in the last four weeks (n=123)</td><td>69 (56.1%)</td><td>53 (43.1%)</td></tr><tr><td>Signed off due musculoskeletal problems last year (n=123)</td><td>11 (8.9%)</td><td>112 (91.1%)</td></tr><tr><td>Doing regularly short breaks for stretching exercises</td><td>36 (22.1%)</td><td>124 (76.1%)</td></tr><tr><td>Any known ametropia</td><td>145 (89.0%)</td><td>17 (10.4%)</td></tr><tr><td>Aggravation of ametropia since working in pathology (n=145)</td><td>82 (56.6%)</td><td>58 (40.0%)</td></tr><tr><td>Eye fatigue symptoms in the last month</td><td>90 (55.2%)</td><td>68 (41.7%)</td></tr><tr><td>Ever experienced occupational injuries in pathology</td><td>135 (82.8%)</td><td>28 (17.2%)</td></tr><tr><td>Experienced such injuries in the last year (n=135)</td><td>37 (27.4%)</td><td>95 (70.4%)</td></tr><tr><td>Remaining permanent damages from such injuries (n=135)</td><td>5 (3.7%)</td><td>127 (94.1%)</td></tr><tr><td>Ever experienced intolerance reactions against formalin</td><td>41 (25.2%)</td><td>118 (72.4%)</td></tr><tr><td>Any known allergy</td><td>55 (33.7%)</td><td>105 (64.4%)</td></tr><tr><td>Since working in pathology ever diseased with...</td><td> </td><td> </td></tr><tr><td>Tuberculosis</td><td>2 (1.2%)</td><td>153 (93.9%)</td></tr><tr><td>Positive tuberculin test only</td><td>31 (19.0%)</td><td>119 (73.0%)</td></tr><tr><td>Hepatitis B</td><td>1 (0.6%)</td><td>154 (94.5%)</td></tr><tr><td>Hepatitis C</td><td>0 (0.0%)</td><td>155 (95.1%)</td></tr><tr><td>HIV</td><td>0 (0.0%)</td><td>154 (94.5%)</td></tr><tr><td>Burnout</td><td>14 (8.6%)</td><td>141 (86.5%)</td></tr><tr><td>Depression</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Hypertension</td><td>11 (6.7%)</td><td>144 (88.3%)</td></tr><tr><td>Diabetes mellitus type II</td><td>3 (1.8%)</td><td>152 (93.2%)</td></tr><tr><td>Malignancies</td><td>3 (1.8%)</td><td>149 (91.4%)</td></tr><tr><td>Sufficient hepatitis B immunisation</td><td>153 (93.9%)</td><td>9 (5.5%)</td></tr><tr><td>Ever received BCG (tuberculosis) immunisation</td><td>128 (78.5%)</td><td>31 (19.0%)</td></tr><tr><td>Smoking</td><td>17 (10.4%)</td><td>145 (89.0%)</td></tr><tr><td>Cut-resistant gloves available at workplace</td><td>99 (60.7%)</td><td>60 (36.8%)</td></tr><tr><td>Regular personal use of cut-resistant gloves at dissections/autopsies</td><td>39 (23.9%)</td><td>108 (66.3%)</td></tr><tr><td>Extraction of air in the dissection room considered sufficient</td><td>94 (57.7%)</td><td>66 (40.5%)</td></tr></table>
a8dd9ca21cebccbb1c9f3642fc8a95e33a972dffe40c5f20b6d7e0bf6cfa8cb2.png
simple
<table><tr><td>Method Label</td><td>Method Description</td><td>Library used within R statistical software</td><td>Number of iterations</td></tr><tr><td>CC</td><td>Complete case analysis: Analyses only cases with complete data for all covariates</td><td></td><td>-</td></tr><tr><td>SI</td><td>Single imputation performed using PMM</td><td>'<i>pmm</i>' function in 'mice'</td><td>20</td></tr><tr><td>MI-NORM</td><td>Multiple imputation (MI) using data augmentation approach [31] with a multivariate normal assumption for all variables</td><td>'norm' [41]</td><td>100</td></tr><tr><td>MI-MIX</td><td>MI using data augmentation approach using a general location model</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MIX-no truncating</td><td>MI using data augmentation approach using a general location model, but imputed values are not truncated to within plausible range</td><td>'mix' [42]</td><td>100</td></tr><tr><td>MI-MICE</td><td>MI using regression switching imputation [9]. Linear model are used for continuous covariates and logistic model for binary covariates and dummy variables for categorical covariates</td><td>'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM</td><td>MI using MICE with PMM</td><td>'<i>pmm</i>' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-MICE-PMM-no transformation</td><td>MI using MICE with PMM without transforming the incomplete covariates</td><td>'<i>pmm</i>' function in 'mice' [43]</td><td>20</td></tr><tr><td>MI-Aregimpute</td><td>MI using flexible additive imputation models [20] with PMM</td><td>'<i>aregImpute</i>' function in 'Hmisc' [44]</td><td>1</td></tr></table>
74c4216008f360e0cafe5770b3497d4b343537f94c6189aa159773f00a3e5bb9.png
simple
<table><tr><td>Case No.</td><td>Age(yrs)</td><td>FIGO score</td><td>AP</td><td>Interval time (mons)</td><td>Pretreatment serum &#946;-hCG level</td><td>Site of metastases</td><td>Chemotherapy</td><td>Cause of death</td></tr><tr><td>1</td><td>53</td><td>15</td><td>Abortion</td><td>180</td><td>99000.0</td><td>Lung/brain/kidney</td><td>Not done</td><td>Brain hemorrhage, respiratory failure</td></tr><tr><td>2</td><td>30</td><td>21</td><td>Abortion</td><td>10</td><td>906720.0</td><td>Lung/brain/liver/kidney</td><td>Not done</td><td>Septic shock</td></tr><tr><td>3</td><td>31</td><td>8</td><td>Mole</td><td>32</td><td>80.0</td><td>Lung/brain</td><td>5-FU*1d</td><td>Brain herniation</td></tr><tr><td>4</td><td>25</td><td>12</td><td>Mole</td><td>27</td><td>57380.0</td><td>Lung/brain</td><td>EMA*1</td><td>Brain herniation</td></tr><tr><td>5</td><td>32</td><td>12</td><td>Term</td><td>6</td><td>200000.0</td><td>Lung/brain/kidney</td><td>FAEV*2d</td><td>Respiratory failure, cardiac arrest</td></tr><tr><td>6</td><td>36</td><td>13</td><td>Mole</td><td>56</td><td>9306.0</td><td>Lung/brain/bladder</td><td>FAEV*1d</td><td>Multiple organ failure</td></tr><tr><td>7</td><td>26</td><td>15</td><td>Term</td><td>3</td><td>60436.5</td><td>Lung/brain</td><td>FAEV*3d</td><td>Brain stem hemorrhage</td></tr><tr><td>8<sup>a</sup></td><td>33</td><td>17</td><td>Mole</td><td>36</td><td>2400.0</td><td>Lung/brain</td><td>FAEV*4d</td><td>Brain herniation</td></tr></table>
52c058b55cf7c34f33340fec7030b4d9688c7244376dc96309fb1119638ebaf1.png
complex
<table><tr><td>Characteristics</td><td colspan="2">Antenatal care utilization (&lt; 4 times and &#8805; 4 times)</td></tr><tr><td> </td><td>BivariateOR (95% CI)</td><td>MultivariateOR (95% CI)</td></tr><tr><td>Education</td><td> </td><td> </td></tr><tr><td>Illiterate</td><td>1</td><td>1</td></tr><tr><td>Informal education</td><td>1.54 (1.22&#8211;1.95)*</td><td>1.39 (1.10-1.77)*</td></tr><tr><td>Primary school</td><td>1.81 (1.34&#8211;2.45)*</td><td>1.38 (1.01-1.90)*</td></tr><tr><td>Secondary school</td><td>2.85 (2.12&#8211;3.78)*</td><td>1.94 (1.43-2.63)*</td></tr><tr><td>Intermediate and above</td><td>3.49 (2.35&#8211;5.17)*</td><td>2.41 (1.55-3.75)*</td></tr><tr><td>Occupation</td><td> </td><td> </td></tr><tr><td>Agriculture</td><td>1</td><td>1</td></tr><tr><td>Service</td><td>1.63 (0.99-2.68)</td><td>1.05 (0.61-1.80)</td></tr><tr><td>Business</td><td>1.95 (0.92-4.15)</td><td>1.34 (0.61-2.93)</td></tr><tr><td>Wage laborer</td><td>1.33 (0.63-2.83)</td><td>1.36 (0.63-2.94)</td></tr><tr><td>Housewife</td><td>1.69 (1.31-2.17)*</td><td>1.44 (1.10-1.89)*</td></tr><tr><td>Other</td><td>1.09 (0.58-2.07)</td><td>0.73 (0.37-1.42)</td></tr><tr><td>Wealth quintile</td><td> </td><td> </td></tr><tr><td>Lowest</td><td>1</td><td>1</td></tr><tr><td>Second</td><td>0.91 (0.69&#8211;1.19)</td><td>1.01 (0.76-1.33)</td></tr><tr><td>Middle</td><td>0.95 (0.71&#8211;1.26)</td><td>0.95 (0.70-1.28)</td></tr><tr><td>Fourth</td><td>1.44 (1.10&#8211;1.90)*</td><td>1.25 (0.93-1.67)</td></tr><tr><td>Highest</td><td>1.72 (1.30&#8211;2.27)*</td><td>1.38 (1.02-1.86)*</td></tr><tr><td colspan="3">Knowledge of danger signs</td></tr><tr><td>No</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>1.99 (1.67&#8211;2.38)*</td><td>1.71 (1.41-2.07)*</td></tr><tr><td colspan="3">Distance to health facility</td></tr><tr><td>&gt; 30 min</td><td>1</td><td>1</td></tr><tr><td>&#8804; 30 min</td><td>1.69 (1.39-2.05)*</td><td>1.44 (1.18-1.77)*</td></tr></table>
7e1855cc3d23779a41a0ec72a82983ccd4112614e35f51876ef1115337ac1f73.png
simple
<table><tr><td>Organism</td><td>BlastX threshold</td><td>Matches against 454 unigenes</td><td>Matches against Sanger unigenes</td></tr><tr><td><i>Arabidopsis </i>(31,921)</td><td>1e-5</td><td>14250 (45%)</td><td>10154 (32%)</td></tr><tr><td></td><td>1e-10</td><td>12347 (39%)</td><td>9561 (30%)</td></tr><tr><td></td><td>1e-20</td><td>9077 (28%)</td><td>8410 (26%)</td></tr><tr><td><i>Arabidopsis </i>with transcript evidence (22,032)</td><td>1e-5</td><td>12790 (58%)</td><td>9542 (43%)</td></tr><tr><td></td><td>1e-10</td><td>11265 (51%)</td><td>9029 (41%)</td></tr><tr><td></td><td>1e-20</td><td>8489 (39%)</td><td>8003 (36%)</td></tr><tr><td><i>Populus </i>(45,555)</td><td>1e-5</td><td>17724 (39%)</td><td>11580 (25%)</td></tr><tr><td></td><td>1e-10</td><td>15383 (34%)</td><td>10962 (24%)</td></tr><tr><td></td><td>1e-20</td><td>11190 (25%)</td><td>9701 (21%)</td></tr><tr><td><i>Oryza </i>(66,710)</td><td>1e-5</td><td>14510 (22%)</td><td>9893 (15%)</td></tr><tr><td></td><td>1e-10</td><td>12139 (18%)</td><td>9193 (14%)</td></tr><tr><td></td><td>1e-20</td><td>8393 (13%)</td><td>7834 (12%)</td></tr></table>
737c9398bd5825a4458d22d7b4d593d1e69a37b7599cf779eebea314610153de.png
simple
<table><tr><td>DATA CATEGORY</td><td>DATA</td></tr><tr><td>Counter IDIN</td><td>37&#8211;95</td></tr><tr><td>Station </td><td>95</td></tr><tr><td>County</td><td>37</td></tr><tr><td>City</td><td>35</td></tr><tr><td>Route</td><td>65</td></tr><tr><td>Mile point</td><td>250.08</td></tr><tr><td>AADT 2009</td><td>115,150</td></tr><tr><td>AADT 2008 </td><td>113,900</td></tr><tr><td>AADT 2007 </td><td>118,520</td></tr><tr><td>AADT 2006 </td><td>117,930</td></tr><tr><td>AADT 2005 </td><td>117,800</td></tr><tr><td>AADT 2004 </td><td>115,060</td></tr><tr><td>AADT 2003 </td><td>113,300</td></tr><tr><td>AADT 2002 </td><td>109,720</td></tr><tr><td>AADT 2001 </td><td>110,210</td></tr><tr><td>K </td><td>10</td></tr><tr><td>D </td><td>65</td></tr><tr><td>TDHV </td><td>8</td></tr><tr><td>TADT </td><td>11</td></tr><tr><td>Heavy </td><td>70</td></tr><tr><td>Functional Class </td><td>11</td></tr></table>
a41359585e5c2096a03621a445e8ce4bbeacd266c020567fe4d6ceb8c557161c.png
complex
<table><tr><td colspan="2">Clinical features</td></tr><tr><td>Number of patients</td><td>13</td></tr><tr><td>Women/men</td><td>7/6</td></tr><tr><td>Age (years), mean &#177; SD</td><td>52.02 &#177; 19.01</td></tr><tr><td colspan="2"><i>Triggering factor</i></td></tr><tr><td> AOSD flare, number (%)</td><td>13 (100)</td></tr><tr><td> Lymphoma, number (%)</td><td>0</td></tr><tr><td> Infectious disease, number (%)</td><td>0</td></tr><tr><td colspan="2"><i>Laboratory features</i></td></tr><tr><td> WBC (10<sup>3</sup>/mL), mean &#177; SD</td><td>3.28 &#177; 1.36</td></tr><tr><td> RBC (10<sup>3</sup>/mL), mean &#177; SD</td><td>3.31 &#177; 0.69</td></tr><tr><td> HB (gr/dL), mean &#177; SD</td><td>9.19 &#177; 2.05</td></tr><tr><td> PLT (10<sup>3</sup>/mL), mean &#177; SD</td><td>55.52 &#177; 46.54</td></tr><tr><td> Serum Ferritin (ng/mL), mean &#177; SD</td><td>4362.15 &#177; 7569.70</td></tr><tr><td> ESR (mm/hour), mean &#177; SD</td><td>71.23 &#177; 30.19</td></tr><tr><td> CRP (mg/L), mean &#177; SD</td><td>74.76 &#177; 46.92</td></tr><tr><td> Triglycerides (mg/dL), mean &#177; SD</td><td>183.12 &#177; 69.33</td></tr><tr><td> ASAT (IU/L), mean &#177; SD</td><td>74.59 &#177; 41.89</td></tr><tr><td> ALAT (IU/L), mean &#177; SD</td><td>129.98 &#177; 91.21</td></tr><tr><td colspan="2"><i>Treatments</i></td></tr><tr><td> High dosage steroid pulses, number (%)</td><td>13 (100)</td></tr><tr><td> Immunosuppressive drugs, number (%)</td><td>7 (53.84)</td></tr><tr><td> Cyclosporine A, number (%)</td><td>5 (38.46)</td></tr><tr><td> Methotrexate, number (%)</td><td>2 (15.38)</td></tr><tr><td> Etoposide</td><td>0</td></tr><tr><td> Biologic drugs</td><td>2 (15.38)</td></tr><tr><td>Deaths, number (%)</td><td>10 (76.92)</td></tr><tr><td>Number of relapses in MAS-survivors patients, mean &#177; SD</td><td>2.66 &#177; 1.69</td></tr></table>
eb959ed92aafe77c4198b5bb09be6b388317a1b7800b9d901a3f826d1c131169.png
complex
<table><tr><td>Section</td><td colspan="2">Conventional<sup>1</sup></td><td colspan="2">Enzymatic</td></tr><tr><td></td><td>%</td><td>(US$ &#215; 100)</td><td>%</td><td>(US$ &#215; 100)</td></tr><tr><td>Grain handling</td><td>8.2</td><td>6,500</td><td>8.7</td><td>6,500</td></tr><tr><td>Steeping (or pretreatment)</td><td>22.3</td><td>17,700</td><td>10.7</td><td>8,000</td></tr><tr><td>Enzymatic treatment</td><td>0</td><td>0</td><td>4.9</td><td>3,700</td></tr><tr><td>Germ separation</td><td>13.5</td><td>10,700</td><td>14.4</td><td>10,800</td></tr><tr><td>Fiber separation</td><td>23.7</td><td>18,800</td><td>25.9</td><td>19,400</td></tr><tr><td>Gluten separation</td><td>27.1</td><td>21,500</td><td>30.0</td><td>22,500</td></tr><tr><td>Starch washing</td><td>5.2</td><td>4,100</td><td>5.5</td><td>4,100</td></tr><tr><td>TOTAL</td><td>100.0</td><td>79,300</td><td>100.0</td><td>75,000</td></tr></table>
8c062e8c447611cf3611127e1271b679558944be47ce8f1ccbfea561fafaaeaa.png
simple
<table><tr><td>Domain</td><td>Scale/items</td><td>Parent-report</td><td>Self-report</td></tr><tr><td>Sexual socialization</td><td>Friendship skills of child</td><td>5 items</td><td>5 items</td></tr><tr><td></td><td>Social acceptance by peers</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Romantic ability of child</td><td>-</td><td>3 items</td></tr><tr><td></td><td>Openness about intimacy</td><td>4 items</td><td>3 items</td></tr><tr><td></td><td>Adequate dealing with boundaries</td><td>8 items</td><td>-</td></tr><tr><td>Sexual selfhood</td><td>Bodily perception</td><td>3 items</td><td>6 items</td></tr><tr><td></td><td>Self-esteem</td><td>-</td><td>12 items</td></tr><tr><td></td><td>Perceived social competence</td><td>-</td><td>12 items</td></tr><tr><td></td><td>Sexual knowledge of the child according to parent</td><td>9 items</td><td>-</td></tr><tr><td>Sexual behavior</td><td>Separate items on age or context appropriate behaviors, intimate experiences including age of onset and sexual orientation</td><td>33 items</td><td>41 items</td></tr></table>
a6b65d57cfed481d78e5a2d4bb4d059394613bbd479c5404cab3690756e09f49.png
complex
<table><tr><td></td><td colspan="2">Moderately/severely thin</td><td colspan="2">Mildly thin</td><td colspan="2">Overweight</td><td colspan="2">Obese</td></tr><tr><td>IMD decile</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td><td>% (n)</td><td>RRR (95 % CI)</td></tr><tr><td colspan="9">Girls</td></tr><tr><td>Most advantaged</td><td>0.71 (855)</td><td>-</td><td>4.14 (4 998)</td><td>-</td><td>14.45 (17 426)</td><td>-</td><td>2.95 (3 563)</td><td>-</td></tr><tr><td>2</td><td>0.76 (868)</td><td>1.08 (0.98, 1.19)</td><td>4.01 (4 606)</td><td>0.98 (0.94, 1.02)</td><td>15.09 (17 334)</td><td>1.06 (1.04, 1.08)</td><td>3.36 (3 980)</td><td>1.19 (1.14, 1.25)</td></tr><tr><td>3</td><td>0.74 (812)</td><td>1.07 (0.97, 1.17)</td><td>4.01 (4 426)</td><td>0.99 (0.95, 1.03)</td><td>15.46 (17 055)</td><td>1.09 (1.07, 1.12)</td><td>3.84 (4 236)</td><td>1.33 (1.27, 1.39)</td></tr><tr><td>4</td><td>0.75 (805)</td><td>1.10 (1.00, 1.21)</td><td>4.02 (4 315)</td><td>1.00 (0.96, 1.05)</td><td>15.97 (17 138)</td><td>1.14 (1.11, 1.17)</td><td>4.04 (4 334)</td><td>1.41 (1.35, 1.48)</td></tr><tr><td>5</td><td>0.79 (876)</td><td>1.17 (1.07, 1.29)</td><td>4.0 (4 408)</td><td>1.01 (0.97, 1.05)</td><td>16.12 (17 761)</td><td>1.16 (1.14, 1.19)</td><td>4.53 (4 990)</td><td>1.60 (1.53, 1.67)</td></tr><tr><td>6</td><td>0.86 (991)</td><td>1.28 (1.17, 1.41)</td><td>4.10 (4 739)</td><td>1.05 (1.00, 1.09)</td><td>16.53 (19 121)</td><td>1.21 (1.19, 1.24)</td><td>5.00 (5 784)</td><td>1.79 (1.72, 1.87)</td></tr><tr><td>7</td><td>0.89 (1 089)</td><td>1.37 (1.25, 1.50)</td><td>4.41 (5 374)</td><td>1.15 (1.11, 1.20)</td><td>17.06 (20 768)</td><td>1.28 (1.25, 1.31)</td><td>5.60 (6 816)</td><td>2.05 (1.96, 2.13)</td></tr><tr><td>8</td><td>1.02 (1 370)</td><td>1.57 (1.44, 1.71)</td><td>4.5 (6 042)</td><td>1.18 (1.14, 1.23)</td><td>16.77 (22 529)</td><td>1.27 (1.25, 1.30)</td><td>6.11 (18 210)</td><td>2.25 (2.16, 2.34)</td></tr><tr><td>9</td><td>1.06 (1 605)</td><td>1.67 (1.53, 1.81)</td><td>4.8 (7 254)</td><td>1.28 (1.24, 1.33)</td><td>17.25 (26 091)</td><td>1.34 (1.31, 1.37)</td><td>6.77 (10 238)</td><td>2.54 (2.44, 2.64)</td></tr><tr><td>Least advantaged</td><td>1.14 (2 009)</td><td>1.80 (1.66, 1.95)</td><td>4.73 (8 317)</td><td>1.27 (1.23, 1.32)</td><td>17.36 (30 561)</td><td>1.36 (1.34, 1.39)</td><td>7.18 (12 630)</td><td>2.71 (2.61, 2.82)</td></tr><tr><td>Total n</td><td>11 280</td><td></td><td>54 479</td><td></td><td>205 784</td><td></td><td>64 781</td><td></td></tr><tr><td colspan="9">Boys</td></tr><tr><td>Most advantaged</td><td>0.65 (828)</td><td>-</td><td>4.88 (6 183)</td><td>-</td><td>9.97 (12 618)</td><td>-</td><td>2.03 (2 573)</td><td>-</td></tr><tr><td>2</td><td>0.68 (822)</td><td>1.05 (0.96, 1.16)</td><td>4.64 (5 608)</td><td>0.96 (0.93, 1.00)</td><td>10.71 (12 932)</td><td>1.08 (1.06, 1.11)</td><td>2.42 (2 920)</td><td>1.20 (1.14, 1.27)</td></tr><tr><td>3</td><td>0.67 (775)</td><td>1.05 (0.95, 1.16)</td><td>4.59 (5 295)</td><td>0.96 (0.92, 1.00)</td><td>11.22 (12 958)</td><td>1.14 (1.11, 1.17)</td><td>2.63 (3 033)</td><td>1.32 (1.25, 1.39)</td></tr><tr><td>4</td><td>0.75 (839)</td><td>1.18 (1.07, 1.30)</td><td>4.77 (5 352)</td><td>1.01 (0.97, 1.05)</td><td>11.61 (13 036)</td><td>1.20 (1.17, 1.23)</td><td>2.89 (3 243)</td><td>1.47 (1.39, 1.55)</td></tr><tr><td>5</td><td>0.78 (911)</td><td>1.25 (1.14, 1.38)</td><td>4.77 (5 544)</td><td>1.02 (0.98, 1.06)</td><td>11.93 (13 863)</td><td>1.25 (1.22, 1.28)</td><td>3.23 (3 748)</td><td>1.65 (1.57, 1.74)</td></tr><tr><td>6</td><td>0.84 (1 026)</td><td>1.37 (1.25, 1.50)</td><td>5.01 (6 088)</td><td>1.08 (1.05, 1.12)</td><td>12.30 (14 947)</td><td>1.31 (1.28, 1.34)</td><td>3.74 (4 539)</td><td>1.94 (1.85, 2.04)</td></tr><tr><td>7</td><td>0.91 (1 153)</td><td>1.49 (1.36, 1.63)</td><td>4.98 (6 328)</td><td>1.09 (1.05, 1.13)</td><td>12.82 (16 285)</td><td>1.38 (1.35, 1.41)</td><td>4.08 (5 188)</td><td>2.15 (2.05, 2.25)</td></tr><tr><td>8</td><td>1.03 (1 443)</td><td>1.71 (1.56, 1.86)</td><td>5.16 (7 242)</td><td>1.14 (1.10, 1.18)</td><td>13.02 (18 286)</td><td>1.43 (1.40, 1.47)</td><td>4.54 (6 384)</td><td>2.42 (2.31, 2.54)</td></tr><tr><td>9</td><td>1.11 (1 765)</td><td>1.87 (1.72, 2.04)</td><td>5.36 (8 504)</td><td>1.21 (1.17, 1.25)</td><td>13.33 (21 170)</td><td>1.49 (1.46,1.53)</td><td>5.08 (8 066)</td><td>2.75 (2.62, 2.87)</td></tr><tr><td>Least advantaged</td><td>1.16 (2 125)</td><td>1.97 (1.81, 2.13)</td><td>5.49 (10 062)</td><td>1.25 (1.21, 1.29)</td><td>13.63 (24 989)</td><td>1.54 (1.51,1.58)</td><td>5.33 (9 769)</td><td>2.91 (2.78, 3.04)</td></tr><tr><td>Total n</td><td>11 687</td><td></td><td>66 206</td><td></td><td>161 084</td><td></td><td>49 463</td><td></td></tr></table>
7206c24f79c539be2c134bf7f9b51a7c0526679e5dc04c74976af8c6374df310.png
simple
<table><tr><td>Species</td><td>Ratio Gavage/i.p.</td><td>Mean Ratio</td></tr><tr><td><i>G. pacificus</i></td><td>&gt;800, &gt;1000, &gt;340</td><td>&gt;713</td></tr><tr><td><i>G. honu</i></td><td>395, 500</td><td>448</td></tr><tr><td><i>G. australes</i></td><td>54, 108, 80, 94, 126, 79, 100</td><td>92</td></tr><tr><td><i>G. cheloniae</i></td><td>369, 170</td><td>270</td></tr><tr><td><i>G. carpenteri</i></td><td>&gt;16</td><td>-</td></tr><tr><td><i>F. paulensis</i></td><td>&gt;63</td><td>-</td></tr><tr><td><i>G. polynesiensis</i></td><td>1.7</td><td>-</td></tr></table>
fb5d82c6cbf925c57c7eef899ac515f89bae45cb6622120e44c803277761d6ea.png
simple
<table><tr><td>Up-regulated miRNAs</td><td>Down-regulated miRNAs</td></tr><tr><td>mmu-miR-2137</td><td>mmu-miR-1199-3p</td></tr><tr><td>mmu-miR-5131</td><td>mmu-miR-218-5p</td></tr><tr><td>mmu-miR-680</td><td>mmu-miR-7a-5p</td></tr><tr><td>mmu-miR-5130</td><td>mmu-miR-374c-5p</td></tr><tr><td>mmu-miR-144</td><td>mmu-miR-449c-5p</td></tr><tr><td>mmu-miR-486</td><td>mmu-miR-450a-2-3p</td></tr><tr><td>mmu-miR-711</td><td>mmu-miR-696</td></tr><tr><td>mmu-miR-449a</td><td></td></tr><tr><td>mmu-miR-193</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-2861</td><td></td></tr><tr><td>mmu-miR-211-3p</td><td></td></tr><tr><td>mmu-miR-763</td><td></td></tr><tr><td>mmu-miR-128-2-5p</td><td></td></tr><tr><td>mmu-miR-542-5p</td><td></td></tr><tr><td>mmu-miR-3473</td><td></td></tr><tr><td>mmu-miR-511-3p</td><td></td></tr><tr><td>mmu-miR-34c-5p</td><td></td></tr><tr><td>mmu-miR-143-5p</td><td></td></tr><tr><td>mmu-miR-5115</td><td></td></tr></table>
387ded1e614fce03bf996c326e9af77523c2e99c9898cc423d1e456735239ad6.png
complex
<table><tr><td colspan="2">Data source</td><td colspan="3">Exhaustive search</td><td colspan="4">KL1LR</td></tr><tr><td></td><td></td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td colspan="2"># of GO terms (# in union)</td><td>AUC</td><td>NCG</td></tr><tr><td>Protein-protein interactions</td><td>OPHID</td><td>192</td><td></td><td>0.82</td><td>201</td><td></td><td>0.89</td><td>83</td></tr><tr><td>Protein domain</td><td>Interpro</td><td>522</td><td>(697)</td><td>0.87</td><td>408</td><td>(518)</td><td>0.89</td><td>266</td></tr><tr><td></td><td>Pfam</td><td>600</td><td></td><td>0.86</td><td>311</td><td></td><td>0.89</td><td>210</td></tr><tr><td>Phenotype</td><td>MGI</td><td>213</td><td></td><td>0.87</td><td>346</td><td></td><td>0.90</td><td>129</td></tr><tr><td>Phylogenetic profile</td><td>BioMart</td><td>33</td><td>(95)</td><td>0.83</td><td>59</td><td>(166)</td><td>0.88</td><td>4</td></tr><tr><td></td><td>Inparanoid</td><td>70</td><td></td><td>0.84</td><td>124</td><td></td><td>0.88</td><td>22</td></tr><tr><td>Disease</td><td>OMIM</td><td>41</td><td></td><td>0.85</td><td>32</td><td></td><td>0.88</td><td>3</td></tr><tr><td>Gene expression</td><td>Zhang <i>et al.</i></td><td>28</td><td></td><td>0.81</td><td>147</td><td></td><td>0.90</td><td>10</td></tr><tr><td></td><td>Su <i>et al.</i></td><td>21</td><td>(55)</td><td>0.82</td><td>158</td><td>(309)</td><td>0.89</td><td>8</td></tr><tr><td></td><td>Sage <i>et al.</i></td><td>16</td><td></td><td>0.83</td><td>113</td><td></td><td>0.90</td><td>7</td></tr></table>
f95ee00effdfc2670e1f8e4d440056df0a2cc1c6cfdd9f8207a871a30eaffd11.png
complex
<table><tr><td rowspan="2"> Criterion</td><td colspan="2">Score</td></tr><tr><td>No</td><td>Yes</td></tr><tr><td>Tortuous vessels</td><td>0</td><td>1</td></tr><tr><td>Large vessels</td><td>0</td><td>1</td></tr><tr><td>Leakage</td><td>0</td><td>1</td></tr><tr><td>Defective flux</td><td>0</td><td>1</td></tr></table>
a836372f29ba4f94e367d5d219f5c23a48f776bf6d553346fcef3bb0942f9374.png
simple
<table><tr><td>BMI classes</td><td>Mean</td><td>95% C.I</td><td>N</td></tr><tr><td>Normal Weight</td><td>21.7</td><td>20.8&#8211;22.6</td><td>84</td></tr><tr><td>Overweight</td><td>19.1</td><td>18.3&#8211;19.8</td><td>123</td></tr><tr><td>Obese Class I</td><td>18.2</td><td>17.3&#8211;19.1</td><td>77</td></tr><tr><td>Obese Class II</td><td>17.4</td><td>16.3&#8211;18.7</td><td>37</td></tr><tr><td>Obese Class III</td><td>17.0</td><td>15.9&#8211;18.1</td><td>59</td></tr></table>
bbb2766af5760cf46c509963ae453f66512aa59aeb7c880158aa97e3ae53843b.png
simple
<table><tr><td></td><td>January</td><td>February</td><td>March</td><td>April</td><td>May</td><td>June</td><td>July</td><td>August</td><td>September</td><td>October</td><td>November</td><td>December</td><td>Total</td></tr><tr><td>Girls</td><td>7057</td><td>6897</td><td>7724</td><td>7414</td><td>7726</td><td>7303</td><td>7600</td><td>7544</td><td>7243</td><td>7078</td><td>6337</td><td>6552</td><td>86475</td></tr><tr><td>Boys</td><td>7280</td><td>7023</td><td>7781</td><td>7750</td><td>8184</td><td>7480</td><td>8021</td><td>7739</td><td>7624</td><td>7199</td><td>6567</td><td>6637</td><td>89285</td></tr><tr><td>Total</td><td>14337</td><td>13920</td><td>15505</td><td>15164</td><td>15910</td><td>14783</td><td>15621</td><td>15283</td><td>14867</td><td>14277</td><td>12904</td><td>13189</td><td>175760</td></tr></table>
4dde64cab867c1bdcf95dcb274d7b66e6cf927716ae654b73df8647a359b7dc3.png
complex
<table><tr><td rowspan="2"> </td><td>Patients with IBS</td><td>Healthy controls</td><td rowspan="2"><i>p</i> value</td></tr><tr><td>(<i>n</i> = 89)</td><td>(<i>n</i> = 13)</td></tr><tr><td>Age in years, mean &#177; SD</td><td>45.7 &#177; 12.9</td><td>43.3 &#177; 8.6</td><td>0.595</td></tr><tr><td>Sex, male/female</td><td>47/42</td><td>9/4</td><td>0.266</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>22.1 &#177; 5.8</td><td>24.5 &#177; 2.9</td><td>0.245</td></tr><tr><td>Anxiety, mean &#177; SD</td><td>5.17 &#177; 3.16</td><td>2.77 &#177; 1.64</td><td>0.009</td></tr><tr><td>Depression, mean &#177; SD</td><td>5.52 &#177; 3.30</td><td>3.54 &#177; 2.50</td><td>0.041</td></tr><tr><td>LES</td><td>40.0 (11.0&#8211;75.0)</td><td>8.0 (0.0&#8211;35.0)</td><td>&lt;0.001</td></tr></table>
c7478d290c95b5a04ef89c20d47b6eaa3b63f2e4781ea670a60afe0c99e23cbe.png
simple
<table><tr><td>Variables</td><td>Overall survival(RR, 95% CI)</td><td><i>p</i></td><td>Disease-specific survival(RR, 95% CI))</td><td><i>p</i></td><td>Disease-free survival(RR, 95% CI)</td><td><i>p</i></td><td>Loco-regional control(RR, 95% CI)</td><td><i>p</i></td><td>Distant metastasis-free survival(RR, 95% CI)</td><td><i>p</i></td></tr><tr><td>T1-2 vs. T3-4</td><td>1.29, 0.56-2.98</td><td>0.56</td><td>1.42, 0.41-4.86</td><td>0.58</td><td>0.85, 0.34-2.16</td><td>0.73</td><td>1.44, 0.27-7.64</td><td>0.67</td><td>1.00, 0.36-2.81</td><td>1.00</td></tr><tr><td>N0-2 vs. N3</td><td>2.47, 0.48-12.71</td><td>0.28</td><td>1.86, 0.15-23.26</td><td>0.63</td><td>2.85, 0.53-15.18</td><td>0.22</td><td>39.06, 1.55-983.27</td><td>0.03</td><td>2.77, 0.54-14.07</td><td>0.22</td></tr><tr><td>Cranial nerve involvement</td><td>0.71, 0.26-1.95</td><td>0.51</td><td>0.73, 0.17-3.13</td><td>0.67</td><td>0.65, 0.18-2.28</td><td>0.50</td><td>0.11, 0.006-2.10</td><td>0.14</td><td>0.95, 0.26-3.46</td><td>0.94</td></tr><tr><td>Supraclavicular nodes</td><td>0.74, 0.15-3.74</td><td>0.71</td><td>0.78, 0.06-9.59</td><td>0.85</td><td>0.45, 0.08-2.50</td><td>0.36</td><td>0.02, 0.001-0.87</td><td>0.04</td><td>0.68, 0.13-3.43</td><td>0.64</td></tr><tr><td>GTVprn (13 ml)</td><td>2.92, 1.22-6.98</td><td>0.02</td><td>4.10, 1.06-15.97</td><td>0.04</td><td>4.81, 1.73-13.36</td><td>&lt; 0.01</td><td>16.83, 1.48-190.78</td><td>0.02</td><td>2.50, 0.84-7.43</td><td>0.10</td></tr></table>
09c6c243eb6e428c47cc335c0355ba6194c9bbd0eb3266e3ccf70bc449663056.png
complex
<table><tr><td>Characteristics</td><td><i>n</i></td><td><i>P</i>-value<sup>a</sup><sup>,</sup><sup>b</sup></td><td>Hazard ratio<sup>a</sup><sup>,</sup><sup>b</sup></td><td>95% CI<sup>a</sup><sup>,</sup><sup>b</sup></td></tr><tr><td colspan="5">Age</td></tr><tr><td>&lt; 20</td><td>18 (82%)</td><td></td><td></td><td></td></tr><tr><td>&gt; 20</td><td>4 (18%)</td><td>0.06</td><td>0.16</td><td>2.3 &#215; 10<sup>&#8722;10</sup>&#8211;1.3</td></tr><tr><td>Median</td><td>13</td><td></td><td></td><td></td></tr><tr><td colspan="5">Gender</td></tr><tr><td>Male</td><td>15 (68%)</td><td rowspan="2">0.05</td><td rowspan="2">0.20</td><td rowspan="2">1.9 &#215; 10<sup>&#8722;10</sup>&#8211;1.2</td></tr><tr><td>Female</td><td>7 (32%)</td></tr><tr><td colspan="5">Tumor volume (cm<sup>3</sup>)</td></tr><tr><td>Median</td><td>1,476</td><td rowspan="2">0.40</td><td rowspan="2">0.48</td><td rowspan="2">0.04&#8211;3.0</td></tr><tr><td>Range</td><td>85&#8211;10,590</td></tr><tr><td colspan="5">Tumor surface (cm<sup>2</sup>)</td></tr><tr><td>Median</td><td>19.2</td><td rowspan="2">0.43</td><td rowspan="2">0.50</td><td rowspan="2">0.02&#8211;3.3</td></tr><tr><td>Range</td><td>3.2&#8211;57.7</td></tr><tr><td colspan="5">Pattern on MRI</td></tr><tr><td>Concentric</td><td>19 (86%)</td><td rowspan="2">0.72</td><td rowspan="2">0.47</td><td rowspan="2">0.10&#8211;2.1</td></tr><tr><td>Longitudinal</td><td>3 (14%)</td></tr><tr><td colspan="5">Histologic response</td></tr><tr><td>Good</td><td>12 (54%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Poor</td><td>10 (46%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Pathologic subtype</td></tr><tr><td>Osteoblastic</td><td>10 (46%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Chondroblastic</td><td>6 (27%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Fibroblastic</td><td>4 (18%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Other</td><td>2 (9%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Location</td></tr><tr><td>Distal femur</td><td>22 (100%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="5">Metastatic disease</td></tr><tr><td>No</td><td>22 (100%)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr></table>
98f89ff9aa0f2e589d9d6f8a52f1016f3fb1bf7a7d79c08cfc9698ce6a861a09.png
simple
<table><tr><td>Date</td><td>Advance</td><td>Applications</td></tr><tr><td>1670s</td><td>Microscope invented by Leeuwenhoek</td><td>Visualize bacteria, protozoa</td></tr><tr><td>1850s</td><td>Puerperal fever identified as infectious and interventions implemented by Semmelweis [23]</td><td>Hospital infection control motivated by growing understanding of microbial etiology</td></tr><tr><td>1864</td><td>Cholera transmission by water proven by Snow</td><td>Risk factor (mode of transmission) and prevention measure for specific infectious syndrome</td></tr><tr><td>1890s</td><td>Proof of parasitic origin (Grassi) and mosquito transmission (Ross) of malaria</td><td>Vector control</td></tr><tr><td>1890s</td><td>Identification of microbial etiologies for tuberculosis, anthrax, and so on; Koch&#8217;s postulates</td><td>Targeted diagnostics, therapeutics, and move from syndromic diagnosis to pathogen identification</td></tr><tr><td>1900-1930s</td><td>Discovery of filterable animal viruses [24]</td><td>Influenza etiology settled (previously thought bacterial) [25]</td></tr><tr><td>1910s-1950s</td><td>Phenotypic subspecies taxonomy: serotyping [26,27], phage typing [28]</td><td>Association of particular types with prognosis [27,29], drug resistance</td></tr><tr><td>1944</td><td>Discovery of DNA as the genetic material [30]</td><td>Basis for genotyping tools for molecular epidemiology</td></tr><tr><td>1970</td><td>Restriction enzymes [31]</td><td>Basis for restriction fragment length polymorphism approaches, including pulsed field gel electrophoresis</td></tr><tr><td>1975-1985</td><td>Sanger DNA sequencing [32], PCR [33]</td><td>Basis for variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) approaches to characterize microbes and their genetic relatedness</td></tr><tr><td>2000s-now</td><td>High-throughput rapid sequencing technologies</td><td>Microbial genome sequencing</td></tr></table>
ce92307b438370f5580bc5b6826c71a604f88fa1790883916fd53135bbf9332b.png
simple
<table><tr><td>Conditions</td><td>Biological Process</td><td>FDRp-value</td><td>Molecular Function</td><td>FDRp-value</td></tr><tr><td>Control</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>transcription factor activity</td><td>3.4e-04</td></tr><tr><td></td><td>response to stress</td><td>1.6e-13</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>7.7e-10</td><td>other molecular functions</td><td>4.5e-02</td></tr><tr><td>Cold</td><td>response to stress</td><td>4.9e-08</td><td>transcription factor activity</td><td>1.7e-07</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-07</td><td>receptor binding or activity</td><td>3.8e-03</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>8.1e-06</td><td>kinase activity</td><td>2.9e-02</td></tr><tr><td></td><td>transcription</td><td>3.3e-04</td><td></td><td></td></tr><tr><td></td><td>signal transduction</td><td>3.2e-03</td><td></td><td></td></tr><tr><td>Genotoxic</td><td>response to abiotic or biotic stimulus</td><td>2.9e-20</td><td>kinase activity</td><td>7.6e-06</td></tr><tr><td></td><td>response to stress</td><td>3.8e-16</td><td>transcription factor activity</td><td>8.9e-04</td></tr><tr><td></td><td>other biological processes</td><td>1.8e-11</td><td>transferase activity</td><td>1.7e-03</td></tr><tr><td></td><td>signal transduction</td><td>7.3e-03</td><td>transporter activity</td><td>1.4e-02</td></tr><tr><td>Osmotic</td><td>response to stress</td><td>1.4e-16</td><td>transferase activity</td><td>7.0e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>1.4e-14</td><td>kinase activity</td><td>1.4e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.3e-08</td><td>transcription factor activity</td><td>1.3e-02</td></tr><tr><td></td><td>signal transduction</td><td>1.3e-02</td><td>other molecular functions</td><td>4.3e-02</td></tr><tr><td>Salt</td><td>response to abiotic or biotic stimulus</td><td>3.0e-12</td><td>structural molecule activity</td><td>1.1e-13</td></tr><tr><td></td><td>response to stress</td><td>6.0e-07</td><td>transferase activity</td><td>2.3e-03</td></tr><tr><td></td><td>other biological processes</td><td>3.3e-03</td><td>other enzyme activity</td><td>2.4e-02</td></tr><tr><td>UV-B</td><td>response to abiotic or biotic stimulus</td><td>3.1e-12</td><td>transferase activity</td><td>1.3e-02</td></tr><tr><td></td><td>response to stress</td><td>2.3e-11</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td>other biological processes</td><td>1.6e-08</td><td></td><td></td></tr><tr><td>Wounding</td><td>response to abiotic or biotic stimulus</td><td>1.4e-17</td><td>other enzyme activity</td><td>6.3e-06</td></tr><tr><td></td><td>response to stress</td><td>1.0e-15</td><td>transferase activity</td><td>2.1e-03</td></tr><tr><td></td><td>other biological processes</td><td>1.1e-10</td><td>transcription factor activity</td><td>2.1e-03</td></tr><tr><td></td><td>other metabolic processes</td><td>4.7e-02</td><td>hydrolase activity</td><td>1.2e-02</td></tr><tr><td></td><td></td><td></td><td>transporter activity</td><td>4.1e-02</td></tr><tr><td>Drought</td><td>response to abiotic or biotic stimulus</td><td>2.8e-19</td><td>structural molecule activity</td><td>7.9e-18</td></tr><tr><td></td><td>response to stress</td><td>6.0e-19</td><td>transferase activity</td><td>6.7e-05</td></tr><tr><td></td><td>other biological processes</td><td>6.4e-10</td><td>other enzyme activity</td><td>3.8e-04</td></tr><tr><td></td><td>other metabolic processes</td><td>1.8e-02</td><td></td><td></td></tr><tr><td>Heat</td><td>other biological processes</td><td>7.0e-12</td><td>transferase activity</td><td>9.3e-04</td></tr><tr><td></td><td>response to abiotic or biotic stimulus</td><td>7.7e-10</td><td>other enzyme activity</td><td>2.1e-03</td></tr><tr><td></td><td>response to stress</td><td>3.4e-08</td><td>hydrolase activity</td><td>3.1e-02</td></tr><tr><td></td><td>electron transport or energy pathways</td><td>9.5e-03</td><td></td><td></td></tr><tr><td>Oxidative</td><td>response to abiotic or biotic stimulus</td><td>7.3e-17</td><td>transcription factor activity</td><td>2.2e-03</td></tr><tr><td></td><td>other biological processes</td><td>6.5e-14</td><td>other enzyme activity</td><td>5.7e-03</td></tr><tr><td></td><td>response to stress</td><td>7.7e-10</td><td>kinase activity</td><td>1.4e-02</td></tr><tr><td></td><td></td><td></td><td>transferase activity</td><td>1.6e-02</td></tr></table>
a4989750a2dda864ebc579c8a78a9f8eb511dd6b111feef8d30d2802d4c56556.png
complex
<table><tr><td rowspan="2"></td><td>Did not require ICU(<i>n</i> = 249)</td><td>Required ICU (severe)(<i>n</i> = 18)</td><td rowspan="2"><i>P</i>b value</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Any medical risk factor a</td><td>115 (46.2)</td><td>11 (61.1)</td><td>.22</td></tr><tr><td>Influenza B strain</td><td>47 (19.0)</td><td>7 (38.9)</td><td>.04</td></tr><tr><td>Iron&#8208;deficient anaemia</td><td>21 (8.4)</td><td>5 (27.8)</td><td>.01</td></tr><tr><td>Food allergy</td><td>6 (2.4)</td><td>2 (11.1)</td><td>.09</td></tr><tr><td>Proportion less than 2 y of age </td><td>150 (60.2)</td><td>14 (77.8)</td><td>.14</td></tr><tr><td>Antiviral prescribed</td><td>34 (13.7)</td><td>2 (11.8)</td><td>.82</td></tr><tr><td>Antibiotic prescribed</td><td>121 (48.8)</td><td>9 (52.9)</td><td>.74</td></tr><tr><td>Co&#8208;infection identified</td><td>99 (39.8)</td><td>8 (47.1)</td><td>.55</td></tr></table>
08fd2a0cad135e41181b932b258fa6759b00db0e909dd311a6b95bb73ba038ce.png
complex
<table><tr><td>Baseline characteristics</td><td></td><td>Missed scheduled appointments (%)</td><td>RR</td><td>95 % CI</td><td><i>p</i> (value)</td></tr><tr><td rowspan="2">Sex</td><td>Female</td><td>4/153 (2.6)</td><td>1</td><td></td><td></td></tr><tr><td>Male</td><td>33/304 (10.9)</td><td>4.2</td><td>1.5&#8211;11.5</td><td>0.004</td></tr><tr><td>Age (years)</td><td>&lt;25</td><td>5/82 (6.1)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>25&#8211;64</td><td>31/360 (8.6)</td><td>1.4</td><td>0.6&#8211;3.5</td><td>0.21</td></tr><tr><td></td><td>&#8805;65</td><td>1/15 (6.7)</td><td>1.1</td><td>0.1&#8211;8.7</td><td>1</td></tr><tr><td>HIV-Status</td><td>Negative</td><td>34/346 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>Positive</td><td>3/108 (2.8)</td><td>0.3</td><td>0.1&#8211;0.9</td><td>0.03</td></tr><tr><td></td><td>Unknown</td><td>0/3 (0)</td><td>-</td><td></td><td>-</td></tr><tr><td>Type of TB</td><td>New SS+</td><td>36/410 (9.8)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>Retreatment</td><td>1/47 (4.3)</td><td>0.2</td><td>0.03&#8211;1.7</td><td>0.16</td></tr><tr><td>Place of treatment</td><td>CNHP-P</td><td>21/259 (8.1)</td><td>1</td><td></td><td></td></tr><tr><td></td><td>DOT clinic</td><td>16/198 (8.1)</td><td>1.0</td><td>0.5&#8211;1.9</td><td>0.99</td></tr></table>
46921367575651aa16bd7a894dcbc987c9e708e3d8318f88a0d3895202c0189a.png
complex
<table><tr><td>Explanatory variable</td><td>Coefficient &#177; Standar Error</td><td><i>P</i></td></tr><tr><td colspan="3">Body Fat at follow-up equation, kg</td></tr><tr><td> Leisure time physical activity at follow-up, METs/wk</td><td>&#8722;0.215 &#177; 0.091</td><td>0.019</td></tr><tr><td> Calorie Intake at follow-up, 100 kcal</td><td>0.328 &#177; 0.142</td><td>0.021</td></tr><tr><td> Age at follow-up</td><td>0.115 &#177; 0.036</td><td>0.001</td></tr><tr><td> Height at follow-up</td><td>0.520 &#177; 0.092</td><td>&lt; 0.001</td></tr><tr><td> Constant</td><td>28.399 &#177; 0.425</td><td>&lt; 0.001</td></tr><tr><td colspan="3">Leisure time physical activity at follow-up equation, METs/wk</td></tr><tr><td> Body fat at follow-up, kg</td><td>1.059 &#177; 0.456</td><td>0.020</td></tr><tr><td> Depression score at follow-up, CES-D*</td><td>&#8722;0.191 &#177; 0.095</td><td>0.045</td></tr><tr><td> Age at follow-up</td><td>&#8722;0.025 &#177; 0.071</td><td>0.722</td></tr><tr><td> Constant</td><td>&#8722;30.038 &#177; 12.750</td><td>0.018</td></tr><tr><td colspan="3">Calorie Intake at follow-up equation, 100 kcal</td></tr><tr><td> Body fat at follow-up, kg</td><td>&#8722;0.341 &#177; 0.183</td><td>0.063</td></tr><tr><td> Depression score at follow-up, CES-D*</td><td>0.188 &#177; 0.048</td><td>&lt; 0.001</td></tr><tr><td> Age at follow-up</td><td>&#8722;0.067 &#177; 0.035</td><td>0.057</td></tr><tr><td> Constant</td><td>9.630 &#177; 5.285</td><td>0.068</td></tr><tr><td colspan="3">Error Covariances</td></tr><tr><td> Calorie intake with physical activity</td><td>&#8722;26.882 &#177; 20.302</td><td>0.185</td></tr></table>
885348360a75b1e94d40f18dee9595953e38215d7904c2fb978d4aebf0d64977.png
complex
<table><tr><td>Brain regions</td><td> </td><td>Voxels</td><td><i>X</i> (MNI)</td><td><i>Y</i> (MNI)</td><td><i>Z</i> (MNI)</td><td><i>T</i> value</td></tr><tr><td>High BrAC group &lt; control</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Superior frontal gyrus</td><td>R</td><td>750</td><td>15</td><td>21</td><td>57</td><td>&#8722;4.6134</td></tr><tr><td>R</td><td>39</td><td>12</td><td>39</td><td>&#8722;24</td><td>&#8722;3.7952</td></tr><tr><td> Inferior frontal gyrus</td><td>R </td><td>37</td><td>54</td><td>21</td><td>18</td><td>&#8722;4.4388</td></tr><tr><td> Hippocampal gyrus</td><td>R</td><td>39</td><td>18</td><td>&#8722;6</td><td>&#8722;33</td><td>&#8722;4.6794</td></tr><tr><td> Inferior temporal gyrus</td><td>R</td><td>30</td><td>33</td><td>9</td><td>&#8722;45</td><td>&#8722;4.2946</td></tr><tr><td>High BrAC group &gt; control</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2"> Middle frontal gyrus</td><td>L</td><td>100</td><td>&#8722;27</td><td>45</td><td>3</td><td>4.7207</td></tr><tr><td>R</td><td>42</td><td>12</td><td>&#8722;21</td><td>60</td><td>6.4199</td></tr><tr><td> Basal ganglia</td><td>L</td><td>468</td><td>&#8722;27</td><td>12</td><td>&#8722;3</td><td>5.7696</td></tr><tr><td> Cerebellum </td><td>R</td><td>114</td><td>9</td><td>48</td><td>&#8722;24</td><td>6.8909</td></tr><tr><td> Internal capsule</td><td>R</td><td>39</td><td>9</td><td>0</td><td>6</td><td>3.9489</td></tr></table>
27ced2db3f8c24ec1cca5d270792e966d17fd60d5c7f282a69ea16680adb4462.png
simple
<table><tr><td>Gene</td><td>Acc. No</td><td>Primer sequence (5&#8242; to 3&#8242;)</td></tr><tr><td><i>Pparg</i> (mouse)</td><td>NM_001127330</td><td>F: GACCACTCGCATTCCTTT</td></tr><tr><td> </td><td> </td><td>R: CCACAGACTCGGCACTCA</td></tr><tr><td><i>Fabp4</i> (mouse)</td><td>NM_024406</td><td>F: AAATCACCGCAGACGACA</td></tr><tr><td> </td><td> </td><td>R: CACATTCCACCACCAGCT</td></tr><tr><td><i>Runx2</i> (mouse)</td><td>NM_001146038</td><td>F: ACTTCCTGTGCTCCGTGCTG</td></tr><tr><td> </td><td> </td><td>R: TCGTTGAACCTGGCTACTTGG</td></tr><tr><td><i>Osterix</i> (mouse)</td><td>NM_130458</td><td>F: ACCAGGTCCAGGCAACAC</td></tr><tr><td> </td><td> </td><td>R: GCAAAGTCAGATGGGTAAGTAG</td></tr><tr><td><i>Tmem64</i> (mouse)</td><td>NM_181401</td><td>F: AGGAAGCGGCCTGAAGGT</td></tr><tr><td> </td><td> </td><td>R: GAAGGAAGAGCCACTGGGAT</td></tr><tr><td><i>&#946;-actin</i> (mouse)</td><td>NM_007393</td><td>F: CTGTCCCTGTATGCCTCTG</td></tr><tr><td> </td><td> </td><td>R: TGATGTCACGCACGATTT</td></tr></table>
fe6c4929fda8844b175be8fa59cbd75836ecb1604876ba88bf149578c97da2a2.png
complex
<table><tr><td rowspan="3">Dataset</td><td colspan="6">Sum of Weights</td></tr><tr><td colspan="3">Deterministic Model</td><td colspan="3">Stochastic Model</td></tr><tr><td>Before Failure</td><td>After Failure</td><td>W-GAP</td><td>Before Failure</td><td>After Failure</td><td>W-GAP</td></tr><tr><td>Dataset_1</td><td>37.6</td><td>33</td><td>12.2%</td><td>36.3</td><td>36.3</td><td>0.0%</td></tr><tr><td>Dataset_2</td><td>35.9</td><td>31.6</td><td>12.0%</td><td>35.3</td><td>33.8</td><td>4.2%</td></tr><tr><td>Dataset_3</td><td>35.9</td><td>26.4</td><td>26.5%</td><td>32.9</td><td>32.9</td><td>0.0%</td></tr><tr><td>Dataset_4</td><td>33.1</td><td>23.6</td><td>28.7%</td><td>32.1</td><td>26.9</td><td>16.2%</td></tr><tr><td>Dataset_5</td><td>27.7</td><td>21.7</td><td>21.7%</td><td>26.5</td><td>21.9</td><td>17.4%</td></tr><tr><td>Dataset_6</td><td>34.6</td><td>30.4</td><td>12.1%</td><td>33.9</td><td>33.9</td><td>0.0%</td></tr><tr><td>Dataset_7</td><td>32.2</td><td>31.1</td><td>3.4%</td><td>31.4</td><td>31.4</td><td>0.0%</td></tr><tr><td>Dataset_8</td><td>34</td><td>25.8</td><td>24.1%</td><td>32.5</td><td>30.9</td><td>4.9%</td></tr><tr><td>Dataset_9</td><td>34.5</td><td>26.9</td><td>22.0%</td><td>32.4</td><td>32.4</td><td>0.0%</td></tr><tr><td>Dataset_10</td><td>29.4</td><td>26.1</td><td>11.2%</td><td>28.3</td><td>28.3</td><td>0.0%</td></tr><tr><td>Average</td><td>33.5</td><td>27.7</td><td>17.4%</td><td>32.2</td><td>30.9</td><td>4.0%</td></tr></table>
4039b2734334d5809c8645d80c30fbf0f70321b27a284f2e6e8ec880bb8d0864.png
complex
<table><tr><td></td><td colspan="2">Girls</td><td>Boys</td></tr><tr><td>Goodness-of-fit statistics</td><td>1-factor model</td><td>2- factor model</td><td>1-factor model</td></tr><tr><td>&#967;<sup>2</sup></td><td>8.13</td><td>4.41</td><td>4.44</td></tr><tr><td>df</td><td>5</td><td>4</td><td>5</td></tr><tr><td>p</td><td>.15</td><td>.35</td><td>.49</td></tr><tr><td>RMSEA</td><td>.028</td><td>.018</td><td>.00</td></tr><tr><td>CFI</td><td>.98</td><td>.99</td><td>1.00</td></tr><tr><td>TLI</td><td>.97</td><td>.98</td><td>1.02</td></tr><tr><td>r</td><td></td><td>.61</td><td></td></tr></table>
e15065c932c2541de2dd9d1deca51c3101d72e57d22cdd6d178cddb2ff53eb52.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td>First outbreak (October 2013)</td><td></td><td>Second outbreak (July 2014)</td><td></td></tr><tr><td colspan="2">Water temperature: 23 &#176;C</td><td colspan="2">Water temperature: 26 &#176;C</td></tr><tr><td>Cage</td><td>Date stocked</td><td>Age at stocking (months)</td><td>Average weight at first outbreak (g)</td><td>Cumulative mortality (%)</td><td>Average weight at second outbreak (g)</td><td>Cumulative mortality (%)</td></tr><tr><td>1</td><td>April 2012</td><td>2</td><td>323</td><td>4,82</td><td>336</td><td>4,86</td></tr><tr><td>2</td><td>April 2012</td><td>2</td><td>319</td><td>5,30</td><td>440</td><td>5,3</td></tr><tr><td>3</td><td>July 2012</td><td>5</td><td>292</td><td>4,76</td><td>441</td><td>4,76</td></tr><tr><td>4</td><td>April 2013</td><td>2</td><td>84</td><td>2,23</td><td>274</td><td>2,23</td></tr></table>
5c8b632deefe62dfe146ff9e84e0987afc0f144c8cee28a658430018792cc9ed.png
complex
<table><tr><td>Treatment</td><td colspan="2">Days from transplant to initial bolting (d)</td><td colspan="2">Days from transplant to 50% bolting (d)</td><td colspan="2">Bolting rate by 30 April (%)</td></tr><tr><td> </td><td>2011</td><td>2012</td><td>2011</td><td>2012</td><td>2011</td><td>2012</td></tr><tr><td>Grand mean</td><td>128.4</td><td>139.7</td><td>140.5</td><td>-</td><td>39.7</td><td>16.0</td></tr><tr><td>Cultivars</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>JinGuan</td><td>110.9c<sup>a</sup></td><td>118.6c</td><td>125.8c</td><td>-</td><td>53.9a</td><td>26.7a</td></tr><tr><td>XiaHei</td><td>145.2a</td><td>158.9a</td><td>-a</td><td>-</td><td>29.3c</td><td>5.9c</td></tr><tr><td>YeFu</td><td>129.1b</td><td>141.6b</td><td>130.8b</td><td>-</td><td>36.0b</td><td>15.5b</td></tr><tr><td>Sowing date</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>08.20</td><td>118.0c</td><td>124.2c</td><td>119.8c</td><td>-</td><td>64.5a</td><td>30.1a</td></tr><tr><td>09.09</td><td>125.6b</td><td>141.9b</td><td>136.8b</td><td>-</td><td>39.7b</td><td>12.6b</td></tr><tr><td>09.29</td><td>141.7a</td><td>152.9a</td><td>-a</td><td>-</td><td>15.0c</td><td>5.4c</td></tr><tr><td>Transplant location</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Open field</td><td>155.0a</td><td>151.9a</td><td>-a</td><td>-</td><td>9.3c</td><td>5.6c</td></tr><tr><td>Cold shed</td><td>123.7b</td><td>138.4b</td><td>132.8b</td><td>-</td><td>44.7b</td><td>16.0b</td></tr><tr><td>Plastic tunnel</td><td>106.6c</td><td>128.7c</td><td>123.8c</td><td>-</td><td>65.2a</td><td>26.4a</td></tr><tr><td>F-test</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cultivar (C)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Sowing date (D)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>Transplant location (L)</td><td>***</td><td>***</td><td>***</td><td>NS</td><td>**</td><td>***</td></tr><tr><td>C*D</td><td>***</td><td>***</td><td>*</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>*</td><td>***</td></tr><tr><td>D*L</td><td>***</td><td>***</td><td>**</td><td>NS</td><td>***</td><td>***</td></tr><tr><td>C*D*L</td><td>***</td><td>***</td><td>NS</td><td>NS</td><td>***</td><td>***</td></tr></table>
090c8168b7e69df332f615d544c57fa69508654b1bacf50189c61c3233081086.png
complex
<table><tr><td rowspan="2">Brain region</td><td>BA</td><td>Cluster sizes</td><td>t-value</td><td>P value</td><td colspan="3">Peak MNI coodinate</td></tr><tr><td colspan="2">(voxels)</td><td colspan="2">(Corr.)</td><td>X</td><td>Y</td><td>Z</td></tr><tr><td>R medial prefrontal cortex</td><td>8</td><td>12</td><td>6.02</td><td>&lt;.05</td><td>9</td><td>27</td><td>57</td></tr><tr><td>R middle frontal gyrus</td><td>9</td><td>211</td><td>10.87</td><td>&lt;.05</td><td>3</td><td>48</td><td>21</td></tr><tr><td>L middle temporal gyrus</td><td>21</td><td>14</td><td>&#8722;5.49</td><td>&lt;.05</td><td>&#8722;66</td><td>&#8722;54</td><td>3</td></tr><tr><td>R superior temporal gyrus</td><td>38</td><td>12</td><td>&#8722;5.59</td><td>&lt;.05</td><td>54</td><td>12</td><td>&#8722;18</td></tr><tr><td>L primary somatosensory cortex</td><td>2</td><td>19</td><td>&#8722;3.88</td><td>&lt;.05</td><td>&#8722;60</td><td>&#8722;21</td><td>42</td></tr><tr><td>R inferior parietal lobule</td><td>40</td><td>10</td><td>&#8722;10.94</td><td>&lt;.05</td><td>66</td><td>&#8722;36</td><td>21</td></tr><tr><td>L parahippocampal gyrus</td><td>&#8213;</td><td>11</td><td>&#8722;5.62</td><td>&lt;.05</td><td>&#8722;9</td><td>&#8722;3</td><td>&#8722;21</td></tr><tr><td>R parahippocampal gyrus</td><td>35</td><td>29</td><td>9.51</td><td>&lt;.05</td><td>30</td><td>&#8722;6</td><td>&#8722;21</td></tr><tr><td>L anterior cingulate cortex</td><td>32</td><td>12</td><td>&#8722;4.74</td><td>&lt;.05</td><td>&#8722;6</td><td>21</td><td>39</td></tr><tr><td>R precuneus</td><td>7</td><td>14</td><td>4.70</td><td>&lt;.05</td><td>18</td><td>&#8722;66</td><td>33</td></tr><tr><td>R insula</td><td>13</td><td>10</td><td>5.47</td><td>&lt;.05</td><td>39</td><td>0</td><td>18</td></tr><tr><td>R cerebellar tonsil</td><td>&#8213;</td><td>13</td><td>5.30</td><td>&lt;.05</td><td>9</td><td>&#8722;60</td><td>&#8722;48</td></tr></table>
4b1d8a4cbf03c98390d4d4ec431f86aa43fb09f9e644a0d77d7a8792550999d8.png
complex
<table><tr><td>Category</td><td>Treatment adherence barriers</td></tr><tr><td rowspan="2">Stigma related factors</td><td>&#9642; Fear of disclosure of child&#8217;s status to the teachers and family members by parents</td></tr><tr><td>&#9642; Segregation by teachers and other children</td></tr><tr><td rowspan="4">Lack of supportive environment at home</td><td>&#9642; Inadequate support from parents</td></tr><tr><td>&#10146; Parents move to farming areas without one to follow up on child&#8217;s treatment schedule</td></tr><tr><td>&#10146; Men do not provide enough treatment adherence support</td></tr><tr><td>&#10146; Extended family members do not provide support</td></tr><tr><td>Lack of supportive environment from school</td><td>&#9642; Teachers do not provide adequate support to children on ART</td></tr><tr><td rowspan="3">Health service delivery factors</td><td>&#9642; Lack of child friendly counseling services</td></tr><tr><td>&#9642; Inconvenient treatment schedule</td></tr><tr><td>&#9642; Longevity of treatment</td></tr><tr><td rowspan="2">Patient factor</td><td>&#9642; Forgetfulness</td></tr><tr><td>&#9642; Feeling better</td></tr></table>
8d0225008b7b48603909bccc03608dd06a86821a010fa8703d4395ef8970876b.png
complex
<table><tr><td rowspan="2"></td><td>Factor</td></tr><tr><td>1</td></tr><tr><td>Me siento cansado y desanimado cuando me levanto por las man&#771;anas</td><td>0.612</td></tr><tr><td>Mis mu&#769;sculos esta&#769;n tensos y doloridos</td><td>0.650</td></tr><tr><td>Tengo ataques de pa&#769;nico</td><td>0.388</td></tr><tr><td>Rechino los dientes o aprieto la mandi&#769;bula</td><td>0.342</td></tr><tr><td>Tengo problemas de diarrea o estren&#771;imiento</td><td>0.400</td></tr><tr><td>Necesito ayuda pare realizar mis actividades diarias</td><td>0.476</td></tr><tr><td>Soy sensible a la luz brillante</td><td>0.440</td></tr><tr><td>Me canso fa&#769;cilmente cuando estoy fi&#769;sicamente activo</td><td>0.724</td></tr><tr><td>Siento dolor en todo mi cuerpo</td><td>0.582</td></tr><tr><td>Tengo dolores de cabeza</td><td>416</td></tr><tr><td>Tengo molestia en mi vejiga o sensacio&#769;n de quemazo&#769;n al orinar</td><td>0.294</td></tr><tr><td>No duermo bien</td><td>0.504</td></tr><tr><td>Tengo dificultad para concentrarme</td><td>0.436</td></tr><tr><td>Tengo problemas en la piel como resequedad, picor o sarpullido</td><td>0.299</td></tr><tr><td>El estre&#769;s hace que mis si&#769;ntomas fi&#769;sicos empeoren</td><td>0.587</td></tr><tr><td>Me siento triste o deprimido</td><td>0.621</td></tr><tr><td>Me siento con poca energi&#769;a</td><td>0.718</td></tr><tr><td>Tengo tensio&#769;n muscular en mi cuello y hombros</td><td>0.555</td></tr><tr><td>Tengo dolor en mi mandi&#769;bula</td><td>0.426</td></tr><tr><td>Algunos olores, como perfumes, me hacen sentir na&#769;useas.</td><td>0.269</td></tr><tr><td>Tengo que orinar frecuentemente</td><td>0.276</td></tr><tr><td>Mis piernas se sienten inco&#769;modas e inquietas cuando intento dormir por la noche</td><td>0.476</td></tr><tr><td>Tengo dificultad para recordar cosas</td><td>0.482</td></tr><tr><td>Sufri&#769; algu&#769;n trauma cuando era nin&#771;o (a)</td><td>0.120</td></tr><tr><td>Tengo dolor en mi zona pe&#769;lvica</td><td>0.289</td></tr></table>
5b785a269eb49f6dad43714f4c71fb9af31f0eb1ca0f916bddfbd4614dc30dc1.png
complex
<table><tr><td rowspan="2">Symbol</td><td colspan="2">2 Days <i>vs.</i> Ctr</td><td colspan="2">4 Days <i>vs.</i> Ctr</td><td colspan="2">7 Days <i>vs.</i> Ctr</td></tr><tr><td><i>P</i>-Value</td><td>Fold Change</td><td><i>P</i>-Value</td><td>Fold Change</td><td><i>P</i>-Value</td><td>Fold Change</td></tr><tr><td>ANKRD50</td><td>2.82 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.323</td><td>2.32 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.191</td><td>2.35 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.749</td></tr><tr><td>ANKRD36B </td><td>4.65 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.292</td><td>1.85 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.546</td><td>9.24 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.979</td></tr><tr><td>C9orf3</td><td>7.91 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;3.622</td><td>5.04 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;3.860</td><td>6.56 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.938</td></tr><tr><td>CCDC88C</td><td>1.82 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.363</td><td>1.51 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.398</td><td>6.70 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.041</td></tr><tr><td>CYP24A1</td><td>9.28 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.027</td><td>8.44 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.060</td><td>3.32 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.011</td></tr><tr><td>DGKH</td><td>3.48 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.619</td><td>8.80 &#215; 10<sup>&#8722;8</sup></td><td>&#8722;2.114</td><td>2.51 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.681</td></tr><tr><td>DHFR</td><td>3.77 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.779</td><td>6.90 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.717</td><td>3.10 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.139</td></tr><tr><td>FAP</td><td>2.07 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.562</td><td>4.72 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.284</td><td>3.01 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.314</td></tr><tr><td>GTF2B</td><td>2.33 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.580</td><td>6.39 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.131</td><td>1.37 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.072</td></tr><tr><td>HDCA1</td><td>8.97 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.015</td><td>2.43 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.147</td><td>1.11 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;3.399</td></tr><tr><td>HAS2</td><td>6.50 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.375</td><td>7.49 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.920</td><td>8.18 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.342</td></tr><tr><td>LIF</td><td>4.97 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.906</td><td>2.85 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.403</td><td>1.23 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.440</td></tr><tr><td>LRRN1</td><td>2.41 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.422</td><td>1.78 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.501</td><td>1.71 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;2.217</td></tr><tr><td>mir-21</td><td>5.77 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.677</td><td>6.96 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;3.347</td><td>7.02 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.131</td></tr><tr><td>MPLKIP</td><td>2.86 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.829</td><td>1.59 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.983</td><td>4.89 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.618</td></tr><tr><td>NPIPL3 </td><td>3.40 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.249</td><td>2.27 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.348</td><td>5.88 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.398</td></tr><tr><td>NRG1</td><td>1.57 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.666</td><td>4.65 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.067</td><td>1.12 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.022</td></tr><tr><td>PLA2G7</td><td>6.14 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.062</td><td>3.73 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.299</td><td>1.61 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.018</td></tr><tr><td>PSD3</td><td>1.43 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.141</td><td>1.78 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.162</td><td>9.70 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.012</td></tr><tr><td>RNF152</td><td>4.83 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.118</td><td>1.16 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.119</td><td>6.23 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.381</td></tr><tr><td>SESN3</td><td>6.85 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.206</td><td>5.50 &#215; 10<sup>&#8722;7</sup></td><td>&#8722;2.044</td><td>6.02 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;1.684</td></tr><tr><td>SLC7A11</td><td>1.55 &#215; 10<sup>&#8722;1</sup></td><td>&#8722;1.279</td><td>3.03 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.078</td><td>1.02 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.963</td></tr><tr><td>SMAD2</td><td>4.59 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.526</td><td>9.51 &#215; 10<sup>&#8722;6</sup></td><td>&#8722;2.195</td><td>2.76 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.848</td></tr><tr><td>SMG1</td><td>1.43 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;2.030</td><td>2.45 &#215; 10<sup>&#8722;5</sup></td><td>&#8722;2.503</td><td>4.67 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.395</td></tr><tr><td>TAF1D</td><td>7.99 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;1.961</td><td>2.85 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.177</td><td>2.71 &#215; 10<sup>&#8722;2</sup></td><td>&#8722;1.770</td></tr><tr><td>TRA2A</td><td>1.38 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.456</td><td>3.45 &#215; 10<sup>&#8722;3</sup></td><td>&#8722;2.229</td><td>6.73 &#215; 10<sup>&#8722;4</sup></td><td>&#8722;1.357</td></tr></table>
4be53f7b3e3c6ef7e6203e7bd900ee7482f20c6399a5f4d14024e2d81fe662cc.png
simple
<table><tr><td>Patient Safety Culture Composite</td><td>Definition: The extent to which....</td><td>Number of Survey Items</td></tr><tr><td>1. Communication openness</td><td>Staff will freely speak up if they see something that may negatively affect patient care, and feel free to question those with more authority</td><td>3</td></tr><tr><td>2. Feedback &amp; communication about error</td><td>Staff are informed about errors that happen, given feedback about changes put into place based on event reports, and discuss ways to prevent errors</td><td>3</td></tr><tr><td>3. Frequency of events reported</td><td>Mistakes of the following types are reported:1) mistakes caught and corrected before affecting the patient, 2) mistakes with no potential to harm the patient, and 3) mistakes that could harm the patient, but do not</td><td>3</td></tr><tr><td>4. Handoffs &amp; transitions</td><td>Important patient care information is transferred across hospital units and during shift changes</td><td>4</td></tr><tr><td>5. Management support for patient safety</td><td>Hospital management provides a work climate that promotes patient safety and shows that patient safety is a top priority</td><td>3</td></tr><tr><td>6. Nonpunitive response to error</td><td>Staff feel that their mistakes are not held against them, and mistakes are not kept in their personnel file</td><td>3</td></tr><tr><td>7. Organizational learning--Continuous improvement</td><td>Mistakes have led to positive changes and changes are evaluated for their effectiveness</td><td>3</td></tr><tr><td>8. Overall perceptions of patient safety</td><td>Procedures and systems are good at preventing errors and there is a lack of patient safety problems</td><td>4</td></tr><tr><td>9. Staffing</td><td>There are enough staff to handle the workload and work hours are appropriate to provide the best care for patients</td><td>4</td></tr><tr><td>10. Supervisor/manager expectations and actions promoting safety</td><td>Supervisors/managers consider staff suggestions for improving patient safety, praise staff for following patient safety procedures, and do not overlook patient safety problems</td><td>4</td></tr><tr><td>11. Teamwork across units</td><td>Hospital units cooperate and coordinate with one another to provide the best care for patients</td><td>4</td></tr><tr><td>12. Teamwork within units</td><td>Staff support one another, treat each other with respect, and work together as a team</td><td>4</td></tr></table>
4a4be3ef8497afcb7ebc9291452ac4b1ac01fe1fe30c459f9b92f23bf05757d8.png
simple
<table><tr><td>Oligonucleotide</td><td>Sequence</td></tr><tr><td>NUCKS F (forward)</td><td>5'-AATTCACAGGAAGATAGTGAGG-3'</td></tr><tr><td>NUCKS R (reverse)</td><td>5'-TCACTGTAG CCTTTAGTCTGGG-3'</td></tr><tr><td>GAPDH forward</td><td>5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'</td></tr><tr><td>GAPDH reverse</td><td>5'-GAACATGGGGGCGTCAGCAGAG-3'</td></tr><tr><td>NUCKS Fq (forward, real-time PCR)</td><td>5'-TCTGATGATGCAGATGAAGATTA-3'</td></tr><tr><td>NUCKS Rq (reverse, real-time PCR)</td><td>5'-CTGCTGAGTGAGAATCATCC-3'</td></tr><tr><td>NUCKS FL probe</td><td>5'-TCTTGGTCTTCACATCTTTGTCTTCT-FL-3'</td></tr><tr><td>NUCKS LC probe</td><td>5'-LC640-AGTCCTCACTATCTTCCTGTGAATTCTTT-3'</td></tr></table>
cc8735b169ca4cda682511a99d58758ee793e20b241737be165e5c7f975290ac.png
complex
<table><tr><td rowspan="2">Characteristics of the partner at the first sexual relation</td><td colspan="2">Sex (%)</td></tr><tr><td>Women</td><td>Men</td></tr><tr><td>Type of relationship</td><td></td><td></td></tr><tr><td><i>Namorado </i>(steady boyfriend/girlfriend)</td><td>86</td><td>45</td></tr><tr><td>Husband/wife/living together</td><td>4</td><td>1</td></tr><tr><td>Eventual partner</td><td>9</td><td>48</td></tr><tr><td>Prostitute</td><td>&#8212;</td><td>5 </td></tr><tr><td>Was it also the partner's first sexual relation?</td><td></td><td></td></tr><tr><td>Yes</td><td>14</td><td>37</td></tr><tr><td>No</td><td>83</td><td>57</td></tr><tr><td>Do not know</td><td>3</td><td>6</td></tr><tr><td>Age difference between the interviewee and the partner</td><td></td><td></td></tr><tr><td>The partner is younger</td><td>2</td><td>10</td></tr><tr><td>Same age (&#177;1 year)</td><td>24</td><td>52</td></tr><tr><td>The partner is older (2&#8211;4 years)</td><td>36</td><td>24</td></tr><tr><td>The partner is much older (5 years and more)</td><td>38</td><td>15</td></tr><tr><td>The partner was in school</td><td></td><td></td></tr><tr><td>Yes</td><td>50</td><td>76</td></tr><tr><td>No</td><td>50</td><td>24</td></tr></table>
43053b2f8580b32dc4c9c9290987e1b6ed7bed4bc4458fd7f096c873ce314a7c.png
complex
<table><tr><td rowspan="2">Type of Patient/Specimen Type</td><td colspan="2">2011</td><td colspan="2">2012</td><td colspan="2">2013</td><td colspan="2">2014</td></tr><tr><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td><td>%</td><td><i>n</i><sup>1</sup></td></tr><tr><td>Inpatients</td><td>88.5</td><td>96</td><td>81.0</td><td>126</td><td>86.1</td><td>216</td><td>90.7</td><td>140</td></tr><tr><td>Respiratory samples</td><td>39.0</td><td>95 <sup>2</sup></td><td>39.7</td><td>126</td><td>61.1</td><td>216</td><td>47.1</td><td>140</td></tr></table>
24bc14970a39984765c577d7f062bfd25683ea96c0bcdfac870522601351509e.png
simple
<table><tr><td>Demographic</td><td>Number (%)</td></tr><tr><td>Gender</td><td> </td></tr><tr><td>Male</td><td>64 (43.2)</td></tr><tr><td>Female</td><td>84 (56.8)</td></tr><tr><td>Marital status</td><td> </td></tr><tr><td>Single</td><td>57 (38.5)</td></tr><tr><td>Married</td><td>44 (29.7)</td></tr><tr><td>Widowed</td><td>10 (6.8)</td></tr><tr><td>Divorced</td><td>36 (24.3)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Educational level</td><td> </td></tr><tr><td>None</td><td>6 (4.1)</td></tr><tr><td>Primary</td><td>45 (30.4)</td></tr><tr><td>Secondary</td><td>83 (56.1)</td></tr><tr><td>University/post graduate</td><td>13 (8.8)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr><tr><td>Diagnosis</td><td> </td></tr><tr><td>Schizophrenia</td><td>53 (35.8)</td></tr><tr><td>Paranoid Schizophrenia</td><td>35 (23.6)</td></tr><tr><td>Delusional disorder</td><td>10 (6.8)</td></tr><tr><td>Bipolar affective disorder (BPAD)</td><td>15 (10.1)</td></tr><tr><td>Psychotic depression</td><td>23 (15.5)</td></tr><tr><td>Other (i.e. schizoaffective disorder; non-specified psychosis)</td><td>10 (6.8)</td></tr><tr><td>Unknown</td><td>2 (1.4)</td></tr><tr><td>Employment status</td><td> </td></tr><tr><td>Unemployed</td><td>68 (45.9)</td></tr><tr><td>Employed</td><td>39 (26.3)</td></tr><tr><td>Homemaker</td><td>35 (23.6)</td></tr><tr><td>Retired/other</td><td>5 (3.4)</td></tr><tr><td>Unknown</td><td>1 (0.7)</td></tr></table>
b9b18391a1f1573dc62bdee1caafcc5f72e4ac42329269d0c7b1c799d89c2311.png
complex
<table><tr><td rowspan="3">Indices of clinical burden of Sickle Cell Disease</td><td colspan="2">Children</td></tr><tr><td><i>n</i></td><td>%</td></tr><tr><td>Duration of care since diagnosis</td><td></td><td></td></tr><tr><td>&#8804; 6 months</td><td>22</td><td>9.8</td></tr><tr><td>&gt; 6 months</td><td>203</td><td>90.2</td></tr><tr><td>Previous hospitalisation (range = 0&#8211;24)</td><td></td><td></td></tr><tr><td>No hospitalisation</td><td>16</td><td>7.1</td></tr><tr><td>Once</td><td>32</td><td>14.2</td></tr><tr><td>Twice</td><td>85</td><td>37.8</td></tr><tr><td>&gt; twice</td><td>92</td><td>40.9</td></tr><tr><td>Previous blood transfusion (range = 0&#8211;10)</td><td></td><td></td></tr><tr><td>None</td><td>67</td><td>29.8</td></tr><tr><td>Once</td><td>53</td><td>23.6</td></tr><tr><td>Twice</td><td>70</td><td>31.1</td></tr><tr><td>&gt; twice</td><td>35</td><td>15.6</td></tr><tr><td>Significant bone pain episodes</td><td></td><td></td></tr><tr><td>None</td><td>13</td><td>5.8</td></tr><tr><td>One</td><td>41</td><td>18.2</td></tr><tr><td>Twice</td><td>25</td><td>11.1</td></tr><tr><td>&gt; twice</td><td>146</td><td>64.9</td></tr></table>
fe808ab93885c8fdf0c8ea34b46410eb52531abebc40a073c9473d7ed1c6f5b1.png
simple
<table><tr><td></td><td>(A) 176 drug products</td><td>(B) 45 drug products</td><td>(C) 162 drug products</td></tr><tr><td>Therapeutic group</td><td></td><td></td><td></td></tr><tr><td> A&#8212;alimentary tract and metabolism</td><td>18</td><td>8</td><td>17</td></tr><tr><td> B&#8212;blood and blood-forming organs</td><td>9</td><td>3</td><td>8</td></tr><tr><td> C&#8212;cardiovascular system</td><td>20</td><td>3</td><td>20</td></tr><tr><td> D&#8212;dermatologicals</td><td>6</td><td>3</td><td>5</td></tr><tr><td> G&#8212;genitourinary system and sex hormones</td><td>13</td><td>1</td><td>13</td></tr><tr><td> H&#8212;systemic hormonal preparations, excluding sex hormones and insulins</td><td>7</td><td>1</td><td>6</td></tr><tr><td> J&#8212;anti-infectives for systemic use</td><td>25</td><td>5</td><td>23</td></tr><tr><td> L&#8212;anti-neoplastic and immunomodulating agents</td><td>10</td><td>3</td><td>10</td></tr><tr><td> M&#8212;musculoskeletal system</td><td>6</td><td>3</td><td>6</td></tr><tr><td> N&#8212;nervous system</td><td>24</td><td>8</td><td>23</td></tr><tr><td> P&#8212;anti-parasitic products, insecticides, and repellents</td><td>2</td><td>0</td><td>1</td></tr><tr><td> R&#8212;respiratory system</td><td>15</td><td>4</td><td>10</td></tr><tr><td> S&#8212;sensory organs</td><td>6</td><td>1</td><td>6</td></tr><tr><td> V&#8212;various</td><td>15</td><td>2</td><td>14</td></tr><tr><td>Re-examination dates</td><td></td><td></td><td></td></tr><tr><td> January 2009 to December 2009</td><td>45</td><td>6</td><td>42</td></tr><tr><td> January 2010 to December 2010</td><td>44</td><td>13</td><td>42</td></tr><tr><td> January 2011 to December 2011</td><td>30</td><td>9</td><td>27</td></tr><tr><td> January 2012 to December 2012</td><td>21</td><td>5</td><td>20</td></tr><tr><td> January 2013 to December 2013</td><td>19</td><td>8</td><td>16</td></tr><tr><td> January 2014 to December 2014</td><td>17</td><td>4</td><td>15</td></tr></table>
2e8b6f5db011f0db8c537b5d5af6f39d50108ea06ec69d99db499a644877cf38.png
simple
<table><tr><td>Variables</td><td>Mean&#177;SD</td></tr><tr><td>BMI (Kg/m<sup>2</sup>)</td><td>43.40 &#177; 20.20</td></tr><tr><td>Post-Load PG (mg/dL)</td><td>80.00&#177;15.80</td></tr><tr><td>SBP (mmHg)</td><td>127.60 &#177; 26.70</td></tr><tr><td>DBP (mmHg)</td><td>80.00 &#177; 15.80</td></tr><tr><td>FPG (mg/dL)</td><td>93.40 &#177; 19.80</td></tr><tr><td>Waist Circumference (CM)</td><td>182.84 &#177; 101.10</td></tr></table>
3f804b6eaef6a1c4ffbf1c578e4f6c57959d13b54076512babceeb45eb5d4ae3.png
simple
<table><tr><td>Indication for surgery</td><td>Frequency</td><td>Percentage</td></tr><tr><td>Bleeding duodenal ulcers not responding to either medical or endoscopic treatment</td><td>5</td><td>26.3</td></tr><tr><td>Gastric malignancy</td><td>6</td><td>31.6</td></tr><tr><td>Gastrointestinal stroma tumour</td><td>8</td><td>42.1</td></tr></table>
77ee500d0e90417bece89b36b8cb9cf247b2b8c20e5b863f4d4535ab1888d7c6.png
complex
<table><tr><td></td><td colspan="4">Survey I (<i>n</i> = 2200)</td><td colspan="4">Survey II (<i>n</i> = 2203)</td></tr><tr><td></td><td colspan="2">VL</td><td colspan="2">H</td><td colspan="2">VL</td><td colspan="2">H</td></tr><tr><td></td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td><td>OR</td><td>95 % CI</td></tr><tr><td>Parent characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Mother&#8217;s education</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>College Grad</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Some college</td><td>1.30</td><td>.96/1.76</td><td>1.35</td><td>.99/1.85</td><td>1.09</td><td>.80/1.49</td><td>1.06</td><td>.77/1.44</td></tr><tr><td>HS Grad</td><td>.73</td><td>.51/1.03</td><td>1.37</td><td>1.19/1.88</td><td>.83</td><td>.58/1.18</td><td>1.50</td><td>1.10/2.04</td></tr><tr><td>Less than HS</td><td>.46</td><td>.21/1.00</td><td>2.27</td><td>1.37/3.75</td><td>.44</td><td>.19/1.03</td><td>1.96</td><td>1.69/3.14</td></tr><tr><td> Parent smokes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Yes</td><td>.76</td><td>.57/1.03</td><td>2.10</td><td>1.62/2.73</td><td>.77</td><td>.56/1.06</td><td>2.08</td><td>1.59/2.70</td></tr><tr><td>Family engagement</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No. of days eat together</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;3</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>3&#8211;5</td><td>1.16</td><td>.84/1.61</td><td>.51</td><td>.38/.67</td><td>1.10</td><td>.79/1.53</td><td>.54</td><td>.41/.73</td></tr><tr><td>6&gt;</td><td>1.54</td><td>1.12/2.11</td><td>.48</td><td>.35/.65</td><td>1.17</td><td>.85/1.62</td><td>.49</td><td>.36/.66</td></tr><tr><td> No. times do things for fun</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;2</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;4</td><td>.79</td><td>.60/1.03</td><td>.73</td><td>.55/.96</td><td>1.18</td><td>.89/1.57</td><td>.52</td><td>.41/.67</td></tr><tr><td>5&gt;</td><td>1.07</td><td>.74/1.56</td><td>.77</td><td>.51/.98</td><td>1.51</td><td>1.05/2.17</td><td>.36</td><td>.23/.55</td></tr><tr><td>Parent monitoring</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No. of four best friends parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0&#8211;1</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;3</td><td>.87</td><td>.59/1.26</td><td>.67</td><td>.48/.94</td><td>.84</td><td>.57/1.25</td><td>.82</td><td>.59/1.18</td></tr><tr><td>4</td><td>1.38</td><td>.95/1.99</td><td>.49</td><td>.35/.70</td><td>1.24</td><td>.85/1.81</td><td>.53</td><td>.37/.77</td></tr><tr><td> No. four best friend&#8217;s parents parents know well</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0&#8211;1</td><td>______</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>2&#8211;3</td><td>1.44</td><td>1.06/1.96</td><td>.60</td><td>.46/.77</td><td>1.07</td><td>.78/1.45</td><td>.62</td><td>.49/.82</td></tr><tr><td>4</td><td>1.87</td><td>1.33/2.65</td><td>.31</td><td>.21/.46</td><td>1.37</td><td>.98/1.91</td><td>.43</td><td>.31/.81</td></tr><tr><td> Your parents tell on friend smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.36</td><td>.78/2.36</td><td>.49</td><td>.34/.70</td><td>1.27</td><td>.64/2.53</td><td>.47</td><td>.29/.77</td></tr><tr><td>Yes</td><td>2.03</td><td>1.24/3.30</td><td>.22</td><td>.16/.31</td><td>1.89</td><td>1.30/2.97</td><td>.28</td><td>.21/.37</td></tr><tr><td> Friend&#8217;s parents tell on you smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td><td>___</td><td></td></tr><tr><td>Not sure</td><td>1.13</td><td>.61/2.09</td><td>.49</td><td>.34/.70</td><td>1.02</td><td>.46/2.22</td><td>.49</td><td>.21/.82</td></tr><tr><td>Yes</td><td>1.51</td><td>.86/2.65</td><td>.22</td><td>.16/.31</td><td>1.56</td><td>.93/2.64</td><td>.22</td><td>.16/.30</td></tr></table>
c0336e1c0d2ddebd5f78d8bb57fee92b9d9096924286bb943a5654dd5efa806d.png
simple
<table><tr><td>Subfamily</td><td>Gene identification</td><td></td><td>Domain organisation</td><td>Amino acids</td></tr><tr><td>ABCB</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCB1</td><td>PFE1150w</td><td>PfMDR1</td><td>(MSD-NBD)<sub>2</sub></td><td>1419</td></tr><tr><td> ABCB2</td><td>PF14_0455</td><td>PfMDR2</td><td>MSD-NBD</td><td>1024</td></tr><tr><td> ABCB3</td><td>PF11_0466</td><td></td><td>MSD-NBD</td><td>872</td></tr><tr><td> ABCB4</td><td>PFC0125w</td><td></td><td>MSD-NBD</td><td>1365</td></tr><tr><td> ABCB5</td><td>PF13_0218</td><td></td><td>MSD-NBD</td><td>925</td></tr><tr><td> ABCB6</td><td>PF13_0271</td><td></td><td>MSD-NBD</td><td>1049</td></tr><tr><td> ABCB7</td><td>PFL0495c</td><td></td><td>MSD-NBD</td><td>855</td></tr><tr><td>ABCC</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCC1</td><td>PFA0590w</td><td>PfMRP1</td><td>(MSD-NBD)<sub>2</sub></td><td>1822</td></tr><tr><td> ABCC2</td><td>PFL1410c</td><td>PfMRP2</td><td>(MSD-NBD)<sub>2</sub></td><td>2108</td></tr><tr><td>ABCE</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCE1</td><td>MAL13 P1.344</td><td></td><td>(NBD)<sub>2</sub></td><td>619</td></tr><tr><td>ABCF</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCF1</td><td>PF11_0225</td><td></td><td>(NBD)<sub>2</sub></td><td>815</td></tr><tr><td> ABCF2</td><td>pfGCN20PF08_0078</td><td></td><td>(NBD)<sub>2</sub></td><td>1419</td></tr><tr><td>ABCG</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCG1</td><td>PF14_0244</td><td></td><td>NBD-MSD</td><td>660</td></tr><tr><td>ABCI</td><td></td><td></td><td></td><td></td></tr><tr><td> ABCI1</td><td>PF14_0133</td><td></td><td>NBD</td><td>347</td></tr><tr><td> ABCI2</td><td>PF14_0321</td><td></td><td>NBD</td><td>171</td></tr><tr><td> ABCI3</td><td>PFC0875w</td><td></td><td>MSD-NBD-MSD</td><td>3133</td></tr></table>
2881fab5c060ab899e3eb7f7d7407d7b5532ebfc39a4f0daecae8c4599288656.png
complex
<table><tr><td></td><td colspan="3">Climate model</td></tr><tr><td>Time period</td><td>Median</td><td>Minimal</td><td>Maximal</td></tr><tr><td>1986&#8211;2005</td><td>20.7 (27.4)</td><td></td><td></td></tr><tr><td>2026&#8211;2045</td><td>22.9 (30.0)</td><td>21.6 (28.9)</td><td>22.9 (30.2)</td></tr><tr><td>2081&#8211;2100</td><td>26.1 (35.1)</td><td>24.6 (32.4)</td><td>28.5 (37.7)</td></tr></table>
8490452076a40dbcbf9cd27587d474139423e3235d473eb2f714956d5eb8bdea.png
complex
<table><tr><td>Patient</td><td>Gene</td><td>Varianta</td><td>Patient cancer historyb</td></tr><tr><td colspan="4"><i>Discovered cancer gene mutations (163 disease-gene panel)</i>c</td></tr><tr><td>BRCA1.60</td><td>CHEK2</td><td>c.573+1G&gt;A</td><td>Breast-47, 49</td></tr><tr><td>BRCA1.61</td><td>ATM</td><td>p.Glu2290&#8270;</td><td>Unaffected-24</td></tr><tr><td>BRCA2.7</td><td>RAD50</td><td>c.3G&gt;A</td><td>Breast-49</td></tr><tr><td>BRCA2.13</td><td>ATM</td><td>p.Glu1978&#8270;</td><td>Breast-28, 39, 55; Skin-49</td></tr><tr><td>BRCA2.65</td><td>CDKN2B</td><td>p.Glu35&#8270;</td><td>Melanoma-50</td></tr><tr><td>BRCA2.93</td><td>CHEK2</td><td>p.Gln20&#8270;</td><td>Breast-37, 61; Ovarian-56</td></tr><tr><td colspan="4">&#8232;&#8232;</td></tr><tr><td colspan="4"><i>Discovered cancer gene mutations (ClinVar)</i><sup>c</sup></td></tr><tr><td>BRCA1.48</td><td>ERCC3</td><td>p.Arg109&#8270;</td><td>Breast-39; Skin-61, 66</td></tr><tr><td>BRCA1.73</td><td>DLEC1</td><td>c.2436-2A&gt;G</td><td>Breast-32</td></tr><tr><td>BRCA1.74</td><td>FANCC</td><td>p.Arg548&#8270;</td><td>Breast-42, 53, 55</td></tr></table>
94afe6212d82708cc1cb4d94161c9e0e565ab31c0941b1ea31443428a65bb1c4.png
complex
<table><tr><td>DPC*</td><td>Type</td><td colspan="3">Pathological findings&#8224;</td></tr><tr><td></td><td></td><td>Lung</td><td>Inguinal Lymph Nodes</td><td>Heart</td></tr><tr><td>14</td><td>I</td><td>Moderate focal/multifocal bronchointerstitial pneumonia (3/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/3)</td></tr><tr><td></td><td>II</td><td>Moderate diffuse/multifocal bronchointerstitial pneumonia (2/3)</td><td>Lymphadenopathy (3/3)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis. (3/3)</td></tr><tr><td></td><td>Control</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td><td>No lesions (2/2)</td></tr><tr><td>21</td><td>I</td><td>Moderate diffuse interstitial pneumonia (2/2), moderate peribronchiolar and perivascular lymphohistiocytic cuffing (2/2)</td><td>Lymphadenopathy (2/2)</td><td>Mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>II</td><td>Mild to moderate diffuse interstitial pneumonia (2/2), severe peribronchiolar and perivascular lymphohistiocytic cuffing (1/2)</td><td>Lymphadenopathy (2/2)</td><td>Very mild multifocal perivascular lymphohistiocytic myocarditis (1/2)</td></tr><tr><td></td><td>Control</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td><td>No lesions (1/1)</td></tr></table>
d87c27328353c713d2c7e9469ece0c74cfeb74f52f5d80ff715ee2467756aa80.png
complex
<table><tr><td rowspan="2" colspan="2"> </td><td colspan="2">Believes PPM has exposed him/her to hazardous chemicals</td><td colspan="2">Felt he/she was coughing, breathless or wheezing due to something in the air</td><td colspan="2">Believes the industry will affect children born in the future in the community</td><td colspan="2">Believes the industry will expose him/her to hazards if it opens in the future</td><td colspan="2">Worries about getting health problems in the future because of a polluted environment</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td rowspan="4">Demographic</td><td>Distance from PPM</td><td>2.747*</td><td>1.199-6.295</td><td>1.039<sup>&#8225;</sup></td><td>0.560-1927</td><td>1.132<sup>&#8225;</sup></td><td>0.502-2.554</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Presence of a child in the HH</td><td>34.769*</td><td>1.390-869.96</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Respondent completed HS</td><td>3.105*</td><td>1.394-6.918</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2.553*</td><td>1.086-6.004</td></tr><tr><td>Employment Status</td><td> </td><td> </td><td> </td><td> </td><td>0.434<sup>&#8225;</sup></td><td>0.188-1.004</td><td>0.383*</td><td>0.167-0.879</td><td>0.365*</td><td>0.150-0.886</td></tr><tr><td rowspan="2">HH health Indicators</td><td>Perception of health</td><td>0.527<sup>&#8225;</sup></td><td>0.239-1.162</td><td>0.479*</td><td>0.261-0.878</td><td>0.299*</td><td>0.135-0.660</td><td>0.237**</td><td>0.108-0.517</td><td>0.332*</td><td>0.149-0.738</td></tr><tr><td>Somebody in the HH has one of the conditions (heart, respiratory or skin disease)</td><td>1.788<sup>&#8225;</sup></td><td>0.755-4.237</td><td>1.980*</td><td>1.031-3.802</td><td>2.192<sup>&#8225;</sup></td><td>0.963-4.990</td><td> </td><td> </td><td>2.594*</td><td>1.096-6.143</td></tr><tr><td rowspan="2">Respiratory symptoms</td><td>Coughed phlegm daily for &#8805; 2 months, 2 yrs in a row</td><td> </td><td> </td><td>2.907*</td><td>1.127-7.498</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Had an attack of whistling or noisy sound in the chest when breathing</td><td> </td><td> </td><td>2.881*</td><td>1.402-5.920</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td rowspan="2">Role of Industrial plant</td><td>Family depended on industry</td><td> </td><td> </td><td> </td><td> </td><td>2.287*</td><td>1.001-5.228</td><td>2.792*</td><td>1.234-6.319</td><td> </td><td> </td></tr><tr><td>Community benefited from industry</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>2.289*</td><td>0.997-5.257</td></tr><tr><td rowspan="2">Environmental awareness/knowledge</td><td>Ever actively looked for environmental health information</td><td> </td><td> </td><td>1.883*</td><td>1.002-3.537</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Willing to participate in environmental campaigns</td><td> </td><td> </td><td>2.297<sup>&#8225;</sup></td><td>0.713-7.396</td><td>2.985*</td><td>1.031-8.645</td><td> </td><td> </td><td>3.127*</td><td>1.100-8.888</td></tr><tr><td rowspan="2">Main Information source</td><td>Friends/relatives</td><td>2.553*</td><td>1.198-5.438</td><td> </td><td> </td><td>0.411*</td><td>0.180-0.937</td><td>0.451*</td><td>0.207-0.981</td><td> </td><td> </td></tr><tr><td>Church/Community leaders</td><td> </td><td> </td><td> </td><td> </td><td>3.148*</td><td>1.303-7.602</td><td>2.368*</td><td>1.090-5.147</td><td>2.447*</td><td>1.089-5.499</td></tr><tr><td>Omnibus Tests of Model Coefficients</td><td>Model (Sig.)</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td><td colspan="2">&lt;0.001</td></tr><tr><td>Correctly predicted observations on average</td><td> </td><td colspan="2">85.6%</td><td colspan="2">79.7%</td><td colspan="2">84.6%</td><td colspan="2">86%</td><td colspan="2">84.4%</td></tr></table>
58a2debeb215df21f123557f4b0e882ee0c55a6cefbb5eecfc6449db6dd18bf9.png
simple
<table><tr><td>Hemi</td><td>Region</td><td><i>&#223;</i></td><td>SE</td><td><i>p</i>-value (uncorrected)</td><td>FDR-corrected <i>p</i>-value</td></tr><tr><td>R</td><td>Nucleus accumbens</td><td>&#8722;0.23</td><td>0.058</td><td>0.000077</td><td>0.0055</td></tr><tr><td>L</td><td>Inferior parietal cortex</td><td>&#8722;0.38</td><td>0.10</td><td>0.00014</td><td>0.0055</td></tr><tr><td>R</td><td>Superior parietal cortex</td><td>&#8722;0.42</td><td>0.12</td><td>0.00056</td><td>0.011</td></tr><tr><td>R</td><td>Caudate nucleus</td><td>&#8722;0.28</td><td>0.081</td><td>0.00064</td><td>0.011</td></tr><tr><td>L</td><td>Putamen</td><td>&#8722;0.24</td><td>0.071</td><td>0.00068</td><td>0.011</td></tr><tr><td>L</td><td>Caudate nucleus</td><td>&#8722;0.23</td><td>0.071</td><td>0.0011</td><td>0.014</td></tr><tr><td>R</td><td>Amygdala</td><td>&#8722;0.21</td><td>0.064</td><td>0.0012</td><td>0.014</td></tr><tr><td><i>L</i></td><td><i>Supramarginal gyrus</i></td><td>&#8722;<i>0.26</i></td><td><i>0.098</i></td><td><i>0.0076</i></td><td><i>0.076</i></td></tr><tr><td><i>R</i></td><td><i>Supramarginal gyrus</i></td><td>&#8722;<i>0.27</i></td><td><i>0.10</i></td><td><i>0.0090</i></td><td><i>0.076</i></td></tr></table>
502b78ffce5b5a8d913937dd1ffa177486235eeb756660c97b33df049a0d3a5b.png
complex
<table><tr><td>Outcome</td><td>General anaesthesia</td><td>Neuraxial anaesthesia</td><td>Combination</td></tr><tr><td rowspan="2">Major VTE and VTE-related mortality</td><td>4.2%*</td><td>3.1%*</td><td>3.1%</td></tr><tr><td>(73/1731)</td><td>(101/3305)</td><td>(35/1147)</td></tr><tr><td>MBE</td><td>1.2%</td><td>1.4%</td><td>1.2%</td></tr><tr><td> </td><td>(27/2311)</td><td>(59/4212)</td><td>(19/1539)</td></tr><tr><td>MBE/CRBE</td><td>4.9%</td><td>5.6%</td><td>5.7%</td></tr><tr><td> </td><td>(114/2311)</td><td>(237/4212)</td><td>(88/1539)</td></tr></table>
8196dc74ed4cf5380cf6514e4c78d449dd2bd132459eedc62f2c8b67021ab63e.png
complex
<table><tr><td rowspan="2"><i>R<sub>FB</sub></i></td><td rowspan="2">Mineral Filler Quantity(g)</td><td colspan="3">Mineral Filler A <i>V<sub>g</sub></i> = 0.26</td><td colspan="3">Mineral Filler B <i>V<sub>g</sub></i> = 0.11</td><td colspan="3">Mineral Filler C <i>V<sub>g</sub></i> = 0.19</td><td colspan="3">Mineral Filler D <i>V<sub>g</sub></i> = 0.32</td></tr><tr><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td><td>S(g)</td><td>F(g)</td><td>S/F</td></tr><tr><td>0.6</td><td>60</td><td>18.72</td><td>81.28</td><td>0.23</td><td>7.92</td><td>92.08</td><td>0.09</td><td>13.68</td><td>86.32</td><td>0.16</td><td>23.04</td><td>76.96</td><td>0.30</td></tr><tr><td>0.8</td><td>80</td><td>24.96</td><td>75.04</td><td>0.33</td><td>10.56</td><td>89.44</td><td>0.12</td><td>18.24</td><td>81.76</td><td>0.22</td><td>30.72</td><td>69.28</td><td>0.44</td></tr><tr><td>1</td><td>100</td><td>31.2</td><td>68.8</td><td>0.45</td><td>13.2</td><td>86.8</td><td>0.15</td><td>22.8</td><td>77.2</td><td>0.30</td><td>38.40</td><td>61.60</td><td>0.62</td></tr><tr><td>1.2</td><td>120</td><td>37.44</td><td>62.56</td><td>0.60</td><td>15.84</td><td>84.16</td><td>0.19</td><td>27.36</td><td>72.64</td><td>0.38</td><td>46.08</td><td>53.92</td><td>0.85</td></tr><tr><td>1.5</td><td>150</td><td>46.8</td><td>53.2</td><td>0.88</td><td>19.8</td><td>80.20</td><td>0.25</td><td>34.20</td><td>65.80</td><td>0.52</td><td>57.60</td><td>42.40</td><td>1.36</td></tr></table>
729e33bd92994207fafcbcd59c3805ea7058131095800d9e65f7bc0ce72af3db.png
simple
<table><tr><td></td><td>Sanger technology</td><td>454 FLX technology</td><td>Sanger + 454 FLX</td></tr><tr><td>Total number of reads</td><td>14,120</td><td>789,105</td><td>-</td></tr><tr><td>Average length of read (bases)</td><td>780</td><td>218</td><td>-</td></tr><tr><td>Total number of reads in the assembly</td><td>12,032</td><td>466,737</td><td>478,769</td></tr><tr><td>Total number of contigs</td><td>2,120</td><td>22,203</td><td>18,690</td></tr><tr><td>Total number of singlets</td><td>4,775</td><td>25,604</td><td>-</td></tr><tr><td>Number of unique sequences</td><td>6,895</td><td>47,807</td><td>-</td></tr><tr><td>Average/Largest contig size</td><td>995/3,560</td><td>1132/4,762</td><td>1180/4,762</td></tr></table>
b07295b39cbff853bb64eb20332203ca4078e909fd4eeedbe866099cc1385f51.png
complex
<table><tr><td> </td><td> </td><td>Sal</td><td>VH</td><td>SS</td><td>ES5</td><td>ES10</td></tr><tr><td rowspan="2">F0</td><td>Area</td><td>160.3 &#177; 23.6</td><td>164.5 &#177; 13.6</td><td>165.3 &#177; 12.5</td><td>160 &#177; 12.1</td><td>166.5 &#177; 26.5</td></tr><tr><td>WCI</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td><td>00.0 &#177; 00.0</td></tr><tr><td rowspan="2">F1</td><td>Area</td><td>115.4 &#177; 15.9</td><td>113.1 &#177; 13.9</td><td>109.6 &#177; 12.1</td><td>95.5 &#177; 11.3<sup><i>&#8727;</i></sup></td><td>76.8 &#177; 16.06<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>31.9 &#177; 17.4</td><td>39.7 &#177; 11.5</td><td>37.7 &#177; 13.1</td><td>32.4 &#177; 11.7</td><td>50.5 &#177; 12.6</td></tr><tr><td rowspan="2">F2</td><td>Area</td><td>30.0 &#177; 11.3</td><td>25.2 &#177; 12.9</td><td>35.3 &#177; 10.4</td><td>15.9 &#177; 8.8<sup><i>&#8727;</i></sup></td><td>16.8 &#177; 8.1<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>84.7 &#177; 9.3</td><td>88.3 &#177; 7.9</td><td>81.3 &#177; 9.1</td><td>89.1 &#177; 6.05</td><td>89.9 &#177; 5.5</td></tr><tr><td rowspan="2">F3</td><td>Area</td><td>10.4 &#177; 3.4</td><td>9.1 &#177; 4.1</td><td>8.18 &#177; 3.6</td><td>2.8 &#177; 1.7<sup><i>&#8727;</i></sup></td><td>3.2 &#177; 1.5<sup><i>&#8727;</i></sup></td></tr><tr><td>WCI</td><td>94.3 &#177; 5.3</td><td>94.0 &#177; 5.3</td><td>94.9 &#177; 2.6</td><td>98.0 &#177; 1.2</td><td>96.7 &#177; 2.4</td></tr></table>